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Functional neuroimaging methods in mice are essential for unraveling complex neuronal 
networks that underlie maladaptive behavior in neurological disorder models. By using fMRI to 
detect intrinsic connectivity networks in mice, we can examine large scale alteration in brain 
activity and functional connectivity to establish causal associations in brain network changes. 
The work presented in this dissertation is organized into five chapters.  Chapter 1 provides the 
necessary background required to understand how functional neuroimaging tools such as fMRI 
detect signal changes attributed to spontaneous neuronal activity of intrinsic connectivity 
networks in mice. Chapter 2 describes the development of our isotropic fMRI acquisition 
sequence in mice and semi-automated pipeline for mouse fMRI data.  Naïve mouse fMRI scans 
were used to validated the pipeline by reliably and reproducibly extracting intrinsic connectivity 
networks. Chapter 3 establishes the development and validation of a novel superparamagenetic 
iron-oxide nanoparticle to enhance fMRI signal sensitivity.  Chapter 4 studies the effects 
norepinephrine released by locus coeruleus neurons on the default mode network in mice.  
Norepinephrine release selectively enhanced neuronal activity and connectivity in the Frontal 
module of the default mode network by suppressing information flow from the Retrosplenial-
Hippocampal to the Association modules.  Chapter 5 addresses the implications of our findings 
and addresses the limitations and future studies that can be conducted to expand on this research.
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CHAPTER 1: DETECTING INTRINSIC CONNECTIVITY NETWORKS IN MICE 
 
USING MICE TO ADVANCE NETWORK NEUROSCIENCE  
Pre-clinical research utilizes animal models to minimize study variability while altering one 
or two experimental variables (e.g. genetic modification, drug treatment, exposure to toxicant, 
toxins or infectious disease, behavioral adaptation, diet modification, gene x environment changes) 
to examine differences between controls and experimental groups.  Animal models allow 
researchers to perform invasive procedures that are otherwise deemed unethical or unapproved to 
be performed on human subjects (e.g. neuronal implantations for stimulation/recording, vector 
transfections of brain cells for functional manipulation, neuronal ablations via toxicant exposures, 
stem cell-mediated neuronal regeneration therapy).  Lastly, animal subjects are typically 
euthanized humanely at the end of each study to histologically verify the accuracy of each 
experiments (e.g. anatomical placement of surgeries, cell-specific transfections, neuronal 
ablations/regenerations).  
Mice are the most utilized of the mammalian models in neuroscience research since they are: 
easy and relatively inexpensive to maintain, they reach adulthood by 9 weeks and live no more 
than 3 years, and researchers have developed a methods to assess behaviors  such as sociability, 
anhedonia, fear, exportability, anxiety, pain sensitivity, memory, aggression, motor coordination, 
gate, strength and sensory acuity.  Lastly, colossal efforts by the researchers of the Allen Institute 
for Brain Sciences have made the most comprehensive brain atlas of the popular inbred C57BL/6J 
strain of mice showing high-resolution anatomical brain reference masks (1-3) overlaid on 
connectivity maps that track neuronal fiber projections (4, 5) as well as gene and protein expression 
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maps (6-8).  This offers neuroscientists a centralized resource to advance research of the 
mouse brain unlike any other compiled databases for humans, non-human primates or other animal 
species.  
Transgenic mouse models generated by incorporating single nucleotide polymorphism 
(SNP) variants identified in patients afflicted with brain disorder using genome-wide association 
studies (GWAS) have been indispensable in studying the genetic contribution of 
neurodegenerative disorders such a Parkinson’s disease (9), Alzheimer’s disease (9), 
frontotemporal dementia (9), amyotrophic lateral sclerosis (9), multiple sclerosis (10), and 
Huntington’s disease (11); neurodevelopmental disorders such as anencephaly (12), blindness 
(13), deafness (13) and cerebellar ataxia (14); neuropsychiatric disorders such as anxiety (13), 
depression (13), attention deficit hyperactivity disorder (13), bipolar disorder (13), and 
schizophrenia (15); and brain tumors such as medulloblastoma (16).  Genome-modifying advances 
such as CRISPR have made producing new transgenic mouse models with SNPs, gene knock-in(s) 
/ out(s), conditional knock-in(s) / out(s), and Rosa26-target expression of genes for bioengineered 
proteins widely accessible to researchers throughout the world.  As neuroscience research 
advances, so have the tools for selectively exciting and inhibiting neuronal activity among 
selective neuronal cells types, allowing researchers to causally determine changes in behavior 
associated with highly-selective neuronal populations through their selectively excitation, 
inhibition or ablation in order to establish causation.   
The ability to perform functional neuroimaging in mice is essential to advance the 
understanding of large scale brain networks. This chapter will address the different functional 
neuroimaging methods successfully implemented in mice and their signal sources, respective 
strengths/weaknesses, and technical limitations. Since the research in this dissertation was 
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predominantly performed using functional MRI (fMRI), additional details on fMRI acquisition 
methods used to study intrinsic connectivity networks in mice will be provided.  
 
ORIGINS OF FUNCTIONAL NEUROIMAGING SIGNALS 
Functional neuroimaging modalities either directly measure neuronal activity or indirectly 
infer neuronal activity by measuring hemodynamic changes as a proxy correlate coupled to 
neuronal activity. The most used direct neuroimaging methods—such as electroencephalography 
(EEG) and electrocorticography (ECoG)—detect and measure neuronal activity associate with 
changes in intra-/extra-cellular concentrations of ions (e.g. electrical potential).  Additionally, 
optical methods have been developed to directly detect and measure fluorescent indicator of direct 
neuronal activity changes attributed to vesicular release, extra-synaptic neurotransmitters or 
neuronal depolarization. Conversely, functional neuroimaging modalities that measure 
hemodynamic markers as a proxy neuronal activity typically detect either cerebral blood flow 
(CBF), cerebral blood volume (CBV) and cerebral metabolic rates of oxygen (CMRO2).  These 
techniques will be covered in detail in subsequent sections. 
 
Direct neuronal activity signals 
The mouse brain consists of 75 million neurons (17) that communicate with one another 
through electrochemical methods.  For instance, sensory signals are typically brought into the brain 
by specialized sensory neurons that convert information derived outside the body into an 
electrochemical signal in the brain. These signals are received as extracellular neurotransmitters 
detected via receptor-mediate signal transduction on neuronal dendrites that rapidly depolarize 
neurons to trigger an action potential.  Action potentials propagate from the dendrites to the soma 
are sent distally along axons to trigger vesicular neurotransmitter release that propagates the signal 
into an effector cell. Synaptic activity generated through neurotransmission produces a post-
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synaptic potential that in itself would be difficult to reliably detect without direct contact by an 
electrode. However, since neurons tend to fire synchronously in clusters of hundreds to thousands, 
they generate electrical fields that are strong enough to be detected by electrodes using techniques 
such as EEG, ECoG and stereotaxic electrophysiology.   Recently, novel optical techniques have 
been developed by transgenetically expressing protein indicators that fluoresce during different 
phases of neurotransmission. Voltage indicators, for instance, are transfected into neurons and 
detect rapid intracellular influxes of Ca2+, Na2+ or K+ ions that spike following neuronal 
depolarzation resulting in indicator fluorescence (18).  Utilizing specific promoters within the viral 
vector can be used to selectively transfect indicators on certain neuronal populations—allowing 
population specific neuronal activity measures. 
Real-time measurement of neurochemical transmission is possible in vivo using fast scan 
cyclic voltammetry (FSCV). FSCV can detect the release and uptake of monoamine 
neuromodulators such as dopamine (DA), serotonin (5-HT), and norepinephrine (NE) by sensingg 
their voltage-dependent oxidation and reduction signatures (19).  Several fluorescent indicators 
that measure vesicular release have been developed to be transgenically expressed on the inner 
walls of neuronal vesicles and fluoresce following pH shifts associated with exocytosis of vesicles 
dumped into the synaptic gap (18).  Lastly, bioengineered fluorescent indicators that detect extra-
synaptic neurotransmitter release have been developed to detect classic neurotransmitters such as 
ATP, glutamate, and GABA and neuromodulators such as acetylcholine (ACh), 5-HT, DA and NE 
(20). 
Indirect neuronal activity signals 
A relationship between CBF and brain function was first proposed in 1881 by Angelo 
Mosso (21) and popularized by Roy and Sherrington in 1890 who proposed that task-induced 
increases in CBF were attributed to vasodilation following an increased demand for cerebral 
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metabolism of oxygen and glucose in response to neuronal activity.  The Roy-Sherrington model 
of neurovascular coupling (NVC) remained unchallenged for nearly a century—since a myriad of 
early functional neuroimaging techniques showed that spontaneous resting-state neuronal activity 
showed elevated CBF, CMRO2 and CMRGlu consumption.  In fact, resting-state fluctuations in 
CBF and CMRO2 changes were highly correlated (22).  Notably, the coupling among these three 
physiological measures begin to partially contradict the Roy-Sherrington model of NVC during 
task-associated changes in neuronal activity—whereby CBF and GMRGlu remained coupled, while 
the relationship between CBF and CMRO2 becomes uncoupled or even negatively correlated (23, 
24).  Interestingly, when concurrently scanned using 1H magnetic resonance spectroscopy (MRS) 
to quantify tissue lactate concentration—allowing for stoichiometric calculation of ATP 
production based on changes of CMRO2 and tissue lactate concentration—correlated relationships 
were observed between CBF, CMRGlu and lactate production rates and between CMRO2 and ATP 
production (23, 24).  Together, these studies indicate that spontaneous resting-state neuronal 
activity changes support the Roy-Sherrington model since ~90% of the cerebral glucose 
metabolism occurs through aerobic glycolysis, requiring greater CMRO2 to produce ATP as 
indicated by heightened partial pressure of CO2 ad O2 (25).  Conversely, task-evoked changes in 
neuronal activity preferentially utilize anaerobic glycolysis, reducing baseline levels of CMRO2, 
that converts glucose to lactate to be utilized by the astrocyte-neuron lactate shuttle (ANLS) as the 
primary source of neuronal energy (26).  The ANLS model of NVC preserves functional 
hyperemia (i.e. the relationship of enhanced CBF following increases in neural activity) but is not 
governed by metabolic needs such as is required by the Roy-Sherrington model. It is thought that 
astrocytes have sufficient energy supplies in glycogen reserves to supply energy to neurons 
following brief stimuli.  
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In both the Roy-Sherrington and ANLS models of NVC, changes in CBF lag between 0.5-
6.0 seconds following changes in neuronal activity as detected by detecting intracellular Ca2+ (27) 
and remained sustained for 4-6 seconds (28) to replenish metabolic supplies, allowing for sustained 
metabolic uptake in cases of prolonged neuronal activity. It is this physiological delay in functional 
hyperemia that is exploited as a proxy measure of neuronal activity by many neuroimaging 
methods converting firing of neuronal action potentials from the nanosecond scale to changes in 
perfusion detected over several seconds.  For instance, the blood oxygen level dependent (BOLD) 
signal measure by fMRI is generated by biophysical and physiological signal changes (29).  The 
biophysical signal of BOLD is associated with the fraction in cerebral blood volume (CBV) that 
contain deoxyhemoglobin (deoxyHb) in brain tissue—which is typically at its highest 
concentration in venous blood vessels—that produces a paramagnetic signal that alters the 
magnetic susceptibility of blood and reduces the MR signal (30).  Several physiological 
components are thought to generate the BOLD signal including CBF, fractional changes between 
CBF/CMRO2 and changes in venous fraction of CBV (30, 31).  Notably, the largest influence on 
the BOLD signal is the concentration of deoxyHb which is dictated by oxygen extraction fraction 
(OEF). OEF is defined as the ratio of blood oxygen that the brain takes from the blood flow to 
maintain function.  Although functional hyperemia is not altered in rats exposed to pure oxygen 
(i.e. hyperoxemia) (32), Ogawa et al. demonstrated the BOLD signal becomes significantly 
degraded under these conditions (29) since the blood is hyper-saturated with dissolved oxygen in 
plasma that freely diffuses into tissue resulting in a reduction in the necessity to extract oxygen 
from hemoglobin.  
At the cellular level, NVC is associated by signal modulators released during neuronal 
activity that directly and indirectly constrict/dilate proximal smooth muscle cells (SMC) and 
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pericytes that ensheathe the capillaries and the arterial fraction of the cerebrovasculature (33) 
(Figure 1.1). Much of mechanism that governs functional hyperemia is attributed to the excitatory 
neurotransmitter glutamate on postsynaptic receptors (34). This is partially attributed to calcium-
mediated neuronal release of vasodilatory nitric oxide (NO) and K+ following the activation of 
ionotropic glutamate receptor (GluR) in postsynaptic neurons (35).  Astrocytes are the other 
cellular contributor to glutamate-mediated NVC serving as functional intermediaries due to their 
anatomical placement between neurons and the cerebrovasculature (36).  Glutamate can bind to 
metabotropic glutamate receptors (mGluR) on astrocytes which release cytosolic phospholipase 
A2 (PLA2) that is converted into arachidonic acid (AA) to generate the vasodilatory prostaglandin 
E2 (PGE2) (37). 
 
Figure 1.1 Illustration of cellular mechanisms thought to drive NVC.  As glutamate is released (1) it can trigger the 
release of vasodilatory compounds from both postsynaptic neurons and astrocytes resulting in regional vasodilation 
of proximal blood vessels.  Glutamate is partially uptaken by astrocytes and recycled back to via the Glu-Gln shuttle 
resulting in heightened oxygen and ATP (2) usage by astrocytes driving enhanced demand of glucose uptake by 
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astrocytes (3) and an increased OEF. Glucose uptake by astrocytes restores ATP deficits (4) and all excess glucose is 
converted to lactate and is (5) shuttled as energy source to neurons via the ANLS to restore all deficits attributed to 
neuronal activation. 
 
FUNCTIONAL NEUROIMAGING MODALITIES IN MICE 
Functional neuroimaging has been at the forefront of neuroscience research when it comes to 
examining interactions among brain regions.  In fact, technological advances in neuroimaging have 
been the funding priorities of many large-scale scientific funding initiative including the Human 
Connectome Project (HCP) and the Brain Research through Advancing Innovative 
Neurotechnologies (BRAIN) Initiative of the U.S. National Institutes of Health.  These initiatives 
challenged engineers, researchers and clinicians to find way to improve the:  
(1) Safety of these techniques to better protect the subject and technicians—with preferences 
towards non-invasive methods that can be translated to humans that do not require 
surgical implantations, potentially harmful injection of contrasts or long-term radiation 
exposure. 
(2) Temporal resolution (i.e. acquisition rate) of the neuroimaging data collection—with 
preferences towards faster acquisitions that approximate the speed of neurotransmission 
in nanoseconds.  
(3) Spatial resolution of the neuroimaging data, specifically the smallest volume by which a 
signal can be accurately detected—with preferences towards high spatial resolutions that 
approximate the size of neuron in nanometers. 
(4) Penetrance refers to how deep into tissue a signal can still be accurately extracted, while 
coverage refers to maximum acquisition spread generated by the transmitter and 
receiver—with preferences towards whole brain penetrance and coverage. 
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(5) Signal-to-noise ratio (SNR) is a measure of the sensitivity of the neuroimaging modality 
to detect the target signal of the modality while reducing background noise generated 
from thermal and physiological noise sources—with preferences towards methods with 
high signal strength and no detectable noise. 
 
Neuronal functional imaging modalities 
Electroencephalography. EEG uses a flexible, multi-electrode helmet with electrodes that 
are evenly spaced throughout the scalp. Extracellular ionic currents caused by dendritic electrical 
activity from a large population of neurons can be detected and measured with a penetrance of 5-
9 cm directly perpendicular to each the electrode.  Greater SNR can be achieved by performing a 
highly invasive craniotomy (i.e. surgical removal of a portion of the skull) to directly implant 
electrodes to the surface of the brain in a technique called ECoG. Due to the thinness of the mouse 
skull and the small size of the mouse brain, ECoG does not afford that much more signal 
penetrance—particularly when weighed against the risk of a post-operative meningeal infection.  
Two major advantages of EEG and ECoG are that these techniques directly measure neuronal 
activity and have extremely high temporal resolution (i.e. nanosecond scale).  This data can 
undergo Fourier or Wavelet transformations to be expressed as changes in power across the 
frequency domain whereby the amplitude and size of delta (>4 Hz), theta (4-8 Hz), alpha (8-12 
Hz), beta (13-30 Hz), and gamma (<30 Hz) rhythms can be distinguish at each electrode (38). The 
main disadvantage of using EEG and ECoG to measure functional networks in mice is the poor 
spatial resolution since the signals represent cumulative measure of the detected ionic currents 
perpendicular to each electrode—which in mice may be intermixed with the detection of 
subcortical ionic currents.  
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Stereotactic Electrophysiology.  Stereotactic electrophysiology is an invasive technique 
whereby single electrodes or multi-channel arrays can be implanted into the brain to detect and 
measures single-unit activity (SUA) within ~50 µm of the electrode and multi-unit activity (MUA) 
and local field potential (LFP) within ~150-200 µm of the electrode with nanosecond temporal 
resolution (38). Though the readout for this technique is hyper localized, it remains the gold-
standard for measuring the ground truth of neuronal activity.   Due to the limited spatial coverage 
of this technique, many electrodes can be implanted and simultaneously measured to establish 
functional connectivity among brain regions. 
In vivo Optical Microscopy.  Two- and three-photon microscopy can be performed in vivo 
but require invasive craniotomies or thinned cranial polished and reinforced thinned-skull (PoRTs) 
windows in conjunction with the surgical expression of fluorescent voltage indicators (18), 
vesicular release indicators (18) and neurotransmitter indicators (20).  This technique provides 
extremely high spatial resolution with a penetrance of 1 and 3 mm into mouse cortical tissue for 
two- and three photon microscopy (39, 40), respectively. Furthermore, to address penetrance 
issues, gradient index (GRIN) lenses can be implanted into the brain and attached to the objective 
to image deep into mouse subcortical regions (39, 40).  Although technological advances in in 
wide field-of-view microscopy have been implemented for functional imaging the entire cortical 
surface of the mouse brain (41), the imaging plane is typically fixed at a specific z-plane depth to 
acquire millisecond scale acquisition limiting the number of recorded neurons despite the ability 
to acquire deeper penetrance. The major disadvantage of this technique is the lack of coverage—
only allowing researchers to examine functional activity in a single hyper-localized region of the 
brain at a time—thus this technique is not suitable for studying functional connectivity among 
distant brain regions away from cortical surface. 
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In vivo Optical Endoscopy. In order to simultaneous images individual neurons in multiple 
brain regions using fluorescent indicators of neuronal activity, neurobiologist developed tiny 
implantable endoscopes that have built-in fluorescent microscopes with one or two-excitation 
lasers that can be implanted into the mouse brain and mounted to the skull allowing for imaging 
of freely-moving mice (42).  As with multi-photon microscopy, GRIN lenses can also be 
implemented in this setup to improve penetrance into subcortical regions. Some major 
disadvantages of this system with respect to functional neuroimaging, is the lack of coverage since 
fluorescent endoscopes have a focusing plane of around 50 µm and when compared to multi-
photon microscopy they have reduced clarity and slower acquisition times (43)—yet it is more 
than suitable to measure neuronal activity changes in tens of neurons per implanted endoscope and 
can be used to study functional connectivity between different brain regions (44). 
Fiber photometry.  Fiber-photometry is an emerging technique in neuroscience since it is 
less destructive to the brain. It only requires optic fiber implantations into brain regions that 
expresses a fluorescent indicators of neuronal or neurochemical activity (45). These fluorescent 
activity changes are either measured using a photomultiplier tube (PMT) or a 
spectrophotometer—which can be implementation in multi-spectral studies to detect the 
emission of multiple non-overlapping fluorescent indicators (46).  A major limitation of fiber 
photometry is that it only detects collective fluorescent signal (per fiber) that represents the total 
fluorescent photon counts from the field of view of the implanted optic fiber—thus losing spatial 
resolution available in multi-photon and endoscopy techniques.  In exchange, the major 
advantages of fiber photometry is that it is relatively inexpensive to setup and can be 
implemented on multiple brain regions to study functional connectivity in freely behaving awake 
animals (45-47).    
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Immediate early gene expression.  Neurons transiently activate what are known as 
immediate-early genes (IEGs) following neuronal activity.  IEGs can be detected 30-60 minutes 
after neuronal activation using immunohistochemistry of ex vivo brain tissue (48, 49).  The most 
common IEGs include the activity-regulated cytoskeletal (Arc) protein Arg3.1 and the synaptic 
proteins egr1 and c-fos which together serve as molecular marker of neural activity localized at 
the cellular level (48, 49). Conditional transgenic mice which allow researchers to capture two 
different neuronal activity map ‘snap-shots’ via distinct fluorophore expression have been 
developed to unbiasedly identify new brain regions associated with behaviors (50).  Although this 
neuroimaging technique lacks temporal resolution and can only be performed post-mortem, the 
main advantage of this neuroimaging technique is that it can be utilized in a hypothesis free manner 
to identify unknown neuronal populations associated with behavior and can be imaged and 
quantified at the single cell level in an intact mouse brain using clearing techniques such as 
iDISCO+ (51). 
 
Hemodynamic functional neuroimaging modalities 
Positron emission tomography.  Positron emission tomography (PET) is a functional 
imaging technique that can be used to measure changes in CBF and glucose metabolism in the 
brain using selective radiotracers. In the early iteration of what would become the PET scanner, 
implanted scintillation counter on the surface of the skull of rodents and primates were used to 
detected circulating [15O]-H2O to accurately measure CBF (52).  The technical limitations of this 
technique, with a half-life of only two minutes and this technique could only be performed at 
facilities that can generate [15O] radioisotope within an onsite cyclotron due to the rapid 
radioisotope decay (52), quickly made this technique obsolete with the emergence of fMRI.  
Today, PET researchers use [14C]-2-deoxyglucose (DG) and [18F]-2-fluoro-2-deoxy-glucose 
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(FDG) that freely penetrate the blood brain barrier to measure cerebral glucose utilization in the 
brain (53) as a measure of neuronal activity.  Differential uptake and distribution throughout the 
brain is thought to reflect enhanced glucose demand following neuronal activation. Although 
glucose metabolism can arguably be considered to reflect a direct measure of neuronal activity, 
only about half of the brain’s glucose uptake is directly utilized by neurons, thus the other half is 
taken up by astrocytes and indirectly provides an energy source for neurons via the ANLS (54). 
Unlike [14C]-2-DG, [18F]-FDG more closely resembles the structure of glucose and lacks the 
hydroxyl groups required for glycolysis, thus cannot be further metabolized or integrated by the 
cells following uptake before radioactive decay (half-life of 110 minutes) accurately reflection of 
the distribution of glucose uptake which typically happens within the first 5 minutes of injection 
(53).  Though one major advantage of [18F]-FDG PET imaging in mice is the high sensitivity 
toward the radioactive tracer with no background noise, yet it suffers from poor spatial resolution 
~1 mm3 voxels and poor temporal resolution since a dynamic PET scan are collected in just under 
one minute (53)—making it impossible to infer functional connectivity relationships among brain 
regions. To further enhance the spatial resolution of this technique, autoradiography can be 
performed ex vivo on brain sections by rapidly sacrificing subjects, sectioning their brains, and 
measuring radioisotope concentrations at very high spatial resolution using autoradiography.  
These images can later be overlapped over tradition histology of the sliced sections to make cell-
type related inferences of neuronal activity.   
Single-photon emission computed tomography. Single-photon emission computed 
tomography (SPECT) is a nuclear medicine tomographic imaging technique using gamma rays to 
measure radiotracers.  Hexamethylpropyleneamine oxime (HMPAO) is lipophilic compound 
bound to a metastable nuclear isomer of Technetium-99 [99mTC] with a half-life of six hours that 
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can be injected intravascularly to measure regional CBF. [99mTC]-HMPAO has been successfully 
measured using SPECT in awake mice to measure self-stimulation of optogenetic activation of 
CAMKII-expressing neurons in the Ventral Tegmental Area with whole brain coverage at a spatial 
resolution of 700 µm (55).  Some major disadvantages of this method are that it has poor temporal 
resolution and is not quantitative. While a major advantage of this methods is that it has excellent 
SNR due to the high sensitivity toward the radioactive tracer with no background noise.  
Microscopy techniques.  Multi-photon microscopy, endoscopy and fiber photometry can also 
be implemented to study hemodynamics in the brain using intravascular fluorescent dyes (e.g. 
Evan’s blue, FITC, Texas Red, AlexaFluor, Quantum Dots) that are bound or endogenous bind to 
large proteins known to circulate in the bloodstream such as dextran (12-80 kDa) and albumin 
(120 kDa).  These methods can rudimentarily be used to measure CBV changes in a given brain 
volume over time to calculate ∆𝐹 𝐹	or the change in fluorescence normalized to the averaged 
background fluorescence (56).  Additionally, multi-photon microscopy and endoscopy can be used 
to measure CBF using a line-scan imaging technique to either longitudinally measure the luminal 
space of a blood vessel whereby the slope of red blood cell shadows correspond to the speed by 
they are traveling or by segmenting a blood vessel and measuring the diameter changes which can 
be used to calculated changes in CBV (56). 
Optical Imaging Spectroscopy.  Optical Imaging Spectroscopy (OIS) can be measured using 
in vivo fluorescent microscope with blue, green and red excitation lasers to detect reflectance data 
at 490 nm that detects oxyhemoglobin (oxyHb), 530 nm which represents the isosbestic point of 
the hemoglobin absorption spectra whereby both oxyHb and deoxyHb have the same absorption 
values (allowing for the total measure of hemoglobin regardless of oxygenation status) and 630 
nm that detects deoxyHb (57). Excitatory neuronal activity increases regional blood flow and 
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oxygenation, most strongly seen in veins through a reduction in baseline concentration of deoxyHb 
and an increase in a whitening of vein structures at 630 nm. Unlike other modalities, OIS can be 
used to differentiate veins from arterioles on the pial surface of the brain since venous blood have 
high concentration of deoxyHb resulting in a dark contrast in reflectance at 630 nm compared to 
the minimal contrast shift at 630 nm in arterial blood that almost entirely comprised of oxyHb (57).  
OIS has excellent coverage across the entire surface of the brain which allow indirect 
measurements of cortical network activity with high spatial and temporal resolutions, yet its major 
disadvantage is a lack of penetrance restricting perfusion-mediated changes in deoxyHb 
concentration measurements only to the surface of the brain (57). 
Functional Magnetic Resonance Imaging. fMRI s a non-invasive functional neuroimaging 
tool that does not require radioactive traces or produce ionizing radiation, instead it uses a strong 
magnetic field and radiofrequency pulses to manipulate and measure 1H protons in tissue.  MRI 
offers many different ways to image hemodynamics in the brain—including BOLD changes in 
activity, CBF through the use of a tagging coil to label water molecules in the heart or carotid 
artery before they enter the brain in a technique known as arterial spin labeling (ASL) or by 
contrast-enhanced imaging of a paramagnetic intravascular contrast agent to measure CBF or 
CBV.  All three techniques can collect functional data covering the entire mouse brain, but vary 
in spatial and temporal resolution—which tend to range in hundreds of µm and second scales. 
 
MOUSE fMRI: INVESTIGATING INTRINSIC CONNECTIVITY NETWORKS  
fMRI was first conducted in mice in 1996 (58), several years after being implemented in 
humans.  This was partially due to the technical constraints required to image small objects in high 
spatial resolution (e.g. voxels 103 order finer than humans) while sampling less signal-contributing 
spins (59).  To address this issue, engineers produced high-field MRI scanners with small bores to 
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increase the magnetization, thus boosting the SNR at the expense of introducing more image 
artifacts.  New methodologies are constantly being developed to improve fMRI in mice including 
contrast agents and cryogenic receiver coils that reduce thermal noise, both of which can further 
boost signal while reducing noise (59). 
 
fMRI imaging sequences in mice 
Briefly, fMRI uses a strong magnetic field to align the nuclear spins of 1H protons 
(primarily brain tissue water) and using a 400 MHz radio frequency (RF) magnetic pulse to 
induce a magnetic resonance signal in 1H protons that is detected by an RF coil. MRI brain tissue 
contrast is produced by measuring the T1 and T2 relaxation times of the magnetic resonance 
signal of 1H protons following RF excitation. T1, also known as the longitudinal relaxation time, 
measures the time required by excited 1H protons to realign with the magnetic field of the 
scanner. T2, also known as the transverse relaxation or spin-spin relation time, measures the time 
required by excited 1H protons to lose phase coherence (i.e. dephasing) resulting in an 
exponential loss of MR signal intensity. The exponential rate of dephasing is termed T2* and 
represents differences in local magnetic susceptibility among different brain tissues.  These 
contrast metrics are typically measured using one of three major fMRI sequences in mice.  This 
section will briefly review the differences between the sequences, their source signals and their 
technical limitations.  Table 1.1 summarizes the respective strengths, weaknesses and technical 






Table 1.1  fMRI Image Sequences for functional connectivity in mice. 
Imaging 
Sequence Signal Source Strengths Weaknesses 
BOLD-fMRI oxy-Hb:deoxy-Hb 
ratio, CMRO2, CBF 
and CBV  
non-invasive, 
endogenous contrast,  
low SNR in mice, signal is 
hard to interpret due to its 
mixed origin  
CBV-fMRI  changes in intraluminal 





anatomical hallmark loss, 




Tagged water in the 
plasma fraction of 




endogenous contrast,  
slow acquisition  
 
Blood-Oxygen Level Dependent-weighted fMRI.  In 1990, Ogawa et al. utilized an 
imaging sequence called the gradient echo MRI in rats to measure the paramagnetic 
susceptibility T2* contrast of exposed Fe2+ in the heme structure of deoxyHb, which possess four 
unpaired electrons for each divalent iron ion, and was significantly reduced by hypersaturating 
the blood with high concentrations of dissolved oxygen to alter the oxyHb:deoxyHb ratio (29).  
This endogenous signal was termed the BOLD signal and has been by far the most widely used 
imaging sequence in human fMRI studies.  Seminal studies (60-62) later confirmed that the 
BOLD kinetics reflects a complex number of physiological signals that can be modeled as the 
Hemodynamic Response Function (HRF). The HRF delineates the response to a neuronal 
impulse and is frequently used to analyze fMRI data.  At its core the BOLD signal is related to 
oxyHb:deoxyHb ratio and the shape of the response illustrates complex interaction between local 
CMRO2, CBF, and CBV (29).  Furthermore, as red blood cells pass through capillaries, the 
distance between red blood cells and brain cells narrows, this combination of small distances and 
oxygen concentration gradients allows oxygen to diffuse from oxyHb-rich erythrocytes to lower-
oxygen-content brain tissue shifting the ratio towards higher concentrations of red blood cells 
with deoxyHb within post-capillary venules and veins. The localization of the BOLD signal 
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primarily to the venous compartment of the vasculature has been verified in mouse (27).  
Although BOLD contrast was originally believed to be in response to output signal of local 
neuronal spiking, a seminal study by Logothetis et al. demonstrated that the BOLD signal more 
closely matches low field potential (LFP) generated from input signal on excitatory and 
inhibitory postsynaptic potentials (EPSPs and IPSPs, respectively) than neuronal spiking (63).   
Cerebral Blood Volume-weight fMRI.  Unlike BOLD, CBV-weighted fMRI often uses 
paramagnetic or superparamagnetic contrast agents injected in the bloodstream to selectively 
isolate the intraluminal volume occupied by blood in the brain—including both the arterial and 
venous compartments of the vasculature.  Although the vasculature system is a closed loop 
system, the bulk of dynamic changes in the CBV signal are attributed to changes in the tone of 
the arterial compartment composed of arteries, arterioles and capillaries through the contraction 
and relaxation of either SMCs and pericytes (64).  Conversely to BOLD, CBV signal changes are 
mainly derived from the arterial compartment as verified in mice (27).  The first CBV study used 
the contrast agent Gd-(DTPA) that has a very short circulating lifetime (lasting ~20 minutes 
before requiring an additional injection) to measure activity in the visual cortex (65).  To address 
this issue, chemists generated a line of super paramagenetic iron-oxide nanoparticles (SPION) 
coated with a large organic shell that permits very long intravascular circulating half-life of 
nearly 81 minutes with an extensive steady state period in circulation allowing for successfully 
function neuroimaging in mice (66, 67).  Unfortunately, SPION contrast agents have not yet 
been approved for CBV-weighted fMRI in humans by the U.S Food and Drug Administration 
(FDA) or the European Medicines Agency (EMEA), resulting in only few human studies having 
been performed using this contrast via ‘off-label’ approval.  At the moment, Gd-based tracers are 
being re-evaluated due to safety concerns in humans (68)—thus it can only be assumed that Fe-
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based tracers may undergo the same rigor to ensure absolute safety from potential heavy metal 
toxicity.  Fortunately, CBV-weighted fMRI using SPION contrast agents have continued to be 
heavily employed in animal fMRI studies primarily since it enhances the sensitivity of fMRI in 
arterioles and capillaries by 6-fold (69-71).  This is particularly helpful at improving the fMRI 
signal contrast in animals with small brain such as mice, yet since the source of the signal is 
different than BOLD it may prove challenging to translate findings to humans. 
Cerebral Blood Flow-weighted fMRI.  Beyond measuring the changes in CBV and the 
ratio of oxyHb:deoxyHb in blood. which are semi-qualitative in fMRI, one can generate a 
quantitative measure of CBF using a technique called ASL.  CBF represents the net blood 
volume perfused per gram of tissue per unit of time. In mice, this method can be measured by 
using a RF-coil located over the heart, also known as cardiac spin labeling (CASL)—rather than 
carotid arteries—to magnetize or ‘tag’ H2O found in blood by flipping the spins 180 degrees and 
observing their spin precession as measurable T1 changes in tissue via a receiving head coil.  
Labeled blood H2O freely penetrates the brain parenchyma through ion channels in the blood 
brain-barrier, resulting in tissue magnetization exchange that is proportional to the flow rate of 
CBF which can be calculate in units of ml of blood / 100 g tissue * minutes.  The major 
downside with using CASL for functional neuroimaging is that the repetition time is subject to 
the time required to label sufficient 1H-protons of serum H2O to yield sufficient contrast.  
Furthermore, in a co-first author study that I conducted measuring perfusion in distinct genetic 
models of collateral vessel expressions following a permanent middle cerebral artery occlusion 
(72), we found the appropriate post-labeling delay between the labeling and acquisition coils is 
also important, since it can be used to target distinct vascular compartment in the brain.   
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Detecting Intrinsic Connectivity Networks using fMRI in mice 
Though fMRI studies are mainly classified as either task-based, pharmacological or 
resting-state designs, this section will focus exclusively on resting-state/task-free fMRI 
experimental designs for detecting intrinsic connectivity networks in mice.  Intrinsic connectivity 
networks, also known as the resting-state or functional connectivity networks, are interconnected 
brain regions that form persistent and stable patterns of low frequency correlations associated 
with hemodynamic fluctuations (73-75). Intrinsic connectivity networks can be divided into 
several spatially segregated large-scale brain networks that form topologically connected 
structures (75, 76) associated with distinct functions and behaviors (77, 78).  Since intrinsic 
connectivity networks are constrained to anatomical regions proven to be functional connected 
by axonal bundles and synchronous neuronal activity (79), they are assumed to represent 
neuronal brain networks integrated through a series of interconnected hubs (80).  Intrinsic 
connectivity networks were originally assumed to be attributed to spurious neuronal activity 
since they were first detected during task-based fMRI studies yielding consistent 
spatiotemporally correlated patterns among different subjects and imaging sessions (73, 77, 78, 
81-83). Recently resting-state fMRI detection of intrinsic connectivity networks have gained 
major traction in detecting network-level changes associated with spontaneous activity in the 
brain, without the need for pharmaceutical manipulations or task-based fMRI study designs—
which has been difficult to carryout in infants and patients with dementia.  Intrinsic connectivity 
networks offer a stable and reproducible tool to functionally map the brain without any complex 
acquisition protocols in attempts to detect network-level biomarkers of neurological disease (84). 
Resting-State fMRI.  Resting-state (i.e task-free) fMRI measures spontaneous low 
frequency fluctuations (i.e. 0.01-0.1 Hz) in the MRI signal over time. Functional connectivity 
measures the temporal correlation of these low frequency fluctuations between spatially distinct 
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brain regions (82, 85-88). Resting-state fMRI measures signal attributed to spontaneous, intrinsic 
neuronal firing and determining which brain regions share temporal coherence in the fluctuations 
(i.e. fire together)—brain regions with a high degree of synchronicity are thought to be 
functionally connected (82, 85-88).  To verify the accuracy of this technique, brain regions that 
have been identified to be functionally connected have also been confirmed to be anatomically 
connected via fiber projections through tract-tracing studies or diffusion tensor tractography.  
Resting-state fMRI has rapidly become the most popular experimental fMRI design in mice 
since it can be used to study the functional architecture of the brain without the need for subjects 
to perform tasks or be exposed to stimulus paradigms and intrinsic connectivity networks are 
detectable under sedation and sleep (82).  Until now, most mouse fMRI studies have primarily 
focused on detection and extracting intrinsic connectivity networks under naïve conditions, yet 
others have shown that this experimental design is also well-suited to investigate the network-
level changes in models of disease (89, 90) and following selective manipulation of input 
systems of neurotransmitter and neuromodulators (91-94).  
Intrinsic Connectivity Networks in Mice 
In humans, intrinsic connectivity networks link resting-state and task-based functional 
connected brain networks forming two large anti-correlated networks associated with ‘task-free’ 
and ‘task-engaged’ behaviors, respectively (96-99).  The most extensively studied ‘task-free’ 
intrinsic connectivity network is the default-mode network, which shows extremely strong low 
frequency coherence along the midline of the brain in resting-state fMRI studies (86, 100, 101).  
Task-engaged intrinsic connectivity networks include several brain networks including 
attentional networks (102, 103), executive control and salience processing networks (104), 
sensory processing networks (74, 78).  Homologous intrinsic connectivity networks have also 
been detected in mice, including several other brain networks (Table 1.2). 
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The DMN and sensory networks are the most consistently detected intrinsic connectivity 
network in mice.  The DMN is an interconnected system composed of the orbital, pre-limbic, 
cingulate, retrosplenial, parietal association and temporal association cortices (90, 95, 109, 112-
115), with some reports include the dorsal hippocampus, prefrontal and visual cortices in rodents 
depending on anesthesia (110, 116).  In most studies the DMN stands out as the most robust of 
the detectable intrinsic connectivity networks in mice because it is thought to integrate sensory 
and affective information to guide behavioral responses to shifting environmental engagement 
(117).  The research presented in Chapter 4 shows that the DMN in mice can be broken down 
into three modules: 1) a frontal module composed orbital, pre-limbic and anterior cingulate 
cortices, 2) a retrosplenial-hippocampal module composed of the dorsal hippocampus and 
posterior cingulate, retrosplenial, medial parietal association and visual cortices, and 3) an 
association module composed of the posterior parietal association and temporal association 
cortices.  
Other mouse intrinsic connectivity networks that are typically detected include 
sensorimotor network typically composed of primary and auxiliary motor and somatosensory 
cortices, lateral cortical network, olfactory network composed of primarily and supplemental 
olfactory systems, thalamic network, cerebellar networks, basal forebrain network and basal 
ganglia/midbrain network.  These intrinsic connectivity networks become highly variable from 
study to study. Unlike the DMN, they require sensory- or task-engagement for optimal activation 
that is not otherwise achievable in awake mice. 
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CHAPTER 2: OPTIMIZING FUNCTIONAL CONNECTIVITY MRI ACQUISITION, 
PREPROCESSING & ANALYSIS IN MICE 
INTRODUCTION 
MRI is one of the most widely used neuroimaging techniques capable of non-invasively 
imaging the structural and functional properties the entire brain. The use of functional MRI to 
detect task-related brain activity and resting-state intrinsic connectivity networks has been 
essential in the study of brain networks and their differentiation in healthy and diseased states.  
Though MRI scanners and the analytical packages used to detect and study intrinsic connectivity 
networks were originally developed for human imaging, technological advances in ultra-high 
field MRI scanners (>7 Tesla) coupled with specially designed head coils has permitted an 
emergence in mouse fMRI studies.  Mice are the most commonly used animal model to study 
human neurological disorders since they are: 1) genetically similar to humans and capable of 
developing many of the same pathologies, 2) inbred, thus reducing genetic variability, and 
maintained under similar conditions to avoid environment-related study variance, 3) capable of 
being genetically modified to express human genetic mutations associated with disease to 
produce more ‘human-like’ disease models, 4) short-lived with accelerated lifespan allowing for 
the study of slow developing conditions such as brain cancers and neurodegenerative disorders, 
and 5) capable of being ethically used for highly invasive procedures (e.g. brain implantations, 
controlled brain activation/inhibition, administration of pharmacological/neurotoxicant agents).  
Studying intrinsic connectivity networks and their dynamics with and without the engagement of 
behavioral tasks and how they are activated, modulated and inhibited remains a daunting 
challenge that will require the use of mouse models to selectively interrogate each of the input 
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and output systems of intrinsic connectivity networks using advanced neuroscience tools such as 
optogenetics and chemogenetics to causally intervene in the activation or inhibition of selectively 
neuronal circuits.  Using mouse models to advance our understanding of intrinsic connectivity 
networks is essential to drive translational research to select better targets for drug interventions 
and advance our knowledge of neuroscience. 
Many tools were developed for the preprocessing and analysis of human MRI data—such 
as FSL (118), AFNI (119), ANTs (120), SPM (121), Freesurfer (122)—some of which were later 
modified to be more versatile, allowing for the use of higher spatial resolution MRI data such as 
that generated from small animals fMRI acquisitions.  Although several mouse fMRI research 
groups have brought up the need to standardize the acquisition, preprocessing and analyses 
methods (58, 115, 123), fMRI data is inherently difficult to compare or replicate between centers 
due to huge differences in the field strengths of MRI scanners, equipment (e.g. gradients and 
coils), acquisition sequences, use of contrast-enhancement, use of sedatives with or without 
mechanical ventilation or awake conditions, and pre-processing methods (e.g. global-signal 
regression).  Such large discrepancies in the collection of mouse fMRI data and analysis have 
stark consequences on the interpretation and reproducibility of results—showing inconsistencies 
among intrinsic connectivity networks (58, 59, 110, 113, 115, 124-128).  Although a number of 
MRI pipelines exist to help researchers automate the pre-processing steps to standardize and 
clean mouse fMRI scans (108, 118, 119, 129-132), we developed our own pipeline solely 
focused on the study of intrinsic connectivity networks in mice with a high degree of flexibility 
in the input fMRI datasets utilized.  Furthermore, to promote the standardization of a common 
orientation and template space in mouse fMRI data processing, we generated a series of 
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functional atlases for spatial normalization into the Allen Mouse Common Coordinate 
Framework (1). 
OPTIMIZING THE ACQUISITION CONDITIONS TO PRESERVE 
NEUROTRANSMISSION 
One major difference between fMRI acquisitions in humans and mice, are that mice are 
typically administered anesthetics to induce ataxia in order to reduce motion and prevent stress-
related alteration in brain activity and physiological responses (133-135).  Though fMRI studies 
have been performed on awake mice (133, 135-140), the extent of how successful habituation 
can extinct restraint- and noise-related stress and fear behavior during fMRI imaging remains to 
be thoroughly evaluated.  For instance, one fMRI study in awake rats found that even though 
stress-related serum levels of corticosterone were reduced to near baseline levels after 8-10 days 
of habituation to restraint- and noise-related stressors using a mock MRI scanner, corticosterone 
levels were found to be significantly elevated following an actual fMRI scan (141).  This 
suggests exposure to high-magnetic fields or sound frequencies beyond the range of human 
hearing—which is typically the cutoff range in most commercial microphones and speaker 
systems—may also be stressors that should be considered while designing appropriate 
habituation paradigms for awake mouse fMRI studies. Furthermore, fMRI habituation in rats has 
also shown long-term rewiring of fear and pain circuits (142).  The transition into awake mouse 
fMRI is likely the only way to approximate human fMRI conditions and avoid disruptions of 
intrinsic connectivity networks that produce non-physiological brain states that appear to be 
somewhere between ‘deep, non-REM sleep’ (143) and a ‘temporary coma’ (144).  Moreover, 
mouse models of human neurological disorders rely on behavioral phenotypes observed during 
awake conditions to assess the extent of network associated pathologies—which has recently 
been carried out successfully with an MRI scanner in a mouse model of autism (140).  Yet, more 
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work needs to be done to accurately bridge the translation between humans and mice. Today, 
awake mouse fMRI studies only account for a tiny portion of the published studies, thus we 
focused our efforts on an anesthetized fMRI acquisition protocol. 
Although intrinsic connectivity networks have been detected in humans during sedation, 
sleep and in patients with non-vegetative state comas (145), the very nature of anesthetics is to 
dose-dependently depress neuronal activity. There are three classes of anesthetics used in mouse 
fMRI studies.  The first class are GABAA receptor agonists, which enhance inhibitory 
neurotransmission of GABA in the brain and spinal cord by binding to the allosteric 
benzodiazepine site on GABAA receptors to systemically inhibit excitatory neurotransmission 
throughout the brain (95). The second class are α2-Adrenergic receptor agonist, which 
suppresses firing of noradrenergic neurons of the Locus Coeruleus and induces auto-receptor-
mediated suppression of vesicular NE release which disinhibits sleep-promoting neurons to 
induce sleep (95). The third class are NMDA receptor antagonists, which induce dissociative 
anesthesia that is associated with hallucinations, yet is commonly used in rodent surgery since it 
does not depresses breathing, body temperature or circulation in the same way as other 
anesthetics (95).  The key challenge of anesthetics is to optimize a low-dose regime of either a 
single or dual-anesthetics to minimally impairs physiological parameters (e.g. respiration rate, 
heart rate, blood pressure), neurotransmission, FC and hemodynamic responses to NVC in order 
to preserve intrinsic connectivity networks that approximate those detected in awake human 
subjects. To achieve this, it is imperative that anesthetized mice undergo rapid preparation and 
achieve stable physiology as quickly as possible after anesthesia induction. 
Several labs use paralytics to eliminate movement in intubated mice while simultaneous 
controlling physiological parameters—allowing researchers to reduce the respiration rate of mice 
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while maintaining high blood oxygen saturation to further reduce nuisance variables during 
acquisitions.  We wanted to generate a protocol that was widely accessible to general imaging 
community without the need for extensive animal protocol justification or U.S. Drug 
Enforcement Agency licensing issues, thus we focused our efforts on detecting intrinsic 
connectivity networks solely under the inhaled GABAA receptor agonists isoflurane. 
 
OPTIMIZING THE fMRI ACQUISITION PROTOCOL 
The most popular acquisition protocols for fMRI in mice are the rapidly acquired echo 
planar imaging (PI) sequences known as spin echo EPI (SE-EPI), which is generated by pairs of 
radiofrequency (RF) pulses, and gradient echo EPI (GRE-EPI), which is generated by pre-
phasing gradient used to refocus the spins to generate echos.  This relatively fast acquisition 
speed is required to capture the hemodynamic response function (HRF) time course which have a 
typical lag time of 1.8-2.3 sec following an evoked excitatory neuronal event (27). Thus 
acquisitions protocols with faster repetition times (~1-2 sec) can better estimate the HRF with 
greater statistical power.  In exchange for their rapid temporal resolution, EPI sequences in mice 
are prone to severe susceptibility artifacts since they are acquired with high field strengths at 
high spatial resolutions resulting in large local field inhomogeneities caused by magnetic 
susceptibility differences in different brain tissues (146).  Consequently, mouse EPI scans suffer 
from distortion in the spatial encoding of the signal, which results in images that are stretched, 
compressed or suffer from severe signal degradation particularly around air-tissue interfaces near 
nasal, mouth and ear cavities (147).  Although EPI images can be warped to address spatial 
distortions, one technical limitation is due to the difficulty in post-acquisition corrections to 
recover lost data voxels associated with susceptibility artifacts or signal drop out.  Instead, 
acquisition methods that adjust slice tilt, phase-encoding direction and shim using several first- 
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and second-order gradients shims have been shown to drastically improve EPI image quality in 
mouse fMRI scans (148).  
Most mouse fMRI studies are performed using EPI protocols that selectively enhance the 
endogenous BOLD contrast that measures neuronal activation as changes in the concentration of 
deoxy-Hb in the local venous blood pool to alter T2* signal intensity detected at BOLD-weighted 
TE of ~15 ms at high magnetic field.  Typical maximal percent BOLD changes in mouse fMRI 
range 1-1.5% in spontaneous fluctuation  and as much as ~3% in stimulus-evoked brain 
activation (149).  To further boost T2* signal intensity amplitude, an injected intravascular iron-
oxide nanoparticle contrast agent can be used to measure luminal volume changes in arterioles 
and capillaries as they constrict and dilate in response to localized neuronal activity changes.  
This method, termed CBV-weighted fMRI detected T2* signal intensity changes at the contrast-
weighted TE of ~8.6 ms.  Some major advantages of performing CBV-weighted fMRI in mouse 
is that the onset of stimulus-evoked neuronal activity as detected by CBV has been shown to be 
nearly instantaneous with significantly higher amplitudes with narrower dispersion that are more 
spatially restricted compared to BOLD (149)—enhancing the overall signal-to-noise ratio.  
Typical maximal percent CBV changes in mouse fMRI range 5-12% in spontaneous fluctuation 
and as much as ~25% in stimulus-evoked brain activation (149). 
To optimize our mouse fMRI acquisition protocol, we first compiled all the known BOLD- 
and CBV-weight fMRI acquisition sequences used on ultra-high field (>7T) mouse fMRI 
studies. Using of a variation on these parameters, constrained by hardware limitations our Bruker 
9.4 Tesla scanner, we performed several BOLD- and CBV-weight fMRI acquisitions ranging 
from 1-3 seconds per scan and analyzed the data looking for optimal quality control variables.  
Our objective was to design an isotropic acquisition protocol that encompassed the entire brain 
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and was versatile enough to be used for both BOLD- or CBV-weighted fMRI acquisition with all 
the same parameter with exception to the TE. 
To compare the performance of each acquisition protocol we used several fMRI 
acquisition quality assessment measurements employed by the Human Connectome Project (150) 
and MRIQC (151) to determine whether difference in imaging hardware, imaging protocols, 
acquisition sequences or reconstruction algorithms in fMRI data result in different signal 
distributions—thus not allowing appropriate statistical comparisons among datasets. We first 
measured SNR, which we defined as the mean signal intensity measure in a region of interest 
within the brain divided by the standard deviation of the signal intensity in a region of interest in 
a non-tissue air compartment outside the head that should represent the variance in background 
noise (i.e. system or thermal noise). Though SNR in fMRI data can be improved linearly with 
greater field strength and by using cryogenic receiver coils, varying imaging parameters that 
influence background noise such as field of view and slice thickness can vastly improve fMRI 
data SNR within a specific MRI scanner setup (152, 153). Therefore, acquisition protocols with 
higher SNR values were preferentially selected.  It should be noted that although background 
noise is dispersed throughout the entire fMRI dataset, improving SNR has no influence on 
physiological noise that stems from nuisance variables such as cardiac and respiratory pulsations 
and head motion in mice.  
Next, since fMRI studies attempt to detect miniscule fluctuations in signal intensity 
changes over time, a static SNR measurement might not be sufficiently suitable to assess the 
quality of the acquisition protocol (154). Therefore, we determined the optimal protocol by 
considering temporal SNR (tSNR) which we define as a voxelwise mean signal intensity 
measure over time divided by the temporal standard deviation map.  As with SNR, the higher the 
31 
tSNR, the better the data quality.  Since this is a voxelwise method, tSNR is known to be 
spatially inhomogeneous showing variance among different brain regions likely due to proximity 
of receiver coil to the imaged tissue, the presence of large vessels or the proximity to signal 
dropout regions near air-tissue interfaces.  Thus, a three-dimensional tSNR map of the brain was 
generated for each acquisition method and an averaged tSNR value was calculated for the whole 
brain for easy comparison among methods.  We also considered global correlation (GCOR) 
which calculates the average voxelwise correlation over all possible combinations of voxels in a 
given time series (155). Similar to tSNR, which is also a voxelwise method, GCOR is also 
spatially inhomogeneous whereby non-brain regions have low global correlations compared to 
brain regions that correlated with many voxels within the brain. This method produces a three-
dimensional GCOR map of the brain and an averaged GCOR value can be calculated for the 
whole brain to assess the difference among the acquisition methods.  As with SNR and tSNR, the 
higher the GCOR score the better the data quality.   
Lastly, since background noise tends to be Gaussian in distribution, we mapped skewness 
and kurtosis of the fMRI time series to capture non-Gaussian noise also known as artifact-
induced noise.  This noise typically reflects ghosting artifacts and phase-encoding errors usually 
results in regions with negative kurtosis values.  When overlapped with skewness, regions with 
negative kurtosis values will also have non-zero skewness values in either the negative or 
positive directions. The presence of non-Gaussian noise, detected using both kurtosis and 
skewness maps, were used to exclude acquisition sequence parameters to minimize ghosting 
artifacts and phase-encoding errors that cannot be corrected using data processing techniques.  It 
should be noted that selecting the optimal sequence optimization variables can be somewhat 
subjective—for instance trading reduced signal-to-noise for greater acquisition speeds may 
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reveal distinct networks than that of a method that utilizes slow acquisition speeds with higher 
signal-to-noise.  Alternatively, methods that have higher spatial resolution may have lower 
contrast signal intensity—thus yielding lower signal amplitudes.     
Using variable such as temporal and spatial signal-to-noise ratio, signal-to-contrast ratio, 
distortion correction, signal drift correction, mean framewise displacement, excluded frames, 
DVARS, CVAR, GCOR we evaluated the fidelity of each fMRI scan to determine the optimal 
acquisition parameters.  Our optimal protocol acquires the entire mouse brain in isotropic 
resolution—whereby each voxel has the same dimensional size—with the in-plane spatial 
resolution of this protocol is 300 µm3 with a total acquisition time of 2 seconds per volume.   
 
MOUSE fMRI PRE-PROCESSING PIPELINE 
Pre-processing fMRI data is a term used to describe the steps taken to normalize the data 
among all study subjects to ensure consistency in comparisons and to extract fMRI signal while 
reducing noise signals from nuisance variable in order to prepare the data for statistical analysis. 
Pre-processing includes methods that correct or adjust fMRI data to take account of time 
differences between acquiring each image slice (i.e. slice-time correction), correct for head 
motion during scanning (i.e. motion correction), to detect ‘artifacts’– anomalous measurements – 
that should be excluded from subsequent analysis; to align the functional images with the 
reference structural image, and to normalize the data into a standard space so that data can be 
compared among several subjects and to apply filtering to the image to increase the SNR. Figure 
2.1 gives a brief outline of our mouse fMRI pipeline.  
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Figure 2.1 Pre-processing pipeline showing the semi-automated steps implement to correct and warp images into a 
common coordinate framework for fMRI analysis. 
 
Bruker to NIfTI data handler 
A data handler termed BrkRaw was developed in order to convert raw Bruker data and 
their headers into single compressed Neuroimaging Informatics Technology Initiative (NIfTI; 
(156)) format files and reconstructs them using absolute range and reorients them into RAS 
orientation to match the template space of the Allen Mouse Brain Atlas.   Additionally, BrkRaw 
sifts through the headers of all the MRI scans acquired during a given session and organizes 
them using Brain Imaging Data Structure (BIDS; (157)) by creating a folder for each subject 
(e.g. sub-01, sub-02, etc.) and within each of these folders sorts the data into three subfolders: 
‘anat’—for anatomical sequences that include T1, T2-weighted RARE, T2*-weighted FLASH; 
‘func’—for fMRI sequences that include spin-echo EPI, gradient-echo EPI, or multi-echo EPI; or 
‘misc’—for all other sequences including ultrashort echo time (UTE), zero echo time (ZTE), 
diffusion tensor imaging (DTI) and susceptibility weighted imaging (SWI).  The BIDS structure 
used is widely accepted by the functional neuroimaging community as the gold standard for data 
organization and storage for repository databases such as OpenNeuro or OpenfMRI. Though 
other data handlers have been developed for rodent imaging (130, 131, 158), one advantage to 
our handler is that the code (https://github.com/BrkRaw/bruker) can be easily imported into high-
level python API to be implemented with nibabel or SimpleITK. 
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Slice-Time Correction 
EPI acquisitions in mice typically takes between 1-3 seconds depending on the gradient 
duty cycle and number of acquired slices. Regardless of the order by which the slices are 
acquired, most acquisition protocols have an offset temporal delays accumulate between the first 
slice until the last slice.  Slice-time correction is a technique that interpolating the temporal 
offsets between slices to a reference time point so that each acquired temporal volume 
approximates an acquisition of the whole brain at a single time point. In mouse fMRI, slices are 
typically acquired in an interleaved, ascending pattern whereby every other slices beginning at 
the bottom of the brain are acquired and the skipped slices are acquired later in order (Figure 
2.2) to allow for partially excited spins in adjacent slices to return to equilibrium to eliminate 
radio frequency pulse excitation leakage artifacts.  This technique has been shown to 
significantly increase the statistical power in fMRI studies with TRs of 2 seconds or longer, 
particularly in the dorsal regions of the brain (159). Though several slice-time correction codes 
exist and have been successfully implement on mouse fMRI data such as slicetimer (FSL) and 
spm_slice_timing (SPM), our pipeline utilizes 3dTshift (AFNI). 
 




Rigid-Body Motion Correction 
Motion correction, also known as time series realignment or rigid-body transformation, is a 
technique that corrects for head motion during fMRI acquisitions. The slightest movements can 
alter voxel locations that may result in spurious correlations if uncorrected.   Motion correction 
techniques aligns each acquired volume in the time series to a single reference volume. Although 
some groups use a mean image of the time series as the references volume, our workflow utilizes 
the tenth volume of every time series.  Though several motion correction codes exist and have 
been successfully implemented on mouse fMRI data such as MCFLIRT (FSL), spm_realign 
(SPM) and antsBrainRegistration / antsMotionCorr (ANTs), our pipeline utilizes 3dvolreg 
(AFNI) since it has proven to be successful at motion correcting mouse fMRI data even among 
subjects with abnormally high MION-dosages that result in severe brain feature loss.  AFNI’s 
3dvolreg performs motion correction using rigid-body transformation along the three translation 
movement directions of the X, Y, and Z axes and the three rotation movement directions 
centered at the X, Y, and Z axes—termed the roll, pitch and yaw, respectively.  Thus allowing 
volumes in a time series (t) to be moved to best align with the reference volume, but do not 
undergo warping. All six measures can be used to calculate a cumulative measure for each time 
point known as the frame-wise displacement (FWDt).   
 
𝐹𝑊𝐷& = 	 𝑅𝑜𝑙𝑙& + 𝑃𝑖𝑡𝑐ℎ& + 𝑌𝑎𝑤& + 𝑋& + 𝑌& + 𝑍&  
 
FWD serves as a quality assurance measure for subject specific fMRI scans since it 
determines displacement associated with head motion allowing for the rapid detection of high-
motion volumes present within a given scan time series (Figure 2.3).  Scans with temporal 
volumes where the FWD exceeds the in-plane resolution of a voxel should be excluded 
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altogether, while scans with FWD of half of in-plane resolution of a voxel can be labelled as 
confounder time points that can be excluded from later analyses or removed from the time series 
using a technique termed scrubbing (160). Though a combination of scrubbing and motion 
regression have been shown to produce the greatest reduction to motion-related artifacts (161), it 
is known that scrubbing alters the integrity of the data for fMRI analysis. 
 
 
Figure 2.3 Representative motion correction displacement plot with FWD for a mouse administered an amphetamine 
at 10 min of a 40 min CBV-weighted fMRI scan. 
 
Brain Segmentation 
Brain segmentation, also known as skull-stripping, is a method used to mask the brain in 
order to distinguish the voxels of the brain from those outside the brain. Most mouse fMRI 
pipelines generate their brain segmentation masks using high-resolution anatomical scans that 
are down-sampled and applied to isolate the brain on EPI sequences.  One common problem with 
this method, particularly due to the high susceptibility artifacts in mouse EPI sequences, is that 
anatomical and functional MRI sequences are prone to distinct distortions resulting in non-
overlapping brain structures that can erroneously exclude brain tissue while also including non-
brain tissue leading to a reduction in statistical power.  One strategy implements to address the 
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mismatch in the brain shape between anatomical and functional MRI sequences has been to 
acquire an addition 3D-EPI volume under the same shimming and B0 map corrections at slightly 
higher-resolution with average volumes allowing for better distinctions between brain and non-
brain tissues in mice (162).  Yet, one major issue with this method is the doubling workload 
since it requires brain segmentation masks for both high-resolution anatomical and 3D functional 
MRI images and an additional non-linear warping step to accurately warp subject-specific EPI 
images into their respective anatomical images before being warped again into the template 
space of a mouse atlas. We attempted a different strategy, focusing our efforts on building a tool 
that could perform automated brain segmentation of functional MRI sequences rather than 
anatomical sequences.  To do this, EPI time series were averaged to single volume and corrected 
for non-uniformities in image intensity that result from tissue penetrance-related magnetic field 
variations using N4BiasFieldCorrection (ANTs).  It should be noted that a group recently 
showed that bias-field correction using multiplicative intrinsic component optimization (MICO) 
resulted in better brain contrast homogeneity than the N4 technique in mouse anatomical and 
DTI images (130), but not functional scans. 
Although brain segmentation can be done manually or in a semi-automated manor using 
active contour segmentation tools in ITK-SNAP (163) to differentiate tissue boundaries using 
either thresholding, edge attraction, clustering or user-defined machine-learning classification 
methods, these strategies are still rather time consuming and labor intensive.  Thus the 
development of a fully-automated brain segmentation tools for mouse MRI studies was rather 
important.  Several fully-automated brain segmentation tools were created and implemented in 
mouse fMRI datasets with mixed accuracies include antsBrainExtraction.sh (ANTs), BET (FSL), 
3dSkullstrip (AFNI), MRTOOL (SPM), atlasBREX (164), PCNN brain extraction tool (165), 
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RATS (166) and SHERM (167). These tools were designed to be performed primarily on 
anatomical images and unlike the rat brain which is suspended in large volume of cerebral spinal 
fluid that forms a distinct boundary between the brain and the skull, the boundaries on 
anatomical scans of the mouse brain are far more diffuse, making it rather challenging for even 
the most sophisticated machine-learning brain segmentation methods to differentiate.  One major 
limitation of these brain segmentation tools is that their performances vary with contrast, proving 
challenging to accurate segment the brain in averaged, bias-field corrected fMRI images of the 
mouse. Our group developed a U-Net-based deep-learning skull stripping tool (Figure 2.4) that 
has been validated to accurately and precisely segment the mouse brain under a variety of MRI 
acquisition sequences (168).  Though the initial implementation of this method requires both 
training (i.e. images with accurate brain segmentation masks) and testing datasets (i.e. without 
mask), the accuracy and precision of this method continuous to improve with usage.   
 
Figure 2.4  U-Net architecture. Boxes represent cross-sections of square feature maps. Individual map dimensions 
indicated on lower left, and number of channels indicated below dimensions. The leftmost map is a 128 × 128 
normalized MRI image patched from the original MRI map, and the rightmost represents binary ring mask prediction. 
Red arrows represent operations, specified by the colored box, while black arrows represent copying skip connections. 
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Spatial Normalization 
Anatomical MRI images in mice typically undergo linear and non-linear warping, also 
known as spatial normalization, into the template space of an established anatomical mouse atlas 
with mask layers that represent fine anatomically-defined brain regions in accordance to the 
stereotaxic atlas developed by Paxinos and Franklin (169).  As neuroimaging laboratories rushed 
to develop the first generation of 3D mouse atlases with brain region masks (170-180) , limited 
consideration was taken to define a standard template space, left- or right-orientation and 
coordinate system for the mouse brain, resulting in labs with different atlas preferences that 
resulted in non-overlapping datasets which made the standardization of data untenable for multi-
center mouse fMRI databases (Figure 2.5).  To address this issue, the Allen Institute for Brain 
Science developed their own mouse atlas using serial two-photon tomography of near 1,700 mice 
and more importantly established the Mouse Common Coordinate Framework to allow 
researchers to overlap their data into the template space in order to standardize the digital 
coordinate space across mouse studies using many modalities The most recent version of the 
Allen Mouse Brain Atlas (v3) has an isotropic resolution of 10 µm atlas with 860 brain structure 
masks (1). Two recently developed mouse fMRI pipelines adopted the Allen Mouse Brain Atlas 
(130, 132), hopefully setting a precedence for standardization among the mouse fMRI 
community. One major advantage of the Mouse Common Coordinate Framework is the gene 
expression (181) and mouse connectome (4) data available via the Allen Mouse Brain API—
which has already been implemented by one mouse fMRI study to map receptor expression 
density on brain region masks (94). 
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Figure 2.5  Mouse atlases lacked a common coordinate space.  Template positioning of the AMBMC (green), Allen 
CCF (orange) and MAP2003 (blue) atlases are shown overlapped against one another.  Featured is the orientation of 
the Allen CCF (v3) atlas—also implemented in the development our own BOLD- and CBV-weighted fMRI atlases. 
 
Though our pipeline is versatile enough to warp anatomical scans into the Allen Mouse 
Brain Atlas template space, we developed it with the intention to directly warp functional scans 
that suffer from low spatial resolution with diminished brain feature detection that would make 
both linear and non-linear warping challenging for any software package. To address this issue, 
we generated a series of mouse fMRI atlases using averaged, bias-corrected single subject 
images for BOLD-weighted (n=29) and CBV-weighted (n=29) fMRI with the ANTs deformation 
template generator antsMultivariateTemplateConstruction2.sh to form averaged atlases for each 
fMRI acquisition method which resulted in functional atlases with significantly improved brain 
feature detection. These averaged functional mouse brain templates were then warped into the 
template space of the Allen Mouse Brain Atlas using antsRegistrationSyN.sh (ANTs) which 
perform both linear and non-linear warping, resulting in the generation of new functional 
templates aligned in the Mouse Common Coordinate Framework.  Among the linear and non-
linear warping packages, we found ANTs showed the best performance for warping functional 
mouse BOLD and CBV images compared to FNIRT (FSL), Normalize (SPM), and 3dAllineate / 
3dWarp / 3dQwarp (AFNI).  Linear affine transformation matrices, which unlike motion 
correction rigid-body transformation also perform zoom and shear transformations, and warp 
field maps generated by the antsRegistrationSyN.sh are applied to the entire functional time 
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series using WarpTimeSeriesImageMultiTransform (ANTs) to warp 4D EPI images into the 
template space of the Allen Mouse Brain Atlas.  Figure 2.6 shows the functional atlases derived 
from mouse BOLD-weighted and CBV-weighted fMRI warped into the Allen Mouse Brain Atlas 
template space. 
 
Figure 2.6 Using the template space of the Allen CCF (v3), we developed our own BOLD- and CBV-weighted fMRI 
atlases used for spatial normalization in our mouse fMRI pipeline. 
 
QUALITY CONTROL OF fMRI DATASETS 
Beyond being able to test the quality of each fMRI scan sequence, it is essential to assess 
intra-subject (e.g. for longitudinal studies), inter-subject (e.g. for cohort studies within the same 
populations) and intra-study (e.g. for distinct study populations) variance to measure the quality 
of each scan and unbiasedly determine whether it should be included, excluded, or re-run. 
Variability in movement and physiology of each subject can be likely attributed to subject-
specific differences in tolerances to anesthesia, FWD and dynamic variance (DVARS) are 
calculated and subjects with excessive motion and variance in more than 5% of all volumes are 
excluded from the study.  As mentioned earlier, FWD detects motion-related changes in time 
series volumes and if FWD exceeds the in-plane resolution of the study the entire scan is 
excluded altogether while displacement great than half of the in-plane resolution are tallied and 
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later scrubbed (along with the frames before and after) from the time series.  FWD are plotted as 
both absolute movement (relative to the central reference frame) and relative movement (relative 
to the preceding frame) to determine the duration of each movement. DVARs is a voxelwise 
method that indexes the root mean squared change of fMRI signals in successive image volumes 
across the all voxels of the brain in a time series (182) to measure dynamic changes in brain 
signal intensity (Figure 2.7). Large shifts in DVARS are thought to be attributed to movement 
(183) rather than spontaneous fMRI signal changes attributed to NVC, thus a mean DVARs time 
series can by calculated to determine the severity by which movement may have altered the 
integrity of the fMRI signal for every scan.  DVARS volumes greater than 0.5% in BOLD-fMRI 
scans and 4% in CBV-fMRI scans are flagged and tallied for QC evaluations.   
 
Figure 2.7  Illustration of motion parameters in the X, Y and Z plane as compared to voxelwise DVARs (each row 
represents a distinct voxel) and the mean DVARs for the entire volume as calculated by averaging the columns.  The 
line within the mean DVARs represents the cut-off threshold for movement and all volumes that fall outside this 
threshold can be counted for QC. 
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ESTABLISHING ANATOMICAL AND FUNCTIONAL SEGMENTATION MOUSE 
ATLASES FOR fMRI ANALYSIS 
Segmentation is a process to divide a brain into defined regions that represent some form of 
neurological unit. Historically, mouse fMRI segmentation was performed by using either 
coordinate-based seeds or ROI mask layers typically associate with anatomical mouse brain 
template to extract an fMRI signal—averaged from all voxel that form every seed or mask layer—
across different anatomical regions of the brain. Although many atlases such as the Allen Mouse 
Brain Atlas has extremely detailed region-of-interest mask layers that represent 860 brain 
structures and substructures, there is a sizeable mismatch between the in-plane resolutions of this 
atlas at 10 µm3 and pre-processed mouse fMRI datasets which range from 100-300 µm3.  Thus, 
anatomical segmentation in mouse fMRI studies typical only utilizes course brain structures masks 
and avoid finer substructure layers that may be composed of sub-voxel sized regions that may lead 
to erroneous findings. Although ROI segmentation can be performed using tools such as SPM’s 
Segmentation, FreeSurfer’s recon-all and FSL’s fslroi, our pipeline allows users to extract average 
signal traces from 44 course ROIs derived from the Allen Mouse Brain Atlas using AFNI’s 
3dROIstats tool (Figure 2.8).  
 
Figure 2.8 Fine brain substructure masks associated with the Allen Brain Atlas was consolidated into 44 course brain 
structure ROIs for anatomical ROI segmentation in our mouse pipeline. 
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Functional Parcellation Techniques 
A variety of data-driven functional parcellation techniques have emerged in recent years.  
Conventionally, these methods were developed to unbiasedly determine the voxels sharing similar 
spatiotemporal features while excluding all unrelated voxels, thus enhancing the statistic power of 
fMRI studies by reducing false positive (type I) errors.  One major strength of functional 
parcellation is that it can be performed using a concatenated dataset composed of a string of fMRI 
data collected across several subjects and thus can isolate group-specific features. Furthermore, 
since functional parcellation is not biased by established anatomical boundaries, it can discover 
new functionally defined brain regions (184) with no distinct anatomical divisions (i.e. hallmark 
tissue boundaries, cellular populations) by detecting functional clusters of voxels with similar 
functional activity to form functionally-defined brain regions. Data-driven functional parcellation 
methods can be classified as either unsupervised clustering or decomposition methods (185). 
 
Decomposition & Unsupervised Clustering Functional Segmentation Techniques 
Decomposition methods, used to reduce dimensionality, are the most popular method of 
functional parcellation of mouse ICNs since voxelwise analysis of resting state fMRI datasets 
have such high data sparsity due to their large dimensionality. Functional parcellation using 
features such as static or dynamic voxelwise FC changes is computationally burdensome, instead 
ICA decomposition was among the earliest functional parcellation techniques deployed and was 
instrumental in detecting the existence of ICNs.  
Independent Component Analysis parcellation.  ICA assumes a linear combination of 
statistically independent sources by sorting voxels by either minimizing mutual information 
between sources or maximizing their non-gaussianity. ICA can identify functional patterns as 
distinct superimposed linear spatial maps with their independent time course traces in fMRI 
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datasets.  These spatial maps are thought to either represent coherent functional networks or 
noise that can be regressed from the data as employed early in our pipeline through ICA 
denoising. Group-wise ICAs can be performed on multiple subjects by concatenated resting-state 
fMRI data sets along the temporal dimension before implementing ICA (186).  IC traces for each 
individual can be isolated and can undergo dual regression to generate individual IC maps to 
preserve statistical independence (187). Our pipeline runs two sets of ICA evaluating 
concatenated group-wise fMRI data for 20 and 100 ICs (Figure 2.9). 
 
 
Figure 2.9  Parcellation of the mouse brain into functionally distinct 100 ICs. 
 
 Unsupervised learning has been implemented in fMRI to untangle structure through 
isolating relevant ICN signals from noise. These methods are routinely used for functional brain 
parcellation into discrete functional structures with similar clustering patterns without any a 
priori anatomical structures. Given the voxelwise, hypothesis-free nature of fMRI datasets that 
contain complex network structures, one advantage of these methods are that they can be 
performed fairly rapidly. Alternately, unsupervised learning has also been successfully applied to 
unmask brain network dynamics—also known as co-activation patterns (CAPs)—that represent 
reoccurring transient activation/deactivation patterns among ICNs (188). Our pipeline uses two 
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major clustering techniques to further segment ICNs in mouse fMRI—K-means clustering and 
hierarchical clustering (Figure 2.10). 
 
Figure 2.10  Model of how the unsupervised clustering techniques in our pipeline are used for functional segmentation 
of mouse ICNs. 
 
K-means clustering.  By far the most popular clustering algorithm, this method partitions 
fMRI data into a user assigned number of distinct clusters (n) by plotting data in a multi-
dimensional space and determining n equidistantly spaced cluster centroids and iteratively 
assigning all data to its nearest cluster and continuously updating the cluster centroids with 
respect to all new assignments.  K-means clustering is versatile since it can be used for 
functional parcellation via the spatial domain of fMRI time series or by correlations in 
connectivity profiles allowing for the identification of reoccurring fMRI co-activation patterns.  
Hierarchical clustering.  This algorithm generates nested partitions that are compared 
iteratively to establish linkage criteria.  The Louvain method is an algorithm commonly used in 
fMRI to detect communities (i.e. module) within large-scale brain networks by recursively 
merging communities into a single node and running modularity clustering on those condensed 
graphs to evaluating how densely connected nodes within a community versus connections 
associated with a distinct network.  Using a multi-modal functional parcellation strategy, we ran 
the Louvain method on the parcellated 100 ICs of the mouse brain and pulled 20 modules.  Our 




Figure 2.11 The 100 ICs of the mouse brain were grouped into 20 functional modules that represent large-scale brain 
regions or networks previously established in neuroscience. 
 
AUTOMATED NETWORK ANALYSIS METHODS 
Functional segregation techniques 
Functional segregation methods are voxelwise techniques that split the brain into function-
specific brain regions.  Our pipeline implements two functional segregation methods, namely it 
measures the Amplitude of Low Frequency Fluctuations (ALFF) and regional homogeneity 
(ReHo).  These techniques provide different information on regional neural activity but cannot 
inform us about the functional connectivity between distant brain regions.  
Amplitude of Low Frequency Fluctuations.  ALFF performs a voxelwise measurement of 
the total power of the fMRI signal within 0.01-0.1 Hz frequencies.  Studies have shown that ALFF 
is proportional to regional brain activity, providing data about information flow with respect to all 
the voxels in the brain.  ALFF can also be displayed along the frequency domain to identify which 
frequency bands show the highest power amplitude. Frequency ranges between 0.010-0.027 Hz 
and 0.027-0.073 Hz preferentially isolated to brain activity in cortical structures and basal ganglial 
structures, respectively, whereas frequency ranges from 0.073-0.198 Hz are associated with 
physiologic noise (e.g. hearth rate, breathing, etc.).  ALFF shows exceptional test-retest reliability 
and is preserved among healthy subject, thus ALFF can quickly and reliably identify functional 
changes in intrinsic connectivity networks associated with altered information flow.  Our pipeline 
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has developed an ALFF atlas of the mouse brain (n=29) and performs group-wise statistical test 
to determine whether ALFF signals are within the standard deviation of the atlas. 
Regional Homogeneity.  ReHo performs voxelwise measurement to establish how correlated 
each voxels are with the most proximal 7 (only facewise neighbors), 19 (facewise and edgewise 
neighbors) or 27 (facewise, edgewise and nodewise neighbors) voxels as scored using the Kendall 
coefficient of concordance of the fMRI time series at each voxel. Studies have shown that ReHo 
inform us about the synchrony of adjacent regions—whereby high ReHo values, that range 
between 0 and 1, can inform us about brain regions that have high coherence and centrality among 
regional brain activity that typically equate to higher synchronized brain activity. ReHo also has 
extremely high test-retest reliability and is consistent among healthy subject, thus it can quickly 
and reliably identify functional changes in intrinsic connectivity networks associated with altered 
regional brain signal synchrony.  Like ALFF, since ReHo is a voxelwise method it does not require 
an a priori definition of brain structures and thus can provide hypothesis-free information about 
changes in regional brain activity. ALFF and ReHo maps can also be applied together to reveal 
brain regions that are not only active within the same time frequency domain but are also 
synchronously active with their neighboring voxels—likely attributed to the synchronous 
engagement of a large group of neurons. We have developed a ReHo atlas of the mouse brain 
(n=29) and our pipeline performs a group-wise statistical test to determine whether ReHo signals 
are within the standard deviation of the atlas (Figure 2.13). 
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Figure 2.12 ReHo atlas of the mouse brain. 
 
Functional integration techniques 
Although functional segregation techniques are fast and can provide a broad, hypothesis-
free overview of changes in local brain activity, our brain are far more complex and more aptly 
represent integrated network rather than isolated functional compartments. Several techniques 
have been developed to study functional integration or the functional connectivity between 
different brain regions.  Another way to interpret functional integration is that we want to 
investigate the transfer of information between different brain areas.  Our pipeline uses three 
functional segregation methods to assess changes in functional connectivity in the brain: functional 
connectivity density (FCD), degree centrality (DC) and functional connectivity (FC).   
Functional connectivity density. FCD is a voxelwise analysis that attempts to identify which 
voxels have the highest of connections with other voxel through functional connectivity analysis. 
FCD can determine the brain regions that serve as highly connected functional hubs. 
We have developed a FCD atlas of the mouse brain (n=29) using AFNI’s 3dLFCD code and our 
pipeline performs a group-wise statistical test to determine whether FCD signals are within the 
standard deviation of the atlas (Figure 2.14). 
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Figure 2.13 FCD atlas of the mouse brain. 
 
Degree Centrality. Degree centrality is a voxelwise measurement that calculates fMRI signal 
correlation between all voxel pairs in the brain and applies a sparsity threshold to exclude long-
range and spurious correlations resulting a DC map describe the number of short-range 
connections for each node—whereby nodes with higher centrality contribute more to the overall 
efficiency of the network. We have developed a DC atlas of the mouse brain (n=29) using AFNI’s 
3dDegreeCenrality code and our pipeline performs a group-wise statistical test to determine 
whether DC signals are within the standard deviation of the atlas (Figure 2.14). 
 
Figure 2.14 DC atlas of the mouse brain. 
 
Functional Connectivity. FC measures the correlation (i.e. degree of synchrony) between the 
fMRI time-series of two different brain regions at a time. The FC is mainly thought to be attributed 
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to anatomic connection such as neuronal fiber projections, it can also be indirectly correlated via 
an intermediate relay or a common source of input signals. Our pipeline is designed to utilize either 
the anatomical or functional segregation atlases to generate FC circos plots. 
 
SUMMARY 
 We developed a pipeline that automates the pre-processing mouse fMRI data sets.  Our 
unique modular setup of our pipeline allows users to input BOLD- or CBV-weighted mouse 
fMRI data and it is aligned and warped using our custom atlases that were designed to accurately 
overlay on top of the Allen Mouse Brain atlas (CCF v3).  Furthermore, several quality control 
measures were incorporated to unbiasedly assess the quality of each data set.  Lastly, our 
pipeline provides basic functional network analysis outputs to help users compare their data to 
established resting-state fMRI data from C57/Bl6J mouse controls.  The automated nature of this 
pipeline will further help mouse fMRI laboratories to standardize the orientation of their data 
into Allen Mouse Brain CCF and better assess their data quality with the intent of improving the 
rigor and reliability of mouse fMRI data.  
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CHAPTER 3: IMPROVING MOUSE fMRI SIGNAL WITH A HOMEMADE BLOOD 
POOL STABLE CARBOXYMETHYL-DEXTRAN COATED IRON OXIDE 
NANOPARTICLE (CION) CONTRAST AGENT 
INTRODUCTION 
Blood-oxygenation-level-dependent functional MRI (BOLD-fMRI) is among the most 
widely used noninvasive imaging modalities for functional brain mapping (189-196). This 
technique indirectly measures neuronal activity by detecting associated changes in regional 
blood oxygenation. In most cases, regional cerebral blood flow (CBF) increases adjacent to 
neuronal activity, resulting in a localized reduction of paramagnetic deoxyhemoglobin and 
subsequent enhancement of the BOLD-fMRI signal (191-193). Though BOLD-fMRI has 
become the cornerstone of brain mapping, this technique suffers from low specificity and 
sensitivity. In preclinical animal models, cerebral blood volume (CBV)-weighted fMRI enhanced 
by exogenous contrast agents is a more sensitive alternative to BOLD (197-200). Additionally, 
CBV represents direct physiological changes to vascular tone, making the metrics more easily 
interpretable. CBV-weighted fMRI has been used for robust functional neuronal circuit mapping 
in preclinical animal models (198, 201-208), surgical planning (209, 210), preoperative brain 
mapping in neurosurgical patients (211), clinical outcome assessment (212, 213) and preclinical 
development of new therapeutic agents for various brain diseases (214-216). As this technique is 
capable of normalizing relaxivity changes to derive percent CBV changes, the resulting values 
can be independent of magnetic field strength and echo time, permitting comparisons across 
various acquisition settings (198, 217-224). 
53 
The first-ever CBV-weighted fMRI study in human was conducted using serial injections of 
gadolinium chelate (195). Although this study demonstrated a significant task-induced 
vasodilation in primary visual cortex and set the tone for MR-based functional brain mapping, 
the rapid washout of contrast required repeated dosing and thus lacked the “steady-state” feature 
of other MRI intravascular contrast agents capable of  circulating for several hours ((225) see 
review in (198)). To date, most clinically-approved gadolinium-based contrast agents (GDCA) 
possess relatively short circulation half-life, which limits their use for repeated CBV 
measurements (195). In addition, GDCA have been associated with long-term toxicity in the 
kidneys and brain (226-229). Developments of MRI contrast agents based on superparmagnetic 
iron-oxide nanoparticles (SPION, mean hydrodynamic diameter > 50 nm) or ultrasmall 
superparamagnetic iron-oxide nanoparticles (USPION, mean hydrodynamic diameter ≤ 50 nm) 
have been increasingly used for diagnostic and theranostic (223, 226, 230-242). Careful 
manipulation of synthesis variables such as the size, magnetization and surface properties of 
SPION/USPION can be easily tailored to achieve longer intravascular half-life, higher MR 
sensitivity and better biocompatibility, as compared to commercially available GDCA. Typically 
composed of polymer-coated magnetite or maghemite nanocrystals, SPION and USPION-based 
nanoprobes can produce highly sensitive negative contrast via T2 and T2* shortening that are 
usually stronger than GDCA (238, 243) With GDCA and standard measurement conditions, 10-
100 µM concentrations are typically required for robust visualization in MRI whereas 
SPION/USPION based contrast agents are detectable at sub-micromolar concentrations (238). 
Unfortunately, except for Resovist® (FUJIFILM RI Farma Co., Ltd., Kyobashi, Tokyo, Japan) 
used for liver imaging in very few countries such as Japan , there currently remain no FDA-
approved iron-oxide contrasts for clinical MRI (244). Numerous first generation USPION 
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contrast agents such as Ferumoxtran-10 (Combidex®/Sinerem®), Feruglose (Clariscan™) or 
Supravist™ were withdrawn from the market following unfavorable safety profiles in phase II or 
III clinical trials (245).  
Recently, most CBV-MRI studies are conducted with Ferumoxytol (FerahemeTM), a second 
generation USPION manufactured by AMAG pharmaceuticals, Inc. This formulation is 
comprised of an aqueous colloidal suspension of USPION, coated with polyglucose sorbitol 
carboxymethyl ether (PSC, a carboxymethylated and reduced dextran composed of 20-22 
glucose units) and made isotonic with mannitol (246). Although Feraheme has been clinically 
accepted for the parenteral therapy of iron-deficiency anemia in adult patients with chronic 
kidney diseases (247-249), the FDA has not yet approved its use for MRI. Nevertheless, the long 
blood pool residence time of Feraheme has made it a preferred contrast agent for CBV mapping 
in a variety of preclinical models including rodents (232, 234, 250-256), rabbits (257-259), cats 
(260-262) and nonhuman primates (263-266). Feraheme has only been used in investigational 
‘off-label’ high resolution magnetic resonance angiography (267, 268), resting state fMRI (269) 
and steady-state CBV mapping  (212, 270, 271)in healthy human subjects or patients. Routine 
application of Feraheme in clinical and even preclinical settings is extremely challenging due to 
numerous reasons. Firstly, to ensure patient safety, many research and clinical institutes as well 
as regulatory agencies in different countries may require an investigational new drug application 
to be approved for any 'off-label' application of Feraheme (272, 273). Secondly, post marketing 
surveillance data has demonstrated the risk of serious and fatal hypersensitivity reactions 
including anaphylaxis in patients receiving Feraheme (274, 275). In 2010, Takeda 
Pharmaceuticals was granted the right to develop and commercialize Ferumoxytol outside the 
US and its territories including Switzerland and the European Union (EU) under the trade name 
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Rienso. Unfortunately, in 2015, the marketing authorization for Rienso was withdrawn in Europe 
at the mutual request of Takeda and AMAG pharmaceuticals due to commercial and regulatory 
reasons (246).    
The sudden unavailability of Feraheme outside the US led to the suspension of many CBV-
MRI studies across the globe.  Although some preclinical iron-oxide based nanoformulations are 
available in the market that could be used for CBV imaging, these formulations are relatively 
costly given that in vivo MRI studies require high contrast agent dosages (15-30 mg/kg) to 
produce robust effects (198, 201-208). Synthesizing a blood pool agent that simultaneously 
exhibit long shelf life, high T2 relaxivity and prolonged intravascular retention has proven 
challenging since in vivo efficacy and safety of nanoparticulate contrast agents depend on 
various parameters including size, magnetization, nature of surface functionality and polymer 
coverage on the surface of nanoparticles as well as their pharmacokinetics and bio-distribution 
following intravenous administration (276-278). In this study, we report a simple, one-pot recipe 
for the synthesis of Carboxymethyl-dextran coated Iron Oxide Nanoparticles, termed “CION”, 
for reliable, preclinical MRI applications. We demonstrate methods to 1) tailor the material and 
pharmacokinetic properties of CION according to specific imaging requirements; 2) validate 
their suitability for various in vivo applications including high resolution micro-magnetic 
resonance angiography (µMRA) (steady-state CBV assessment), and stimulus-evoked CBV-
fMRI; 3) evaluate their toxicity in vivo; and 4) conjugate CION with a fluorescent dye for cross-
modality imaging. We have compared and validated our results against Feraheme. At the time of 
preparation of this manuscript, the cost of all equipment needed to perform in-house CION 
synthesis was ~ $3,000 USD and the supplies/reagents needed to synthesize a batch of 150 ml of 
20 mg Fe/ml CION is ~ $330 USD. The ease of production and cost-effectiveness of this CION 
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synthesis protocol should make CBV-MRI platform openly accessible and affordable to all 
preclinical MRI research laboratories.  
 
MATERIALS AND METHODS  
CION synthesis 
We synthesized CION using controlled, alkali-mediated co-precipitation of iron (III) chloride 
hexahydrate (FeCl3.6H2O) and ammonium iron (II) sulfate [FeSO4. (NH4)2SO4.24 H2O] in 
presence of Carboxymethyl-dextran (CMD) Sodium Salt (average molecular weight 10-20 KD) 
(Figure 3.1). All equipment, reagents/chemicals and laboratory supplies required for CION 
synthesis including their corresponding sources and tentative cost have been listed in Table S3.1.  
In order to determine the effect of reaction variables on the physicochemical and 
pharmacokinetic (PK) properties of CION, we initially prepared several formulations with varied 
stoichiometric ratio of CMD and iron-precursors. These compositions are designated as 
CION120000, CION60000, CION30000, CION17143 and CION12000, where the numbers in subscript 
represents the theoretical molar ratio of total iron precursor to polymer used for the synthesis, 
considering the molecular weight of CMD to be 10 KD. Among these, we selected three 
compositions to illustrate how the MR relaxivity and PK properties of CION are adjustable by 
changing reaction variables.  Our step-by-step synthesis are described as follows and further 
illustrated in Figure 3.1.   
1. Dissolve FeCl3. 6H2O (4 mmol) and (NH4)2Fe(SO4)2.6H2O (2 mmol) in 20 ml of de-
ionized water deoxygenated via thermo-mechanical degasification prior to addition of the 
reagents. Stir the resulting solution at 800-1000 rpm and 80-90˚C in a 250 ml beaker.   
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2. To synthesize CION60000, CION17143 and CION12000, dissolve 1, 3.5 and 5 g of CMD 
respectively in minimum volume of de-ionized water. Add the resultant solution slowly to 
the mixture of ferric and ferrous salt solution.  
3. Initially, an orange precipitate would be observed, which would dissolve following the 
addition of 30% aqueous ammonia. Keep adding ammonia solution until all the precipitate 
dissolve and a silky, black colloid is obtained.  
4. Add a Phosphate Buffered Saline (PBS) tablet to the resultant colloid for tonicity 
adjustment and stir the mixture for additional 3h at 80˚C to complete the nucleation and 
growth of nanoparticles.   
5. Thereafter, cool the reaction mixture and centrifuge at 4000 rpm for 30 min in-order to 
facilitate separation of unreacted precursors and/or bigger particles, if any.  
6. Transfer the nanoparticle solution to a Slide-A-LyzerTM dialysis cassette/flask (Molecular 
weight cut-off: 20 KD) and dialyze against PBS. Replace the dialysis media with fresh PBS 
every 2h. After 24h, transfer the colloidal suspension to a beaker and concentrate by 
evaporation on a hot plate at 40˚C.  
7. Adjust the final volume to approximately 20 mg Fe/ml theoretical concentration. Caution: 
Give special attention to the reaction mixture as soon as the volume reaches close to 15 mg 
Fe/ml to avoid gelling.  
8. Sterilize the resultant colloid by passing through 0.2 µm PTFE syringe filters.  
9. Transfer the final sterile solution was to a sterile vial. 





Validation of CION  
Physicochemical Characterization. To demonstrate the physicochemical properties of 
CION resulting from the above-mentioned one-pot synthesis protocol, we provide 
characterization data using procedures detailed below.  
Iron concentration. Iron (Fe) concentration per milliliter (ml) for every synthesized 
batch of CION were determined using inductively coupled plasma mass spectrometry (ICP-MS) 
with a Nexion 300D ICP-MS equipped with collision cell and autosampler. Samples for ICP-MS 
analysis were directly submitted to the Nanomedicines Characterization Core Facility at the 
University of North Carolina (UNC) at Chapel Hill. To determine iron concentration per unit 
volume of the colloidal sample, a given volume of CION (50-100 µl) was digested with a given 
volume of concentrated nitric acid. Thereafter, a small portion of this digested sample was 
transferred to de-ionized water. ICP-MS data was acquired after further diluting this sample with 
DI water. Iron concentration in the analyte was determined by running a calibration curve with a 
known concentration of Fe. The intensity of the 57Fe isotope was considered for quantification of 
Fe concentration. ICP-MS data was reported as concentration in ppb, which was converted into 
mg/ml and multiplied with total dilution factor to determine the amount of Fe present per unit 
volume of the contrast agent.  
Size and morphology. The size and morphology of nanoparticles were examined using a 
JEOL 2010F FAsTEM, a high-resolution transmission electron microscope (HRTEM) equipped 
with a 2KX2K Gatan CCD bottom mount camera and electron dispersive X-ray (EDX) 
attachment. The TEM samples were prepared by depositing a few drops of the respective 
nanoparticle preparations ultrasonically dispersed in water for 2 min on separate carbon-coated 
copper grids and air-dried at room temperature. An acceleration voltage of 200 kV and variable 
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magnification (20kX- 500kX) were used for imaging the samples. The hydrodynamic diameter 
(z-average) and polydispersity index (PDI) of the formulations were determined by dynamic 
light scattering (DLS) using a Malvern Zetasizer (Malvern Instruments, Malvern, UK). 
Hydrodynamic diameter measurements were performed in clear, disposable zeta cells, after 
diluting 1 µl of CION with 999 µl of DI water. Each sample was analyzed three times for a total 
period of analysis of 10 min.  Samples with visible aggregation were not subjected to TEM or 
DLS analysis. Only nanoparticle preparations that were stable in physiologically compatible 
buffers at high concentrations (> 5 mg Fe/ml) for at least a week were characterized.  
Surface chemistry and composition. The surface chemistry of CION was studied using 
attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy using a Thermo 
Nicolet Nexux FTIR model 870 spectrometer.  Measurements were done with colloidal samples. 
The surface composition of different CION preparations were obtained by X-ray photoelectron 
spectroscopy (XPS) using Al Kα excitation source in a Kratos Axis Ultra DLD X-ray 
Photoelectron Spectrometer with a base pressure of ca. 6 ×10-9 torr. Pass energies of 80 eV and 
20 eV were used for survey and high-resolution scans, respectively. Atomic concentrations were 
determined in the Kratos Vision software. Shirley backgrounds were used and the software 
calculated the area under each peak.  Relative sensitivity factors were used to determine atomic 
concentrations using the Kratos Vision software.   
 
MRI 
Equipment. All MRI studies were conducted using a Bruker 9.4 T/30-cm bore small 
animal MRI system. In vitro relaxometry studies were performed with a home-made sample 
holder and a quadrature transceiver volume coil with 35 mm diameter. For in vivo rat MRI 
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studies, animals were affixed on a home-made, custom-built holder and headpiece equipped with 
ear and tooth bars to minimize motion artifacts during imaging. A home-made surface coil 
(internal diameter ~1.6 cm) was placed directly over the head of the subject and used as a RF 
transceiver. Mouse imaging was performed on a commercial mouse holder using a 72 mm quad-
transmit only volume coil and a quad-receive only mouse brain coil.   
Animals. All in vivo MRI studies and surgical procedures were conducted in accordance 
with the Guide for the Care and Use of Laboratory Animals, as adopted by the National Institutes 
of Health, and approved by UNC IACUC. Pharmacokinetic profile of different CION 
formulations as well as the suitability of CION17143 for CBV-fMRI and multimodal applications 
were assessed on adult Sprague Dawley (SD) rats between 400-500 g weight (n = 20). The 
efficacy of CION17143 as a µMRA contrast agent and its toxicity evaluation compared to 
Feraheme were tested on adult C57BL/6J mice (n = 11) between 26-32 g of weight.  
In vitro Relaxometry. Relaxometry of CION60000, CION17143 and CION12000 and 
Feraheme were evaluated in vitro with a custom-designed sample holder (Figure 3A) securing 
the samples in the volume coil. The samples tested were serially diluted and placed into a 1 ml 
syringe. From each test sample, we prepared 7 different Fe concentrations: 0 (saline), 3.48746E-
06, 6.97491E-06, 1.74373E-05, 3.48746E-05, 6.97491E-05 and 0.000174373 M. T1-T2 maps of 
these phantoms were acquired using a standard spin-echo sequence featuring multiple repetition 
time (TR: 5000, 3000, 1500, 800, 400 and 200 ms) and echo time (TE: 11, 33, 55, 77 and 99 ms) 
with acquisition matrix of 256x256, field of view (FOV) of 40 mm2, slice thickness of 1 mm, and 
3 averages.  
Pharmacokinetic MRI. For pharmacokinetic (PK) assessment, each rat was anesthetized 
with urethane (1.3 g/kg) prior to experimentation. Throughout the experiment, heart rate and 
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oxygen saturation (SpO2) were continuously monitored using a non-invasive physiological 
monitoring system equipped with MR-compatible sensors and maintained within normal ranges 
(300-350 bpm and above 96%, respectively).  Warm-water circulating pads were used to 
maintain rectal temperatures at 37±0.5°C. After initial positioning and pre-scan adjustments, 
magnetic field homogeneity was optimized using Bruker FASTMAP shimming up to second 
order with an isotropic 7 mm3 voxel encompassing the imaging slices. A fast-spin-echo T2-
weighted image was taken in the mid-sagittal plane to localize the anatomical position by 
identifying the anterior commissure at 0.36 mm posterior to bregma.  For PK assessment, we 
used a single shot gradient-echo (GE) echo-planar-imaging (EPI) sequence with acquisition 
matrix =80 x 80, FOV= 2.56 x 2.56 cm2, slice thickness= 1 mm, spectral bandwidth = 250 kHz, 
TR = 1000 ms, TE = 8.3 ms. To ensure consistency of the imaging location, 8 coronal slices 
were acquired with the fourth anterior slice aligned with the anterior commissure. To monitor the 
clearance of CION from cerebrovasculature, EPI data was continuously acquired for 260 min 
and animals were intravenously injected with CION60000 (n=2), CION17143 (n=5), CION12000 (n=3) 
and Feraheme (n=3) at a dose of 30 mg Fe/kg through a tail vein catheter at 20 min after scan 
onset.  
In vivo fMRI applications. Among all the CION formulations, only CION17143 presented 
optimal physicochemical and pharmacokinetic properties for long-term vascular imaging 
applications (See Results and Discussions for details). To further verify if CION17143 offers 
robust contrast for dynamic CBV-fMRI study, we performed several fMRI experiments 
including gas challenge, visual stimulation, and optogenetic stimulation in adult SD rats. As 
well-established procedures with well-documented biological outcomes (200, 260, 279-289), 
these studies were not designed to address any specific biological or neural circuit related 
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questions, but rather focused on demonstrating the utilization of CION for these experiments (n= 
1 or 2 for each study). Animal preparations were similar to those recently published (203, 204, 
290-292). Briefly, each rat was endotracheally intubated and ventilated with 1-1.5% isoflurane in 
medical air using a small animal ventilator (CWE Inc., SAR-830/PA, Armore, PA). Ventilation 
rate and volume were adjusted as required to maintain EtCO2 within a range of 2.6-3.2% and 
SpO2 above 96%. All other experimental protocols including animal monitoring, physiology 
maintenance, imaging hardware and pulse sequences were described in the PK measurement 
section. During all fMRI experiments, a cocktail of dexmedetomidine (0.1 mg/kg/hr) and 
pancuronium bromide (1.0 mg/kg/hr) were infused intraperitoneally to the animals. The level of 
isoflurane anesthesia was lowered to 0.5% at 30 min after the start of infusion (293). All CBV-
weighted fMRI responses were measured by injecting a bolus dose of CION (20 mg Fe/kg) via a 
tail vein catheter. Specifically, these experiments include:  
▪ Hypercapnia-evoked fMRI with CION17143. To evaluate the effect of hypercapnia on 
steady-state CBV, animals were exposed to 5% CO2 (in 95% air) challenge using a 180 s 
OFF, 180 s ON, and 360 s OFF paradigm post-CION injection.  
 
▪ Visual stimulation-evoked fMRI with CION17143. To evaluate the effect of visual 
stimulation, animals were exposed to 10 Hz blue light visual stimuli using a 40 s OFF, 10 s 
ON, and 40 s OFF paradigm repeating 8 times in a post-CION injection scan.   
 
▪ Optogenetic fMRI with CION17143. To stimulate pyramidal neurons in the motor cortex 
(M1), rats were microinjected with 1 µl of purified and concentrated adeno-associated virus 
(~1012 infections units per ml, packaged by the UNC Vector Core Facility) encoding 
channelrhodopsin-2 (ChR2) under Ca2+/calmodulin-dependent protein kinase II promoter 
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(CaMKIIα) and an enhanced yellow fluorescent protein (EYFP), or sham vector controls that 
do not express ChR2 (n=2 each). Injection coordinate from bregma were anterior/posterior 
(AP): +3 mm, medial/lateral (ML): ±2.5 mm, and dorsal/ventral (DV): -1.5 mm. A control 
vector was injected into the M1 of the contralateral hemisphere. A 26-gauge injection needle 
connected to a 2 µl Hamilton syringe was used; each microinjection was performed over 10 
min followed by another 10 min to allow diffusion of viral particles away from the injection 
site. After virus injection, chronic optical fibers were stereotactically implanted directly over 
the site of virus injection (DV: -1.0 mm) for light delivery. The time from virus injection to 
the start of the MRI experiments was 4-5 weeks. Before sending the animals inside the 
magnet, optical fibers were connected via 3-m patch cables to a solid-state laser (473 nm 
wavelength) located outside of the magnet room delivering ~10 mW light to virus-transfected 
region. We acquired stimulus-evoked fMRI data for 100 s during which light stimulation was 
applied in a 20 s OFF, 10 s ON, 30 s OFF, 10 s ON, and 30 s OFF paradigm. All subjects 
underwent 2-5 repeated trials at 40 Hz and 5 ms pulse width.  
 
High resolution µMRA. CION17143-enhanced FLASH MR micro-angiography acquisition 
was used to generate a 3D map of the cerebrovasculature with a spatial resolution of 50 µm3. 
Three repetition scans were corrected for spatial drift and averaged to improve SNR and skull-
stripped. The final image was processed and displayed using Amira (FE1, V5.3.3 or Avizo 
software, TGS, San Diego, CA, USA) by masking only the brain and superficial blood vessels on 
the Amira segmentation editor and overlaying this 3D-rendering of the cerebrovasculature data 




To demonstrate the utility of CION platform for cross-modality application, we conjugated 
CION with a red-fluorescent dye, Rhodamine B (Laser Grade, +99%, ACROS Organics™). 
Rhodamine B is widely used in CBV measurement with two-photon microscopy (294, 295). 
Rhodamine B is usually conjugated with the antibiofouling polymer Dextran to prevent rapid 
bloodstream clearance. In this study, we conjugated Rhodamine B with CION with instead of 
Dextran, which not only endowed additional stability to the dye for optical measurements of 
local CBV with high temporal resolution (> 10 Hz), but also enabled brain-wide CBV mapping 
using simultaneous fMRI. Additionally, Rhodamine B can be measured simultaneously with a 
genetically encoded green fluorescent calcium indicator GCaMP6f—facilitating direct 
assessment of neuronal activity during neurovascular coupling.  
Animal Preparation and Surgery.  In this study, we expressed GCaMP6f in neurons of the 
forepaw area of the somatosensory cortex (coordinate from bregma: AP = +1.0, ML = +3.7, DV 
= -1.2 mm) in rats (n=4) via an intracranial injection of genetically engineered Adeno-Associated 
Viruses (AAV9-Syn-GCaMP6f-WPRE-SV40, #100837-AAV9, Addgene, Cambridge, MA). 
Rats were anesthetized initially by 5% isoflurane and maintained by a constant flow of 2-3% 
isoflurane mixed with medical air. Rectal temperature was continuously monitored and 
maintained within 37 ± 0.5 °C using a feedback-controlled heating pad. Rats were head-fixed to a 
stereotactic frame (Kopf Instruments, Model 962, Tujunga, CA). An incision was made to the 
exposed skull surface and a burr hole were prepared at skull above the infusion coordinate. 
Microinjection was performed at a flow rate of 0.1 µl/min, and an additional 10 min was given 
for virus diffusion prior to slow retraction of the micro syringe needle. Subsequently, the incision 
was closed with 4.0 silk suture, and the rats were recovered from anesthesia. After two weeks of 
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incubation, an optical fiber (#CFMLC12U-20, Thorlabs, Newton, NJ) was chronically implanted 
at a position that was at 0.3 mm above the virus injection site. Four MR-compatible miniature 
brass screws (Item #94070A031, McMaster Carr, Atlanta, GA) were anchored to the skull. 
Thereafter, the surface of the skull was covered with dental cement to seal implanted 
components and the wound was sutured to further protect the surgical site. Lidocaine jelly 
(#1043377, Henry Schein, Queens, NY) was applied around the surgical wound to relieve pain 
and prevent the rat from scratching the wound. Meloxicam (1.5 mg/kg for 2 days; #049755, 
Henry Schein, Queens, N) was also given for further pain relief. Lincomycin hydrochloride (30 
mg/kg, i.m.) was administrated to prevent infection.  Rats were allowed at least 1 week for 
recovery before any further experiment. 
Fiber photometry setup for simultaneous fMRI and optical imaging. We used an 
established fiber-photometry setting (296) for concurrent fMRI applications. Briefly, we used a 
488 nm continuous wave (CW) laser (OBIS 488LS-60, Coherent, Santa Clara, CA) to excite 
GCaMP6f, and a 561 nm CW laser (OBIS 561LS-60, Coherent, Inc.) to excite Rhodamine B. 
These two lasers were aligned, combined, and subsequently launched into a fluorescence cube 
(DFM1, Thorlabs, Newton, NJ). The fluorescence cube contained a dichroic mirror 
(ZT488/561rpc, Chroma Technology Corp) to reflect and launch the combined laser beam into 
the core of a multi-mode optical fiber patch cable (#M43L02, Thorlabs, Newton, NJ), which was 
connected to the chronically implanted optical fiber probe of rats. The emission fluorescence 
collected from the same fiber probe travelled back along the patch cable into the fluorescence 
cube, passed through the dichroic mirror and an emission filter (ZET488/561 m, Chroma 
Technology Corp, Bellows Falls, VT), and launched into the core a multi-mode patch cable 
(M200L02S-A, Thorlabs, Newton, NJ) connected to a spectrometer (QE Pro-FL, Ocean Optics, 
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Largo, FL) for data acquisition. Spectral data was processed using a UI software from Ocean 
View (Ocean Optics, Largo, FL). When trigger mode was setup in Ocean View, the spectrometer 
recording was synchronized with MRI TTL via an Arduino micro-controller board.  
Simultaneous fMRI and fiber photometry in GCaMP6f rats.  The animal preparation for 
CBV-fMRI experiment was the same as aforementioned. Briefly, a pair of electrodes was 
inserted into the left forepaw between second and third and third and fourth digits for electric 
stimulation. The stimulation paradigm was 60s OFF - 30s ON - 60s OFF - 30s ON - 60s OFF. 
During the on blocks, electric stimulation was applied using a constant current stimulation 
isolator (#A365RC, WPI, Sarasota, FL) with following parameters: 3 mA, 9 Hz, 0.5 ms pulse 
width. The stimulation isolator was synchronized with MRI using a National Instruments DAQ 
board to receive TTL triggers from MRI scanner, and send out stimulus triggers according to the 
stimulus paradigm set in a homemade program. 
 
MRI data processing and analysis  
Relaxometry. In vitro relaxometric analyses were performed using a custom-written 
MATLAB (Math-Works, Natick, MA) script. Signal intensity corresponding to each Fe 
concentration at different TR and TE was extracted by placing identical size of region of 
interests (ROIs) on each phantom image. Relaxation curves for T1 calculation was obtained by 
plotting signal intensities (SI) against variable TRs corresponding to the shortest TE.  The T1 
recovery was plotted using a one phase exponential association fitting:  
SI = a*(1-exp (-b*TR)) + c  
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where a, b, c denotes the fitting parameters. Similarly, the T2 values were obtained by plotting SI 
against variable TEs corresponding to the longest TR. The T2 decay was plotted using a one 
phase exponential decay:  
SI = a*exp(-b*TE) 
The relaxivity values (r1= (1/ΔT1)/ [Fe] and r2 = (1/ΔT2)/ [Fe]) were determined by linear fitting 
to the relaxation rates (1/ΔT1 and 1/ΔT2) vs Fe concentration [Fe].  
Pharmacokinetics and Clearance. All EPI data acquired for pharmacokinetic evaluation 
of CION were corrected for motion using Analysis of Functional Neuroimages (AFNI) software. 
Because the clearance of CION is a slow process with respect to our EPI temporal resolution, the 
time-series EPI data were smoothed by moving average using a 30 s sliding window to avoid 
noise influence on pharmacokinetic assessment. The resultant images were skull-stripped and co-
registered to a template space using MATLAB and SPM scripts (203, 290, 297, 298). To extract 
the time-course data from the acquired images, motion corrected raw data from each subject was 
skull-stripped and registered to the template space using Analysis of Functional Neuroimages 
(AFNI) program. Region of interest (ROI) was placed on the dorsal hippocampus to extract the 
time-course data. The ΔR2* values were calculated as follows:  
ΔR2* = - 
6
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 ln [S(t)/mean(So)], 
where S(t) represents the MR signal intensities over time and So represents the average 
signal intensity of baseline before CION injection.  In order to accommodate for slight temporal 
delays due to manual CION injections, PK curves were aligned according to onset signal 
changes. The PK curves were smoothed by implementing a moving average for every 60 s across 
the 15300 time frames. To calculate various pharmacokinetic parameters, such as elimination 
constant (Ke) and half-life (T1/2) of the contrast agent, we assumed that the maximum signal 
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intensity change (ΔR2*max) caused by each CION formulation during the post-contrast injection 
period is directly proportional to the maximum (or peak) serum concentration that the contrast 
agent achieves in a specific compartment or test ROI. We assumed that the distribution and 
elimination of CION follows a one-compartmental model and accordingly, fit the decay of all 
contrast agents within a given ROI using a one-phase exponential decay model and ΔR2*max as 
the initial value, i.e. t=0. The pharmacokinetic profile of each CION was analyzed using the 
following equation: 
Y=(Y0 - Plateau)*exp(-K×t) + Plateau 
where, Y0 is the Y value when t (time) is zero, Plateau is the Y value at infinite times, K is a rate 
constant expressed in reciprocal of the t axis time units. Except for CION60000, which decays to a 
non-zero, steady plateau within two hours of contrast-agent administration, the plateau was 
constrained to 0 for CION17143, CION 12000, and Feraheme, each of which tends to reach Y=0 at 
infinite time.  
fMRI data. All EPI data acquired for pharmacokinetic evaluation of CION were slice-time 
corrected, motion-corrected, skull-stripped, and registered to the template space using AFNI. For 
the hypercapnia experiment, we performed an independent component analysis (ICA) and 
compared ΔR2* derived between before and after the hypercapnic challenge. Signal before and 
after the initiation of the CO2 challenge was compared using a two-sample t-test based on the 
response pattern identified from ICA. For the visual and optogenetic stimulation studies, a 
general linear model (GLM) with third-order polynomial regression was used as we have 
previously published (290). Except for hypercapnic challenge study, the contrast maps were 
normalized to a standard Z score to minimize subject-wise variance. Benjamini–Hochberg’s 
False discovery rate (FDR) correction procedure was applied for the multiple comparison (299). 
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Finally, the imaging results have a threshold of p < 0.01 to demonstrate statistically significant 
clusters. To showcase functional relaxivity changes under CION, we did not normalize the signal 
to form percent CBV changes, but instead express all fMRI time-series data in ΔR2*. 
 
Toxicity, Biodistribution, and Histopathology 
To assess the biocompatibility of CION, toxicity studies were carried out in C57BL/6J wild-
type mice (n=5).  Mice were intravenously injected with CION at a higher 40 mg Fe/kg dose to 
ensure biosafety in a wider dosing range. A separate group of mice (n=5) was treated with 
Feraheme at the same dose to serve as a positive control. General health and weight of animals 
were regularly monitored up to 7 days post-injection and humanely sacrificed with pentobarbital. 
All major organs such as liver, spleen, kidney, lungs and brain were immediately excised, 
submersion-fixed in 10% PFA for 72 h at 4°C, processed on an ASP 6025 automated tissue 
processor (Leica Biosystems), and embedded in paraffin wax.  Tissues were sectioned at 4 µm 
thick and mounted on glass slides.  Tissue sections were deparaffinized prior to 
staining.  Hematoxylin and eosin (H&E) staining was performed using pre-mixed hematoxylin, 
clarifier, bluing reagent, and eosin (Richard Allan Scientific).  For Prussian blue staining, 
Gomori’s method for iron staining was used, employing a 1:1 hydrochloric acid-Potassium 
ferrocyanide solution made from 20% hydrochloric acid and 10% potassium ferrocyanide, and a 
nuclear fast red counter stain. Immunohistochemistry for CD45 was performed on the Discovery 
Ultra (Ventana Medical Systems) using manufacturer reagents.  Antigen retrieval was performed 
using CC1 pH 8.5.  CD45 antibody (BD Pharmigen, Cat # 550539) was used at a final 
concentration of 1:2000 in Discovery PSS Diluent followed by anti-rat OmniMap HRP-
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conjugated antibody. Antigen detection was performed using Discovery Chromomap DAB, and 
nuclei were counterstained with Hematoxylin II and Bluing Reagent. 
 
Statistical Analysis 
All data unless otherwise specified are expressed as mean ± SEM. Statistical analysis was 
performed with Graph Pad Prism 8.30. The hydrodynamic sizes, PDI and ΔR2*max of various 
CION formulations were compared using a one-way analysis of variance (ANOVA). Multiple 
comparison tests were performed using Tukey-Kramer HSD post-hoc analyses. To compare the 
contrast properties between a pair of CION formulations at different time points, the delta R2* 
values of a given formulation corresponding to baseline, as well as 0-20 min, 40-60 min, 120-
140 min and 220-240 min post-injection were averaged. We performed two different types of 
comparison: 1) within group comparison intended to compare the averaged ΔR2* across different 
time points of a given formulation; and 2) inter-group comparison to compare the ΔR2* of 
different formulations at a particular time interval. Statistical analysis was performed using a 
two-way ANOVA, followed by Tukey’s multiple comparison tests. P < 0.05 was denotes 
statistical significance.   
 
RESULTS 
CION synthesis and characterization 
The synthesis of CION has been schematically illustrated in Figure 3.1 and further 
detailed in Video S3.1. We observed that CION synthesized with the molar ratio of Fe: CMD 
above 60000:1 (assuming molecular weight of CMD = 10 KD) were prone to agglomeration and 
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therefore did not consider evaluating the product with a higher ratio. In contrast, all 
nanoformulations synthesized with Fe:CMD ratio equal to or lower than 60000:1 were stable in 
PBS with no visual aggregation for at least a month. The hydrodynamic diameter and PDI of 
CION synthesized with different Fe: CMD molar ratio are presented in Table S3.2. As the molar 
stoichiometric ratio of Fe: CMD was decreased from 60000:1 to 17143:1, a statistically 
significant (p < 0.0001) decrease in the hydrodynamic size from 365.68 ± 5.04 nm to 50.65 ± 
2.49 nm was observed. Concomitantly, a significant (p < 0.01) decrease in PDI from 
0.423±0.021 to 0.240±0.018 was noted. Further reduction in Fe:CMD ratio (e.g. 12000:1) had no 
significant effect on the PDI of nanoparticles though a notable (p < 0.0001) increase in 
hydrodynamic size (96.30 ± 2.67 nm) occurred. Among all nanoformulations, CION17143 
presented the smallest hydrodynamic size ranging between 45-60 nm. We tested 4 different 
batches for reproducibility assessment (Figure S3.1); the mean hydrodynamic diameter of the 
nanoparticles was calculated to be 50.65 ± 2.49 nm with a variance of 18.69.  
Figure 3.1 Synthesis of CION. (A) An illustration chemical conjugates used for CION synthesis. (B) A schematic 
methodology depicting the one-pot synthesis of CION via in-situ, alkali-mediated co-precipitation of metal 
precursors in presence of carboxymethyl dextran (CMD) sodium salt. 
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This nanoformulation did not show any visual aggregation in PBS for at least 6 months 
within a concentration of 10-30 mg Fe/ml. Figure 3.2A presents the high resolution TEM images 
of CION60000, CION30000, CION17143 and CION12000. In all cases, nanoparticles were spherical or 
quasi-spherical in shape with particle size ranging between 5-10 nm. The electron dispersive X-
ray spectrum of CION17143 (Figure S3.2) confirmed the presence of Fe, C and O in the sample. 
The ATR-FTIR spectrum of CION17143 (Figure 3.2B) displayed characteristic peaks at around 
1105 cm−1 and 1015 cm−1, ascribed to the presence of C-O bonds, and α-glucopyranose ring 
associated with the surface-dextran coat. The presence of prominent stretching vibration band at 
1637 cm−1   was indicative of the presence of carboxylic acid groups (-COOH) on the NP surface.  
Additionally, a broad band was observed in the frequency range of 3000-3500 cm-1, ascribed to 
the -OH stretching vibration of -COOH and -OH functional moieties associated with the CMD 
surface-coat on iron-oxide. A typical survey XPS spectrum of CION17143 is presented in Figure 
3.2C. The survey scan revealed the presence of C1s, O1s, Fe2p and Fe3p peaks at binding 
energy values of 285, 531, 710 and 725 eV. The high resolution C1s spectrum of CION17143 
(Figure 3.2D) showed three distinct peaks at 285, 287 and 288 eV corresponding to the C-C, C-
O and C=O bonds inherent to chemical backbone of CMD present on the surface of CION. The 
Fe2p doublets with binding energy values of 710 and 725 eV (Figure 3.2E) were representative 
of Fe-O bonds, typical of magnetite. We also used XPS to quantify the atomic concentrations 
(%) of Fe, O and C on the surface of CION. Our results indicated that increasing the amount of 
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polymer during co-precipitation reaction led to an increase in surface C:Fe atomic ratio (Figure 
S3.3, Table S3.3).  
	
Figure 3. 2  Physicochemical Characterization of CION. (A) Representative high-resolution TEM images of 
CION60000, CION30000, CION17143 and CION12000.  Scale bar represents 50 nm. (B) ATR-FTIR spectrum of CION17143. 
(C) Full XPS spectrum for CION17143 and isolated high-resolution XPS scans of (D) C1s and (E) Fe2p peaks. 
 
In vitro relaxometry 
Representative MR phantom images of CION60000, CION17143, CION12000 and Feraheme 
acquired at different TRs and TEs using a custom-built holder (Figure 3.3A) showed a 
concentration-dependent negative contrast enhancement when compared to saline control 
(Figure 3.3B). The T1 and T2 relaxations of various CION compositions are presented in Figure 
3.3C. Among all the formulations tested, CION60000 exhibited the highest r2/r1 ratio (r1 = 3.173 
mM-1s-1; r2 = 1204 mM-1s-1) at 9.4T, followed by CION12000 and CION17143.  The relaxivity of 
CION17143 (r1 = 1.412 mM-1s-1; r2 = 109.8 mM-1s-1 ) was comparable to that of Feraheme (r1 
=1.412 mM-1s-1; r2 = 144.9 mM-1s-1) measured in this study as well as dextran-coated 
monocrystalline iron oxide nanoparticles (MION) reported by Zhao et al. at 9.4T (r1 = 1-1.7 mM-




Figure 3. 3  In vitro relaxometric analysis of CION. (A) Custom-design holder for relaxometric analysis. (B) 
Representative T1- and T2-weighted MR phantom images of various CION compositions and Feraheme acquired at 
different TR and TE.  (C) T1 and T2 relaxation plots of phantoms. (D) Quantification of r1 and r2. 
 
In vivo Pharmacokinetics and Clearance   
Figure 3.4A presents the R2* signal change profile of CION60000, CION17143, CION12000 
and Feraheme on EPI scans of the rat brain. A two-way ANOVA examining the effect of all 
contrast agents on R2* signal change in the hippocampus in 30 min intervals compared to 
baseline found a statistically significant interaction between the effects all contrast agents and the 
enhancement of ΔR2* signal compared to pre-contrast baseline (F(3, 324) = 216.6, p < 0.0001) in 
the 30 min following tail vein administration (Figure 3.4, B and C). CION12000 and CION60000 
displayed rapid intravascular clearances with respective circulating half-lifes of 60.5 min and 14 
min. CION60000 had a rapid, one-phase exponential decay with ΔR2* reaching near baseline 
levels within 170 min of being administered. In contrast, CION17143 displayed an ideal 
pharmacokinetic profile for steady-state applications. A bolus, intravenous injection of 
CION17143 increased the maximum ΔR2* to 102.342 ± 5.937 s-1 following administration, which 
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was comparable to the maximum ΔR2* of Feraheme (p = 0.0636). Tukey-Kramer HSD post-hoc 
analysis indicated that ΔR2* change following CION17143 administration remained statistically 
unaltered for the first hour (p = 0.0556). Using a one-phase, exponential decay model, the half-
lives of CION 17143 and Feraheme were calculated to be 472.3 min (7.87 h) and 468.4 min (7.81 
h) respectively (Figure S3.4). Because the CION17143 and Feraheme exhibited linear-like pattern 
of clearance, we also fit the clearance of both formulations using a linear regression and their 
slopes were found to statistically comparable (p = 0.2186 ; Figure S3.5). Due to its long 
intravascular half-life, CION17143 was selected for subsequent in vivo fMRI evaluations. The 
derivation of various pharmacokinetic parameters such as elimination constant (Ke) and half-life 
(T1/2) from are shown in Figure S3.4. 
 
Figure 3. 4  In vivo pharmacokinetic evaluation of CION conjugates and feraheme in rat brains. (A) Group-averaged 
EPI images of rat brains at various time points after CION60000 (n=3), CION17143 (n=6), CION12000 (n=4) and 
Feraheme (n=3) administration. (B) Hippocampal R2* signal changes were evaluated with a 20minpre-contrast 
baseline and for a subsequent 4h following administration of each CION conjugate and feraheme.  (C) ΔR2* signal 
decay from maximum were calculated for every half-hour period and statistically compared to the first half-hour 
period for each contrast agent to investigate decay. *denotes p<0.05, **denotes p<0.01, ***denotes p<0.001, 
***denotes p<0.0001. 
76 
In vivo fMRI applications 
We selected well-established fMRI procedures (200, 260, 279-289) to demonstrate the 
feasibility of using CION17143 for fMRI with no intention to power the experiment to address any 
novel biological effects. Figure 3.5 shows the use of CION17143 in several common stimulus 
evoked-fMRI paradigms, including hypercapnic CO2 challenge, visual stimulation, and targeted 
optogenetic stimulation. With the steady-state created by 20 mg/kg of CION17143, 5% CO2 
challenge induced ΔR2* increases throughout the brain, with the changes up to 15 s-1 (Figure 
3.5A). Visual stimulation at 10 Hz induced site-specific ΔR2* increases by 2 s-1 in the rat 
superior colliculus – a brain area processing visual inputs (Figure 3.5B). Optogenetic stimulation 
at 40 Hz induced ΔR2* increases by 10 s-1 in the targeted primary motor cortex (M1) where 




Figure 3. 5  In vivo fMRI applications of CION17143 in rodents. (A) CBV activation map and global signal time-course 
R2* changes in response to hypercapnia. (B) CBV activation map and time-course ∆R2* changes in the visual cortex 
in response to visual stimulation. (C) Viral transfection of EYFP-expressing empty and ChR2-EYFP-expressing 
vectors into left (gray) and right (green) hemispheres of M1, respectively, and confirmed via neuronal EYFP 
expression at target sites. CBV activation map and M1 time-course R2* changes in response to optogenetic stimulation. 
Threshold applied at p < 0.05 with FDR correction. 
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High resolution µMRA 
To determine the utility of CION17143 as a µMRA contrast agent, we performed a proof-
of-concept experiment in a mouse. Figure 3.6A presents the pre-and post-contrast FLASH-3D 
images of a mouse brain imaged at 100µm3 spatial resolution. The post-contrast image revealed 
the presence of several cerebral vessels in the cortical and subcortical regions not clearly visible 
prior to CION17143 injection. The long intravascular half-life of CION17143 enabled the acquisition 
of images at higher spatial resolution (50 µm3 isotropic for the provided example). Figure 3.6B 
shows the representative 3D cerebrovasculature of the mouse brain. We were able to identify 
several key arteries and veins from this dataset including rostral rhinal vein, galeno vein, 
collicular vein, transverse hippocampal arteries/veins, thalamostriate perforating arteries/veins, 
medial internal frontal artery, supracollicular arterial network, dorsal and medial cerebral 
arteries, lateral superior cerebella arteries and anterior medial striate artery.  
 
Figure 3. 6  MR angiography using CION. (A) FLASH-3D images of mouse brain captured at 100 µm3 spatial 
resolution before and after injection of CION17143. (B) Representative 3D cerebrovasculature of the mouse brain 
generated from a post-contrast FLASH 3D image acquired at the spatial resolution of 50 µm3. 
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Fluorescent-tagged CION for multimodal application 
To demonstrate the utility of CION platform for cross-modality application, we 
conjugated CION with Rhodamine B, a red-fluorescent dye, using the protocol shown in Figure 
3.7A and Supplementary Materials, and administered this conjugate intravenously via tail vein 
in rats. Figure 3.7B shows the photometry experimental setup and Figure 3.7C shows 
photometry-measured normalized pharmacokinetic time-courses of Rhodamine-CION conjugate 
within 30 minutes after the injection (black), compared with injection of Rhodamine B alone 
(red) in the same animal with a few days apart. Notably, Rhodamine-CION appeared reaching a 
steady state faster than Rhodamine B alone. Rhodamine-CION also exhibited higher signal to 
noise ratio (SNR) than Rhodamine B (Figure 3.7D). These data indicated that the conjugate was 
feasible and successful, and Rhodamine-CION helped stabilize the pharmacokinetics, which 
should allow better CBV measurement using optical methods. To demonstrate a possible cross-
modality application, we conducted simultaneous fMRI and fiber-photometry recording using 
the conjugated Rhodamine-CION with conventional forepaw electrical stimulation. Similar to 
prior in vivo application studies, we chose a well-established protocol to showcase the feasibility 
with no intention to address any novel biological effects thus did not fully power the experiment. 
Figure 3.7E showed that GCaMP6f (green, which measures neuronal calcium activity) and 
Rhodamine-CION (red, which measures CBV) both increased during the stimulation period, and 
the CBV-fMRI time-course concurrently measured by Rhodamine-CION (black) showed highly 
consistent pattern with the photometry CBV signal in red.  
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Figure 3.7  Cross-modality application of a fluorescent-labeled CION. (A) A schematic methodology depicting how 
CION17143 is conjugated with the fluorophore Rhodamine B. (B) Our fiber-photometry system uses a two lasers to 
excite GCaMP (λ=488 nm) and Rhodamine (λ=561 nm) and a spectrometer to detect changes in emitted photons over 
time. (C) Intravascular clearance studies (n=4/contrast) of the Rhodamine-CION conjugate (black) shows faster 
achievement of steady-state compared to Rhodamine B (red). (D) Signal to noise ratio (SNR) of Rhodamine-CION 
conjugate is higher compared to Rhodamine B (n=4/contrast). (E) In vivo forepaw electric stimulation studies in rats 
conducted simultaneously while recording fMRI and fiber photometry data found rises in Rhodamine-CION conjugate 
fluorescence and CBV signal were locked to periods of forepaw electric stimulation (blue shading, 3 mA, 9 Hz, 0.5 
ms pulse width) and increases in neuronal activity associated to intercellular calcium release. 
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In vivo biocompatibility  
To study the biocompatibility of CION17143, we examined toxicity using histology. 
CION17143 was administered intravenously in mice at a higher dose of 40 mg Fe/kg and the 
results were compared with that from a separate group of mice receiving Feraheme injection at 
the same dose. As a preliminary step towards toxicity evaluation, we monitored the general 
health conditions of mice up to 7 days post-injection. We did not observe any notable alterations 
in their usual behaviors such as vocalization, breathing, normal movement, hunching or 
interactions with cage mates. No significant changes in body weight was encountered during the 
post-injection period (Figure S3.6). All animals were sacrificed for histological assessment on 
day 7 after CION17143 injection. H&E and Prussian blue staining, as well as CD45 labeling was 
performed on subsequent tissue sections to assess representative organ histopathology. The data 
were reviewed by a board-certified veterinary pathologist (S.A.M.) blinded to the treatment 
groups at time of analysis. As evident from both H&E as well as CD45 staining (Figure 3.7), 
livers from both groups displayed mild lymphocytic inflammation, with the CION17143 treated 
group displaying comparable, if not less inflammation than the Feraheme-treated group. Livers 
from both groups displayed similar amounts of extramedullary hematopoiesis, a common, 
nonspecific finding in mice. H&E findings of the kidney, spleen, brain, and lung in both groups 
exhibit normal feature. Prussian blue staining of the kidney revealed occasional iron deposition 
within the nephron, suggestive of renal filtration of the compounds. Prussian blue staining of 
spleens in both groups revealed moderate-numbers of iron-laden macrophages, which is expected 




Figure 3.8 Toxicity and organ deposition of CION17143 (n=5) and Feraheme (n=5) in mice 7 days after administration 
of a bolus 40 mg/kg dose. (A) Histological staining with H&E and Prussian Blue were conducted on sectioned liver, 
spleen, kidney, lung and brain showing no gross organ toxicity and iron-deposition was restricted to cells in the liver 
and spleen. (B) Immunohistochemistry against CD45+ Kupffer macrophages in the liver revealed both CION17143 and 
Feraheme displayed comparable mild lymphocytic inflammation (black arrows). 
 
DISCUSSION 
Over the past several years, many studies have proposed long-circulating, blood pool MR 
contrast agents (301) synthesized by coating SPION/USPION with dextran (302, 303), PEG-
(304), PEG-derivatized phosphine oxide(305), PEGylated-silica (306) and bisphosphonate-
anchored PEG (307). Many of these formulations such as crosslinked iron-oxides (CLIO) 
developed by Weissleder (303) or PEGylated-silica coated iron oxide nanoparticles developed by 
Wu et al. (306) have shown promise for preclinical MRI application including cerebrovascular 
and cardiovascular imaging. However, these syntheses are based on a relatively complicated 
workflow that involves multistep reactions with tedious purification steps and/or costly 
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equipment and reagents, posing reproducibility and scaling-up challenges for laboratories 
lacking state-of-the-art chemistry resources. This paper provides a detailed step-by-step 
guideline on how to synthesize an iron-oxide based MRI contrast agent from scratch using an 
extremely streamlined and affordable protocol (Table S3.1). We also provide steps to tune the 
synthesized properties that maybe suitable for other in vivo applications. The simplicity of our 
one-pot method allows any researcher to reproduce this method in their laboratory easily and 
tailor their nanoparticles according to their imaging need by controlling the reaction variables. 
For instance, CION17143 is an ideal choice for steady-state CBV assessment due to its long 
intravascular half-life. However, the short-circulating CION60000 may be best suited for 
applications such imaging of the liver, spleen, tumor, or when selective targeting is needed for 
the contrast agent to flush out rapidly from the vascular compartments, leaving only targeted 
agent bound to disease-specific biomarkers.  It is our hope that making our recipe publicly 
available will benefit chemists and MRI researchers alike in advancing the field.  
To identify the optimal reaction conditions that can lead to maximum CMD grafting on 
nanoparticles while still having a decent iron payload per particle, a series of nanoformulations 
were formulated with varying stoichiometry of Fe to CMD. As observed by DLS, a decrease in 
Fe:CMD molar ratio from 60000:1 to 17143:1 led to a diminution in hydrodynamic size from 
365.36 ± 5.04 nm to 50.65 ± 1.00 nm due to the increased polymer coating associated with 
nanoparticle surface, enhancing steric and electrostatic stabilization. But after a certain 
concentration of CMD in solution, the trend was reversed. Subsequently, a decrease in Fe: CMD 
molar ratio from 17143:1 to 12000:1 increased the nanoparticle size to 96.30 ± 2.67 nm. This 
observation is not surprising and may be attributed to depletion flocculation which occurs when 
the amount of polymer in the solution exceeds the threshold required to completely cover the 
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surface of nanoparticles. When the excess polymer exists in the reaction mixture and the fully 
coated nanoparticles approach closer (i.e. less than the radius of gyration), the non-adsorbed free 
polymers between them are subject to exclusion due to entropic effects. Subsequently, the local 
concentration becomes lower than the surrounding level. The difference in concentration leads to 
an osmotic pressure difference, attracting two particles and eventually increasing the aggregate 
size.  The TEM image of all nanoformulations prepared with Fe:CMD ratio between 60000:1 to 
12000:1 showed hundreds of ultrafine, spherical to quasi-spherical particles with diameter 
ranging between 5-10 nm. Unlike DLS, an increase in the amount of coating agent during 
synthesis had nominal impact on the core size of nanoparticles. For all nanoformulations, particle 
sizes measured in TEM were at least 10-15 times smaller than their corresponding hydrodynamic 
sizes. This difference can be attributed to the differences in underlying principles involved in 
size measurement using these techniques. While TEM is used to image dry nanoparticles, DLS 
measures the size of hydrated nanoparticle, which include the contribution of the surface coating 
associated with the nanoparticle core and their solvation in the dispersion medium. The surface 
chemistry of CION was studied using ATR-FTIR spectroscopy. All tested nanoformulations (i.e. 
CION60000, CION17143 and CION12000) presented identical spectral pattern except for increasing 
C-O stretching vibration intensity at around 1105, and 1015 cm−1. The intensity of these bands 
can be qualitatively related to CMD functionalization density associated with the iron oxide core 
as we observed a smaller signal intensity for CION60000 and a stronger intensity band for 
CION12000 possessing a higher polymer content. We also observed a strong stretching vibration at 
1637 cm-1 band, which was ascribed to the presence of carboxyl functionality associated with the 
CMD coat. This band, however, undergoes a hypsochromic (blue) shift when compared to the 
expected stretching region of carboxyl group, which is between 1700-1725 cm−1.  This blue shift, 
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in part, could be contributed by the complexation of carboxyl groups on metal surface and/or 
presence of extensive hydrogen bonding between surface carboxyl groups. The presence of 
CMD coating on the surface of CION was further confirmed using XPS. As evident from the 
high resolution C1s XPS spectrum of CION17143, these NPs contained reactive carboxyl groups 
on their surface to allow further modification with functional biomolecules including proteins, 
antibodies, aptamers and therapeutic drugs. A thorough analysis of surface functionality and 
elemental composition using XPS conferred that the C:Fe atomic ratio on nanoparticles critically 
depended on the stoichiometric ratio of metal precursors to polymer used during nanoparticle 
synthesis.   
           To examine how variation of Fe:CMD molar ratio affects the relaxivity of nanoparticles, 
we measured the r1 and r2 for various CION compositions viz. CION60000, CION17143 and CION12000 
using a conventional spin-echo based T1-T2 mapping protocol. Among all the formulations, 
CION60000 exhibited the highest r2/r1 ratio, followed by CION12000 and CION17143. Two factors that 
determine the contrast enhancement of CIONs might help explain our results: 1) iron-oxide core 
(size and material); 2) thickness (coating and chemical composition).  SPION are known to shorten 
T2 in MRI, which is governed by the translational diffusion of H2O molecules in the 
inhomogeneous magnetic field surrounding the nanoparticles (308). According to quantum-
mechanical outer sphere theory, the T2 relaxivity of CION in solution can be expressed by the 
following equation:  
 
                                      1/T2 = (256π2γ2/405) V∗ Ms2 a2/D (1 + L/a)      
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where γ denotes proton gyromagnetic ratio; V*, Ms and a represented the volume fraction, 
saturation magnetization and the radius of iron oxide core, respectively; D is the diffusivity of 
water molecules, and L is the thickness of an impermeable surface coating (309-311). Of note, 
the coating molecules associated with iron-oxide nanocore can result in exclusion of water from 
its surface, prevent water diffusion, or immobilize surrounding water molecules through 
formation of hydrogen bonds (310); all these factors can affect the nuclear relaxation of water 
protons. In this case, as the Fe:CMD ratio was lowered from 60000:1 to 17143:1, the 
hydrodynamic size of CION decreased with a concomitant increase in CMD coating thickness on 
the nanoparticle surface, resulting in a lower r2/r1 ratio, which was slightly less than Feraheme 
but greater than MION. However, a further increase in the amount of polymer during CION 
synthesis, increases the r2/r1 of CION. This observation, albeit off-the-trend, can be explained by 
an increased polymer coating thickness, which is supposed to have a deleterious effect on the 
saturation magnetization of the iron-core.  
          We evaluated the pharmacokinetic properties of three representative CION composition, 
namely, CION60000, CION17143 and CION12000. Although intravenous injection of CION60000 in 
rats led to reasonable contrast enhancement in vivo, our preliminary data indicated the half-life of 
this agent (11.2 min) was too short to meet prolonged imaging requirements, critical for most 
functional neuroimaging applications. This fast-clearing CION, however, can be well-suited for 
studies that have a shorter acquisition window such as liver and spleen imaging, cell-labeling and 
tumor targeting where fast clearance is essential to have unbound contrast agent removed 
from the vessels eliminating unnecessary background signal. Among all the three formulations, 
CION17143 presented the best results with regards to circulation stability (T1/2  ~ 10h), while 
maintaining reasonable T2* contrast in vivo.  Our results indicated that the r2 and intravascular 
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half-life of CION17143 is comparable to Feraheme, which makes it an ideal contrast agent for 
steady-state MRI applications.  
We have also presented a few proof-of-concept studies covering different types of fMRI 
applications. Of note, these studies were not intended to test the efficacy of our contrast agent in 
a large cohort and address specific neuroscience questions. Among these studies, hypercapnia or 
an elevated pCO2 acts as a potent stimulator of vasodilation (312-317), while visual stimulation 
increases CBV in activated brain regions (200, 318, 319). Using CION17143, we were able to 
detect robust, site-specific ΔR2* changes in rats exposed to visual stimulation and hypercapnic 
challenge under lightly anesthetized conditions similar to that reported by others (316, 318, 320). 
CION17143 also demonstrated success in detecting robust optogenetic fMRI response in the area 
expressing ChR2 as previously (321, 322). Together, these results confirmed the efficacy of 
CION17143 for fMRI applications. Due to its long plasma half-life and robust T2 effects, this 
nanoformulation also showed excellent performance as a µMRA contrast agent, allowing 
improved visualization and delineation of cerebromicrovessels in vivo. To validate the efficacy 
of CION for simultaneous fMRI and optical fiber photometry, we conjugated CION with a red 
fluorescent dye, Rhodamine B. The presence of reactive carboxyl groups enabled facile 
immobilization of rhodamine B on the surface of CION through a short, PEG- type spacer, 
namely 2,2′-(ethylenedioxy)-bis-(ethylamine) (EDEA) using the well-established carbodiimide 
chemistry (323). Although further characterizations are required to confirm the chemical 
structure of CION-rhodamine conjugate, our preliminary cross-modality experiments suggested 
that Rhodamine-labeled CION could serve as a platform for bridging tools across different 
spatiotemporal scales.   
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To determine the biocompatibility of CION17143, we also performed toxicity study in 
mice and compared the results with Feraheme. For toxicity analysis, we used a dose (40 mg/kg) 
that was higher than the highest dose (30 mg/kg) typically used for CBV-fMRI studies (203, 290, 
297, 298). We did not observe any abrupt changes in body weight up to 7 days post-injection; 
animals from both treatment group were apparently healthy and resumed their normal behavior 
and activities. Although H&E staining revealed the presence of mild lymphocytic inflammation 
in the livers from both treatment groups, the CION-treated group displayed slightly lower 
inflammation than Feraheme. For both treatment groups, no abnormalities were observed in the 
histopathological sections of kidney, spleen, brain and lung. To examine the biological fate of 
CION after 7 days post-administration, histopathological sections of liver, spleen, kidney, lungs 
and brain were also stained with Prussian blue, a common stain used by pathologists to detect the 
presence of iron in tissue specimens.  Although we did not observe any iron accumulation in 
brain or lungs, purple deposits of iron were visible in liver and spleen. This distribution profile is 
consistent with the proposed mechanism of iron metabolism for USPION (244). These results 
further indicate that both CION and Feraheme are eventually cleared from the intravascular 
space and enters the liver and spleen where they are most likely cleared by macrophages of the 
reticuloendothelial system (RES). As previously reported, it is possible that the nanoparticle 
coating is cleaved by lysosomal enzymes and the iron core is incorporated into the body’s iron 
stores, where it is metabolized over 6-12 weeks. (324)  Prussian blue staining of kidney also 
revealed minimal iron deposition within the nephron, indicating renal excretion of the 
nanoformulations. In summary, our results suggest that CION17143 is a robust, reproducible, and 




We have developed a simple, inexpensive method to synthesize high-performance 
intravascular CION for MRI applications. By tuning the material and pharmacokinetic properties 
of CION through careful surface modulation, we have formulated an ideal blood pool agent that 
offers robust and stable contrast for high resolution CBV anatomical and functional imaging. 
Additionally, we developed and characterized other CION variants with shorter circulation half-
life and high r2/r1 ratio; although these compositions cannot be used for blood pool steady-state 
imaging, they hold significant promise for liver or spleen imaging, cell labeling and tumor 
targeting in vivo. Finally, CION possesses a reactive carboxyl handle that enables conjugation 
with a variety of functional biomolecules and imaging entities. By labeling CION with a red 
fluorescent dye, Rhodamine B, we demonstrated the effectiveness of CION for simultaneous 
fMRI and optical fiber photometry. Our future studies will be focused on further optimization of 
Rhodamine-CION conjugate for various multimodal studies and developing new molecular MRI 
contrast agents using CION as the platform material.  
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CHAPTER 4: NOREPINEPHRINE FROM LOCUS COERULEUS MODULATES THE 
DEFAULT MODE NETWORK 
 
INTRODUCTION 
The default mode network (DMN) is among the most robust networks detected by 
functional magnetic resonance imaging (fMRI) due to its highly synchronized activity in the 
absence of cognitive tasks or salient stimuli (101). DMN is evolutionarily conserved across 
rodents, non-human primates, and humans (117, 325-328), and is essential in a wide range of 
behaviors (328, 329), integrating interoceptive and exteroceptive information from multiple brain 
networks (117) and maintaining the brain in a semi-vigilant ‘default’ state (188, 330). 
Dysregulation of DMN has been implicated in several neurological and neuropsychiatric disorders 
(100). In order to make causal interpretations of behaviorally relevant DMN changes and design 
network-based treatment regimens for DMN-related disorders, identifying the neuromodulatory 
mechanisms controlling DMN is of paramount importance.  
Norepinephrine (NE) is likely a key modulator of DMN since: 1) NE receptors are heavily 
expressed in all DMN-related brain structures (331); 2) NE can engage or suppress attention 
reorientation from ‘day-dreaming’ or ‘mind wandering’ states (332-335); 3) degeneration of NE 
neurons and disruption of DMN are both found in depression (336), traumatic brain injury (337), 
Parkinson’s disease (338, 339), Alzheimer’s disease (338, 340, 341) and aging (84); and 4) 
pharmacological treatment of pathological NE level reduces attentional lapses (342) and restores 
DMN integrity in attention deficit hyperactivity disorder patients (343-345). Despite these 
pharmacology findings, the association between NE and DMN modulation remains circumstantial 
91 
due to inherent non-selective binding of NE-related agents on dopaminergic, cholinergic and 
serotonergic receptors (346, 347). Furthermore, systemic administration of these agents 
indiscriminately target all NE-producing neurons in the brain and dorsal root ganglia, making it 
difficult to investigate the cellular origin of the NE that modulates the DMN.  
The locus coeruleus (LC) accounts for 80% of NE release in the brain (348), and is one of 
the first brain regions to degenerate in PD and AD (338, 349, 350)– both of which have been shown 
to have marked changes in DMN (339-341). Additionally, degeneration of LC-NE neurons and 
disruption of DMN are also found in depression, traumatic brain injury and normal aging. 
Importantly, LC-NE neurons sends widespread innervations that release NE in brain regions that 
form the DMN (331, 333). While mounting evidence supports the plausible role of LC-NE neurons 
in modulating the DMN, selective manipulation of LC-NE is currently impossible in humans due 
to technical constraints. Robertson et al. developed a dual Flp/Cre transgenic design to isolated a 
subpopulation of NE neurons (DbhFlpo) that transiently express the transcription factors Engrailed-
1 (En1Cre) during neurodevelopment and are located exclusively in the LC and the subcoeruleus 
(351). Using intersectional genetics, a triple transgenic En1Cre ; DbhFlpo ; RC::FL-hM3Dq-mCherry 
line was developed to express the excitatory Designer Receptor Exclusively Activated by Designer 
Drugs (DREADD) receptor hM3Dq on LC-NE neurons, allowing for highly selective and 
reproducible manipulation of their NE release (352, 353). 
In this study, we examined how LC-NE controls the DMN and identified the circuit model 
by which the DMN is modulated.  Given that NE constricts blood vessels (354, 355) through direct 
actions on NE receptors expressed on pericytes (356) and arterial smooth muscle cells (357), and 
also alters glucose uptake (358-363) and post-synaptic neuronal activity (364-366), we measured 
all these parameters using fMRI, spectral fiber-photometry, and positron emission tomography 
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(PET) to reveal potential confounders in interpreting the influence of LC-NE on DMN activity 
across different spatial and temporal scales. We used an established data-driven approach to 
analyze DMN in mice (116) and selectively manipulate LC-NE release using a triple transgenic 
mouse line expressing excitatory DREADDs. Our findings highlight the circuit mechanism by 
which LC-NE modulates DMN and should pave the way towards a better understanding of how 
large-scale brain networks are altered by neuromodulatory pathways.  
 
MATERIAL AND METHODS 
Animals 
All animal procedures were performed in strict compliance with ethical regulations for 
animal research and approved by the Institutional Animal Care and Use Committee of the 
University of North Carolina at Chapel Hill.  Transgenic mouse lines were generated at the 
National Institute of Environmental Health Sciences.  Triple transgenic LC-NE mice (En1Cre ; 
DbhFlpo ; RC::FL-hM3Dq-mCherry (352, 353)) were generated by first crossing RC::FL-hM3Dq-
mCherry mice (Gt(ROSA)26Sortm2.3(CAG-EGFP-CHRM3*/mCherry/Htr2a)Pjen, (353)) with heterozygous 
DbhFlpo mice (B6;129-Dbhtm1(Flpo)Pjen, (351)) mice. Their offspring were backcrossed to generate 
mice that were heterozygous for DbhFlpo and homozygous for RC::FL-hM3Dq-mCherry.  Lastly, 
these dual transgenic mice were crossed with heterozygous En1Cre mice (B6.Cg-En1tm2(cre)Wrst, 
(367)) to generate the LC-NE line.  Single- and double-transgenic littermates served as controls to 
account for CNO-related effects. For histological assessment of projections, En1Cre ; DbhFlpo ; 
RC::FLTG mice expressing EGFP on axonal projections of LC-NE neurons were generated using 
the aforementioned crossing scheme but substituting the RC::FL-hM3Dq-mCherry mice with 
RC::FLTG mice (Gt(ROSA)26Sortm1.3(CAG-tdTomato-EGFP)Pjen, (368)). Mice were euthanized at the end 
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of each study using sodium pentobarbital and exsanguination via transcardial perfusion with 4% 
paraformaldehyde in 0.1 M phosphate buffered saline (PBS). 
  
CBV-fMRI acquisition 
For fMRI studies, LC-NE (n=9) and control mice (n=12) were initially anesthetized using 
2-3% isoflurane and maintained under light anesthesia (1% isoflurane) while preserving 
physiological homeostasis. All MRI experiments were performed on a Bruker BioSpec 9.4-Tesla, 
30 cm bore system (Bruker BioSpin Corp., Billerica, MA) with ParaVision 6.0.1 on an AVANCE 
II console. An RRI BFG 150/90 gradient insert (Resonance Research Inc., Billerica, MA) paired 
with a Copley C700 gradient amplifier (Copley Controls Corp., Canton, MA) were used for all 
experiments. A 72 mm volume coil was used as the transmitter and quadrature mouse brain coil 
was used as the receiver (Bruker BioSpin Corp., Billerica, MA). Magnetic field homogeneity was 
optimized first by global shimming, followed by local second-order shims using a MAPSHIM 
protocol. All CBV-fMRI data were acquired using a 2D multi-slice, single-shot, gradient-echo 
echo-planar imaging sequence: TR (repetition time) = 3000 ms, TE (echo time) = 7.9 ms, 
bandwidth = 250 kHz, flip angle = 70 degrees, FOV (field of view) = 19.2 x 19.2 mm2, matrix size 
= 64 x 64, slice number =26, slice thickness =0.3 mm, resulting in isotropic voxel size of 0.3 mm3. 
Subjects were continuously scanned for 40 min with a 1 mg/kg dose of CNO administered via an 
intraperitoneal catheter 10 min after scan onset. CBV-weighted fMRI was achieved by a bolus 
dose of an in-house developed iron oxide nanoparticles (30 mg Fe/kg, i.v.). Rectal body 
temperatures were continuously maintained at 37±0.5°C by a temperature controller (OAKTON 
Temp9500, Cole-Parmer, Vernon Hills, IL, USA) coupled to a circulating water bath (Haake S13, 
Thermo Scientific, Waltham, MA, USA) that heats the MRI mouse cradle. Respiration was 
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monitored through a pneumatic pillow (Respiration/EEG Monitor, SA Instruments, Stony Brook, 
NY, USA) and maintained between 90-110 breaths/min. 
 
fMRI data analysis 
Pre-processing of images: All fMRI data were first corrected for slice timing and motion 
using AFNI. Brain data were isolated for each subject using a U-Net deep-learning skull stripping 
tool (168) by averaging temporal data into a single volume. Skull-stripped data were spatially 
normalized to our EPI template using ANTs. Additionally, de-spiking, ICA de-noising (369, 370), 
and nuisance variable regression of the six motion parameters estimated from motion correction 
and the CSF signal extracted using a mask of the major brain ventricles.  Dataset were then 
smoothed using a Gaussian kernel with full width half maximum (FWHM) at 0.6 mm, de-trended, 
and temporally filtered by applying a high-pass filter between > 0.01 Hz.  Datasets underwent 
manual quality control by measuring frame wise displacement (FD), temporal SNR (tSNR), and 
DVARS (temporal derivative of the root mean squared variance over voxels)(182). A detailed 
description of the preprocessing pipeline can be found in the Supplementary Methods. 
ICA and modularity analyses: MRI data were decomposed into 100 functional 
components using baseline data from all subjects via a group-level ICA (FSL MELODIC). ICA 
spatial maps were back-reconstructed for each subject to estimate subject-specific temporal 
components and associated spatial maps using dual-regression analysis and a t-test was performed 
to generate group component maps. Time courses from 17 pre-selected DMN nodes to were 
extracted from first stage of dual-regression and the Fisher z-transformed Pearson correlation were 
computed among all node pairs to form a correlation matrix. To keep the strongest connections 
while no isolated nodes in 17 DMN nodes, the z-threshold = 0.26 (connection density = 48%) was 
set in the mean FC matrix across all subjects. Functional modules of the DMN were parcellated 
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using Louvain community detection algorithm (371, 372). The modularity analysis method is 
detailed in the Supplementary Methods.  
Functional segregations analyses of DMN modules: Functional segregation methods in 
fMRI focus on node properties derived from the fMRI signal, as opposed to functional connectivity 
which measures the edge properties among spatially distinct regions. ReHo is a voxelwise analysis 
to determine local synchronization of fMRI signal among all brain regions. Higher ReHo scores 
typically represent greater neuronal coherence and centrality within nodes but does not necessarily 
equate to higher neuronal activity.  ALFF is a voxelwise technique to calculate the total power of 
regional neuronal activity within 0.01-0.1 Hz. Overlapping regions that share high ALFF and 
ReHo scores are thought to have enhanced synchronization of low frequency neuronal activity. 
FC analysis within and between DMN modules: Within- and between-module 
connectivity was defined as the average of FC across ROI pairs within or between the identified 
DMN modules. The PC and WD were estimated to identify hubs and connectors in DMN (373). 
We conducted NBS (374) to investigate the significant connection changes. For each comparison, 
a primary component-forming threshold (p<0.05, uncorrected) was applied to form a set of supra-
threshold edges and all the remaining connected subnetworks in the matrix were then evaluated 
under the null hypothesis of random group membership (5,000 permutations).  
DCM analysis: We specified a DCM model with full connectivity consisting of three 
modules from DMN. After extracting the fMRI time series from the DMN modules through dual-
regression analysis, we used spectral DCM in SPM12 (375) to estimate pairwise EC among the 
DMN modules and constructed a directed and weighted graph (representing an EC network) for 
each subject.  
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Mediation analysis: We applied serial-multiple mediation analysis model using the 
structural equation modeling method (376) in AMOS 17.0 (SPSS Inc., Chicago, IL, USA) to 
uncover underlying functional pathways within DMN. Specifically, we first estimated the direct 
relationships between dependent variable (EC from RSC-HIPP module to Association module) 
and independent variable (FC within Frontal module). Then, in a mediation model, the FC between 
Association and Frontal module was added as a mediator. In this context, full mediation occurs 
when the relationship between the independent variable and the dependent variable is no longer 
significant with the inclusion of a mediator variable (377). For each pathway, we utilized the 
bootstrapping test for 1,000 times to test the significance. Finally, the mediation effect was 
evaluated using the Sobel test (378). The Supplementary Methods details the Sobel test analysis 
method.  
 
FDG PET procedure 
Mice were fasted 12h prior to undergoing 18F-FDG PET scans to reduce variability in blood 
glucose levels that could alter 18F-FDG uptake (117). Static PET scans were collected over two 
scan sessions on LC-NE (n=5) and control (n=6) subjects to represent sham-treated baseline or 
CNO conditions (in the same animal?).  Mice were briefly anesthetized under 1-3% isoflurane and 
injected with either a saline + DMSO vehicle or CNO (1 mg/kg, i.p.) and subsequently received 
an i.v. injection of ∼0.2 mCi of 18F-FDG after 5 min. Mice were recovered in their home cages 
for a 45 min uptake period.  Mice subsequently were anesthetized with isoflurane (2%) and 
underwent a 10 min CT and 20 min PET scan on a small animal PET/CT scanner (Argus-2R, 
Sedecal, Madrid, Spain). PET data were reconstructed using the 2D ordered subset expectation 
maximization (OSEM) algorithm expressed in standardized uptake values (SUV) and normalized 
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using muscle uptake of 18F-FDG using PMOD (PMOD Technologies LLC, Zurich, Switzerland).  
Data were represented as % changes in SUV between saline vehicle and CNO scans. 
 
Fiber-photometry procedure 
Surgical AAV microinjection and fiber implantation: LC-NE (n=5) and control (n=5) 
mice were microinjected 0.3 µl of AAV5-hsyn-NE2.1 (h-N01, WZ Biosciences) and 0.5 µl of 
AAV9-hsyn-jRGECO1a (100854, Addgene) to the left Cg1 (AP=2.2mm, ML=0.2mm, DV=-
1.6mm). The NE2.1 (a green fluorescent norepinephrine sensor) and the jRGECO1a (a red-shifted 
intracellular calcium sensor) were used for determining the NE release and postsynaptic neuronal 
activity, respectively. An optic fiber was implanted 0.3 mm above the injection site and imbedded 
to the skull using dental cement (C&B Metabond, S380, Parkell). 
Fiber-photometry recording: All recordings began at least four weeks after surgery. CY5-
conjugated Dextran fluorescent dye (20 mg/kg, R-FN-006, RuixiBio) was injected intravenously 
for CBV measurements. Animals were prepared and maintained under the same conditions as 
fMRI experiments. Detailed methods can be found in the Supplementary Methods. 
 
Immunohistology procedure 
PFA-fixed mouse brains were cut into 40 µm thick sections and placed in blocking solution 
(5% normal goat serum in PBS with 0.1 % Triton X-100) for 1 h prior to incubating in primary 
antibody overnight at 4°C. Primary antibodies were against dsRed (632496, Clontech 
Laboratories), GFP (AB13970, Abcam) and NET (1447-NET, Phosphosolutions). Sections were 
washed in PBS 3x and incubated for 2 h in the secondary antibody the following day. Secondary 
antibodies were Alexa Fluor 488, 568, 648 (Invitrogen). Sections were mounted onto glass slides 
and imaged on a Zeiss LSM 780 inverted confocal microscope. Background fluorescence was 
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 We compared the triple transgenic mouse line that expresses hM3Dq on LC-NE neurons 
against their respective hM3Dq-null littermate controls to account for off-target effects of 
clozapine-n-oxide (CNO) and clozapine (380). Using fluorescent immunohistology, we confirmed 
En1Cre ; DbhFlpo ; RC::FL-hM3Dq-mCherry neurons were predominately in the LC and sparsely 
in the subcoeruleus (Figure 4.1A) sending innervations primarily via the dorsal adrenergic bundle 
into the forebrain and sensory cortices, including canonical DMN regions (Figure 4.1B). Control 
mice showed no expression, confirming their lack of hM3Dq-DREADDs (Figure S4.1). 
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Figure 4.1 Histological verification of the LC-NE chemogenetic line and its projections.  (A) 
Schematic diagram of the transgenic crosses used to generate the triple transgenic mice 
expressing the RC::FL-hM3Dq allele, whereby the recombination of both En1Cre and DbhFlpo  
results in the expression of hM3Dq-mCherry on the cell bodies of LC-NE neurons that are 
localized exclusively in the LC and the SubC. (B) Schematic diagram of mice expressing the 
fluorescent indicator RC::FLTG allele, whereby the recombination of both En1Cre and DbhFlpo  
results in the expression of EGFP on axonal projections of LC-NE neurons.  Co-immunostaining 
using a Dbh antibody (red) show that LC-NE neurons exclusively project into conical DMN 
brain regions (co-localization of red and green). 
 
To functionally delineate the DMN and study selective NE modulatory effects, we 
performed in vivo CBV-weighted fMRI scans on LC-NE and control mice (n=9 and 12, 
respectively) under light isoflurane (~1%) anesthesia using an isotropic echo-planar-imaging 
protocol and spatially warped each imaging dataset into the Allen Mouse Common Coordinate 
Framework ((1); Figure S4.2). Though medetomidine is considered the preferred sedative for 
mouse fMRI (113, 381-384), we avoided its usage since it suppresses NE release (385). We 
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collected a 10 min resting-state baseline scan prior to administering a 1 mg/kg intraperitoneal 
injection of CNO, an established dosage capable of altering behavior in the LC-NE mouse line 
(352, 353), to selectively activate hM3Dq-expressing NE neurons (Figure 4.2A). We functionally 
parcellated the baseline fMRI data from all subjects (n=29) by performing a high model order 
(100-component) independent component (IC) analysis (386) (Figure 4.2, B and C) and verified 
their reproducibility (Figure S4.3). We identified 17 DMN related ICs (Figure S4.4A) according 
to previous rodent DMN studies (115-117, 387, 388). The areas showing significant temporal 
correlation associated with the 17 identified DMN ICs were reconstructed using dual regression 
(389), and one-sample t-test was performed to generate the group-level maps representing the 
connectivity of these ICs. These maps showed high spatial similarity compared to an RSC seed-
based connectivity map commonly used to depict DMN (Figure S4.4, B and C). Louvain 
community modularity analysis (390) clustered the 17 DMN ICs into three distinct modules (Q = 
0.10, p<0.01; Figure 4.2D). A Frontal module comprised of pre-limbic/infra-limbic (PrL/IL), 
lateral orbital (LO), cingulate 1 (Cg1) and anterior cingulate 2 (aCg2) cortices, a RSC-HIPP 
module comprised of the dorsal hippocampus (HIPP) and posterior Cg2 (pCg2), medial parietal 
association (MPtA), retrosplenial granular (RSG), retrosplenial dysgranual / visual (RSD / Vis) 
cortices, and an Association module comprised of posterior parietal (PPtC) and auditory (Aud) 
cortices. No significant difference among the connectivity of DMN ICs were found across baseline 
subject groups (PFDR-corrected > 0.05, Figure S4.4D). 
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Figure 4.2 Experimental design and identification of DMN modules. (A) Our studies used an experimental design 
comparing a 10 min baseline established prior to CNO administration to a post-CNO segment at 20-30 min following 
CNO administration. (B) 100 ICs were derived from group IC analysis of baseline scans among all subjects and DMN 
ICs were anatomically specified with respect to established brain regions found in canonical rodent DMN. (C) 
Correlation among the 100 ICs including the anatomically selected DMN ICs (red) were plotted with a threshold 
Fischer | z | > 0.3. (D) Modularity analysis of DMN ICs shows that the mouse DMN has a Frontal (yellow), RSC-
HIPP (pink) and Association module (blue). 
 
Using the Frontal, RSC-HIPP, and Association modules ROIs (one-sample t-test, P < 
0.0001) and striatum as a reference region due to sparse NE neuron innervation (Figure 4.2D), we 
examined how NE release from distinct neuronal populations modulate fMRI-derived CBV, 
regional homogeneity (ReHo) (391) and amplitude of low frequency fluctuation (ALFF) (392) 
changes among the DMN modules. To avoid transition-related effects we compared a 10 min 
baseline fMRI segment prior to administering CNO with an fMRI segment acquired between 20-
102 
30 min post-CNO in accordance with optimal CNO kinetics in fMRI (91, 93, 94, 393, 394) and 
behavior studies (352, 353). CNO-evoked NE release significantly decreased CBV in all DMN 
modules in LC-NE (unpaired t test, PFDR-corrected < 0.05) but not controls (Figures 4.3A and S4.5A). 
Interestingly, the ReHo (Figures 4.3B and S4.5B) and ALFF (Figure 4.3C and S4.5C) changes 
contradicted the intuitive interpretation of our CBV findings, implying a possible increase of 
synchronous, low-frequency activity in the Frontal and RSC-HIPP DMN modules in LC-
NE. Specifically, LC-NE mediated ALFF changes were found predominately between 0.01 and 
0.05 Hz (unpaired t test, PFDR-corrected < 0.05; Figure S4.5D). LC-NE induced CBV changes in the 
striatum despite the absence of direct NE innervations, likely due to LC-NE induced 
vasoconstriction at the trunk of the middle cerebral artery upstream of the watershed arterioles that 




To validate these fMRI findings, we employed spectral fiber-photometry (Figure 4.4A) in 
separate groups of LC-NE (n=5) and control mice (n=4). We virally expressed a genetically 
engineered NE2.1 sensor (71) and a red-shifted jRGECO1a calcium activity sensor (72) under the 
pan-neuronal human Synapsin-1 (hSyn) promoter in the Cg1 of the Frontal module (Figure 4.4B), 
where the effects of LC-NE were most robust. Additionally, we intravenously administered a CY5-
conjugated Dextran far-red fluorescent dye to measure CBV (Figure S4.6), allowing us to 
Figure 4.3 Changes in DMN modules between baseline and post-CNO in LC-NE and control groups. (A) CBV 
decreased significantly following LC-NE release across all DMN modules compared to baseline and controls. LC-NE 
release significantly increased (B) ReHo in the Frontal DMN module and (C) ALFF in both Frontal and RSC-HIPP 
modules compared to baseline and controls. * p < 0.05, ** p < 0.0001, error bars represent ±SD. 
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simultaneously detect changes in synaptic NE release, neuronal activity-mediated calcium influx 
and CBV in Cg1 (Figure 4.4C). After CNO administration, we observed significant increases in 
NE release (unpaired t test, PFDR-corrected < 0.05; Figure 4.4D), decreases in CBV (unpaired t 
test, PFDR-corrected < 0.05; Figure 4.4E), and increase in neuronal activity (unpaired t test, 
PFDR-corrected < 0.05; Figure 4.4F) in LC-NE group compared to controls. Notably, the number 
of calcium spikes also increased significant following CNO administration (unpaired t test, PFDR-
corrected < 0.05; Figure 4.4G), showing a hallmark of NE by tuning the signal-to-noise ratio of 
downstream neuronal firing (73). These findings also corroborate well with our fMRI results (Fig. 
3) and indicate that driving LC-NE release can concurrently induce regional vasoconstriction while 
enhancing neuronal activity in Cg1. Given that fMRI does not directly measure neuronal activity, 
these results highlight the importance of cautiously interpreting fMRI-derived DMN results when 




Figure 4.4  Triple-spectral fiber photometry measuring the NE release, CBV, and calcium-weighted neuronal activity 
in Cg1. (A) Experimental setup of the spectrally resolved fiber-photometry system. 488, 561 and 640 nm lasers were 
used to excite the targeted NE (NE2.1), CBV (CY5-Dextran dye), and neuronal activity (jRGECO1a) sensors, 
respectively. (B) Confirmation of viral transfection and expression of NE2.1 (green) and jRGECO1a (red) sensors on 
Cg1 neurons. (C) Spectral profiles of the NE, CBV, and neuronal activity sensors. Effects of CNO on NE release, 
CBV, and neuronal activity in Cg1 from representative subjects and group level bar graphs are shown in (D-F), 
respectively.  (G) CNO-induced LC-NE release altered post-synaptic calcium spiking pattern resulting in a significant 
increase in spike counts. (* p < 0.05 and ** p < 0.01) 
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 We also examined the effect of NE on brain glucose uptake in a subset of LC-NE (n=5) 
and control (n=5) mice using an established [18F]-fluorodeoxyglucose (FDG)-PET protocol (396). 
Interestingly, we found CNO-induced LC-NE release significantly decreased glucose uptake in all 
three DMN modules (unpaired t test, PFDR-corrected  < 0.001), but not control subjects (Figures 5 and  
S4.7). Though there are mixed findings on how NE alters glucose uptake (358-363), most studies 
using pharmacology to enhance NE release showed suppressed glucose uptake (358-363) by 
shifting astrocyte metabolism to preferentially utilize glycogen reserves (362, 363). Taken 
together, these findings suggest additional caution should be considered in cases when FDG-PET 




To shed light on how selective NE release modulates DMN connectivity and network 
properties, we examined FC changes within and between Frontal, RSC-HIPP, and Association 
modules in LC-NE (n=9) and control mice (n=12). We found that CNO significantly enhanced FC 
within Frontal (F(2,26)=5.2, PFDR-corrected < 0.05) and between Frontal and Association modules (F(2,26) 
Figure 4.5 Changes in glucose metabolism in DMN modules following CNO-evoked LC-NE neuronal firing were 
evaluated to levels in the same subjects following sham treatment.  (A) LC-NE release significant decreased FDG 
uptake compared to saline-treated sham and controls showing (B) significant reduction in difference in standard uptake 
values (SUV) in all DMN regions compared baseline uptake levels. (* p < 0.001 and ** p < 0.0001, error bars represent 
SEM)	
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=6.0, PFDR-corrected < 0.05) of the DMN in LC-NE, but not control groups (Figure 4.6, A and B). 
Notably, the high intramodular connectivity characterized by within-module degree (WD) indicate 
that Cg1 and RSC serve as provincial hubs for the Frontal and RSC-HIPP modules of the DMN, 
respectively (Figure S4.8, A and B). The high intermodular connectivity characterized by 
partition coefficient (PC) indicate aCg2 within the Frontal module serves as a connector hub 
throughout the entire DMN and may control the FC between Frontal and other modules (Figure 
S4.8, A and B). Given the putative causal control of the insula on the Frontal module of the DMN 
(327), we also examined the effects of LC-NE on their FC changes and found that enhanced LC-
NE release significantly enhanced anti-correlation between these regions (Figure S4.8, C and D).    
 
 
To further unravel the causal influences in the FC of DMN modules by enhanced LC-NE 
release, we conducted a dynamic causal modeling (DCM) analysis (87) and found LC-NE 
significantly reduced effective connectivity (EC) from RSC-HIPP to the Association module (two 
Figure 4.6  DMN functional connectivity (FC) changes. (A) Within and between DMN module FC changes. (B) Network-
based statistic (NBS) analysis showing significant differences in FC among edges in LC-NE > Control. (* PFDR-corrected 
< 0.01, error bars represent SD) 
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tailed t-test, PFDR-corrected < 0.05, Figure 4.7A) compared to control subjects (Figure S4.9). Together 
with the robust NE modulatory effects in the Frontal module, these findings prompted us to 
conduct a mediation analysis to determine the origin of the FC changes in the Frontal module. 
Using a general linear model (GLM) we demonstrated that the reduction in EC observed from 
RSC-HIPP to the Association module causally manipulates the FC changes within the Frontal 
module (coefficient = -0.53±0.13, P < 0.001; Figure 4.7B). When we incorporated the FC 
increases between the Frontal and Association modules as a mediator, we observed a full 
mediation effect of the reduced EC to the Frontal module FC changes while the relationship 
became no significant between the reduced EC from RSC-HIPP to the Association module and the 
increased FC within Frontal module (coefficient = -0.26±0.13, N.S.). The Sobel test (397) further 
indicated the significant mediation effect (Sobel z = -2.02, P < 0.05; Figure 4.7B). In contrast, we 
did not observe the reduced EC from the RSC-HIPP to Association module being mediated by the 
Frontal FC changes via the FC increases between Frontal and Association modules (Figure 
S4.10). Collectively, these findings indicate that LC-NE modulates the DMN by strengthening 
connectivity within Frontal and between Frontal and Association modules, and these changes are 
causally mediated by reducing the RSC-HIPP control over the Association module. 
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Figure 4. 7 Dynamic causal modeling (DCM) and mediation analysis among DMN modules. (A) DCM analysis among 
DMN modules found RSC-HIPP causal modulates the Association module upon evoking LC-NE release. (P-value 
was FDR corrected) (B) Mediation analysis was performed with direct effect (a, b, c) and with a mediator (c’). A 
Sobel test was also performed (red line) to evaluate the significance of mediation effect (Sobel z-value = -2.02, p < 
0.05). (P-values are denoted as * < 0.05, ** < 0.01, *** < 0.001, n.s. = no significance)	
 
DISCUSSION 
The Mouse DMN 
Structural homologues to the human DMN have been reported in mice by multiple 
neuroimaging modalities including fMRI, optical imaging and functional ultrasound (64, 109, 
115, 326, 387, 388, 398-400).  Most studies extract the mouse DMN using ICA or seed-based 
connectivity analyses, resulting in consistent DMN architectures. A multi-center study led by 
Grandjean et al. analyzed several resting-state mouse fMRI datasets acquired under various 
conditions (e.g. magnetic field strengths, coils, imaging parameters, and anesthesia protocols) 
and generated a group ICA atlas delineating mouse brain connectivity (115). The results pulled 
three DMN modules that include prefrontal, cingulate/retrosplenial, and temporal association 
areas. Similar to those findings, analysis of our data revealed three modules including Frontal, 
110 
RSC-HIPP, and Association modules, where the Frontal and RSC-HIPP modules in our results 
included prefrontal and posterior cingulate components, respectively (Figure 4.2C). Those three 
modules were also evident in a recent study dissecting the constituents of the rat (401) and 
human DMN (402), and supported by structural connectivity using diffusion tractography (403).  
Structural connections within and between these three DMN modules in mice have been 
established using neuronal tract-tracing (404), lending further support to the validity of the DMN 
modules used for subsequently analyses in this study. 
 
LC-NE Modulates DMN Activity 
Several research groups have pioneered chemogenetic fMRI and PET approaches to map 
the influence of neurotransmitters and neuromodulators on brain networks (91, 94, 394, 405, 
406). Our experimental design employing intersectional chemogenetic mouse lines presented a 
unique opportunity to investigate DMN modulatory effects by enhanced NE release from 
ontogentically distinct brain regions.  We demonstrated that chemogenetic activation of LC-NE 
neurons showed significant reduction in CBV and glucose uptake among all three DMN modules 
compared to hM3Dq-null controls (Figures 4.3 and 4.5). Utilizing rigorous designed controls is 
essential in chemogenetic studies (407) since off-target binding of CNO or clozapine through 
reverse-metabolism of CNO (380) can generate detectable effects as observed in our hM3Dq-
null control data.   
While both fMRI and fiber-photometry showed robust CBV reduction in the Frontal DMN 
module following stimulation of LC-NE neurons, we observed a concurrent increase of 
synchronous low frequency activity as measured by ReHo, ALFF, and changes in calcium activity 
in our experimental condition (Figure 4.4, D-G). The most straightforward interpretation of the 
fMRI data based on well-documented neurovascular coupling rule (408) does not apply directly in 
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this scenario due to the potent vasoconstrictive properties of NE (354, 355). The neuromodulatory 
effect induced by NE release appears inconsistent in literature, likely due to differences in brain 
states, basal firing rate, and the experimental parameters utilized to induce NE release (94, 364-
366, 409). Literature has also shown mixed findings regarding the effects of NE on both cerebral 
hemodynamics and metabolism. This is likely because common pharmacological agents used to 
induce NE release suffer from differential actions and non-selective binding that can either 
increase (410) or decrease perfusion (354, 355) and increase (358, 359) or decrease glucose 
metabolism (360, 361).  Of note, the changes observed in glucose metabolism following LC-NE 
stimulation could also be attributed to doses-dependent shifting of brain metabolism among 
astrocytes, which at high NE levels shift to preferentially metabolize glycogen deposits over 
utilization of blood glucose (362, 363). Unlike many studies that use pharmacological 
manipulations of NE release, our chemogenetic approach coupled with multimodal measurement 
of NE, neuronal activity, and CBV revealed the NE effect in increasing synchronized low 
frequency activity, strengthening neuronal firing, and decreasing CBV. This has significant 
implications for the use of fMRI in interpreting DMN neuronal activity, whereby ‘deactivation’ of 
raw fMRI signal caused by LC-NE may not necessarily represent reduced DMN neuronal activity.  
Nevertheless, enhanced LC-NE release in human fMRI studies using atomoxetine (409, 
411) and pupillary dilation under dark settings (412) support that higher levels of tonic LC-NE 
release enhance synchrony within local rather than distant brain regions, and that NE shifts resting-
state activity from widely distributed patterns to tighter clustered patterns dominated by the 
strongest input networks. This interpretation is well supported by our findings showing enhanced 
ReHo within the Frontal DMN module following CNO-evoked LC-NE release. Our ALFF results 
also showed that modulation of the Frontal DMN by LC-NE release was coupled with enhanced 
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low-frequency power. We found that the LC-NE induced low-frequency power changes is 
restricted to a frequency band ranging from 0.01 to 0.05 Hz — a range associated with robust 
changes in human DMN (413). Alterations in the power within this sub frequency band of ALFF 
play a vital role in attention reorientation during visual-motor attentional tasks (413), which has 
also been linked to changes in cortical NE levels (414).  
 
LC-NE Modulates DMN Connectivity 
LC-NE enhanced FC within the Frontal module and between Frontal and Association 
modules. In agreement with our finding, a recent study virally transfecting hM3Dq via the Dbh 
promotor into the LC found significant FC enhancement in the Cg1, Cg2 and RSC following 
chemogenetic stimulation (94).  The increased FC within the Frontal modules of the DMN aligns 
with the findings that spontaneous rises in tonic LC-NE release, as detected by changes in pupil 
dilation, disrupts FC network integration and shift towards segregated network topologies with 
enhanced temporal correlation within local brain networks (334, 412). Furthermore, our findings 
show LC-NE enhance the anti-correlation between the Frontal DMN module and the insula 
(Figure S4.8, C and D), a key node of the salience network that may causally suppress DMN 
(327). This enhanced polarization among networks also supports the plausible mechanism by 
which NE-targeting pharmacological agents like atomoxetine, clonidine and guanfacine are 
effective in treating ADHD patients since they strengthen the FC within the Frontal DMN module 
resulting in improved attention (415, 416). Additionally, abnormally heightened FC in Frontal 
DMN regions have been associated with anxiety and depression (417, 418), which coincide with 
anxiety-like behavioral phenotypes such as reduced locomotor activity when placed in a novel 
environment and anhedonia following chemogenetic stimulation LC-NE in awake mice (352). 
Optogenetically driving LC-NE neurons at frequencies above 5 Hz have been shown to entirely 
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suppress novelty-seeking behavior and result in freezing (419), which is likely driven by impaired 
FC in Frontal DMN brain regions associated with the activation of lower affinity adrenergic 
receptors signaling to induce an aversive affective states (420). 
Our DCM and mediation analyses show that enhanced Frontal module connectivity in the 
DMN was causally manipulated by reducing RSC-HIPP control of the Association module, with 
the connectivity between the Association and Frontal modules serving as a key mediator.  These 
findings reveal a new understanding of how LC-NE controls the signaling cascades within DMN 
modules and achieve its control of the Frontal cortical regions, which are among the most well-
studies projection targets of LC-NE due to their importance in shaping multiple behaviors (420). 
LC-NE neuronal loss and the subsequent depletion of cortical NE are widely considered to be 
among the first sites of neurodegeneration in Parkinson’s (338, 339) and Alzheimer’s disease (338, 
340, 341), resulting in behavioral pathologies linked to alterations in DMN such as delayed 
attention shifting (421, 422), enhance mind-wandering (423, 424) and reduced cognitive and 
emotional processing of sensory information (422, 423). Optogenetically-evoked LC-NE release 
into prefrontal and orbitofrontal cortices enhances stimulus and goal-directed attention with 
decreased impulsivity (425). Conversely, the suppression of LC-NE exacerbates distractibility and 
impulsivity (425) — similar to that observed in Parkinson’s and Alzheimer’s disease patients (422, 
423). Thus, alterations within Frontal and between Frontal and RSC-HIPP DMN modules may 
serve as early biomarker associated with pathologies of the LC-NE. Our circuit-level findings 
could also pave the way towards a novel means to causally control the Frontal DMN via the RSC-
HIPP module when LC is degenerated, such that the behavioral traits relevant to the Frontal DMN 
may be restored when endogenous NE is diminished.  
114 
CHAPTER 5: GENERAL DISCUSSION 
 
SUMMARY OF FINDINGS  
The studies described in this dissertation helped establish reliable and reproducible 
methodologies for acquisition and analysis of intrinsic connectivity networks in mouse fMRI data 
sets. We validated these techniques by revealing that LC-NE modulation can orchestrate changes 
in DMN activity and connectivity.  In Chapter 2, we provide detailed mouse fMRI pipeline 
integrating AFNI and ANTs tools to standardize both BOLD- and CBV-weighted mouse fMRI 
data sets within the Allen Mouse Atlas Common Coordinate Framework (v3). This pipeline will 
improve the ability for mouse researchers to perform multimodal analytics across several 
neuroimaging platforms. In Chapter 3, we developed and validated a long-circulating iron oxide 
nanoparticle contrast agent termed CION for use to enhance fMRI signals in mice.  Our findings 
show that CION serves as a comparable alternative to Feraheme.  In Chapter 4, we utilized our 
iron oxide contrast agent and automated mouse fMRI pipeline to investigate the role of LC-NE on 
the modulation of the DMN.  Our study present evidence that LC-NE can selectively enhances 
functional brain activity in the Frontal DMN module that are counterintuitive to the observed 
reduction in CBV and glucose uptake changes—implicating that the modulation of LC-NE on 
many brain regions that form the Frontal DMN present a mismatch in neurovascular coupling. 
LC-NE release selectively enhanced functional connectivity within nodes of the Frontal and 
between Frontal and Association DMN modules, while strengthening anti-correlations between 
the Frontal DMN module and Insula.  Lastly, LC-NE modulates these DMN changes by disrupting 
the information flow between Retrosplenial-Hippocampal and the Association module to resulting 
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in the aforementioned alteration to the functional connectivity observed in DMN. These 
findings reflect a key neurobiological understanding of the functional flow of DMN in mice that 
may underpin many maladaptive DMN-related behaviors observed in the neuropathologies with 
alterations to LC-NE neuronal firing patterns or LC-NE neurodegeneration.    
 
GENERAL IMPLICATIONS OF FINDINGS  
Several studies, including those in this dissertation, have shown that mouse brains have 
intrinsic connectivity networks that are homologous to those detected in humans.  These intrinsic 
connectivity networks are dynamic and are continuously engaged regardless of task, stimulation 
or level of consciousness. The first aim of this dissertation was to design an acquisition protocol 
and analytical pipeline to detect and measure intrinsic connectivity networks in mice.  By 
functional parcellating the brain into 100 ICs and clustering these ICs using modularity analysis 
we identified 20 intrinsic connectivity networks in the mouse brain, including three modules that 
form the mouse DMN. The intrinsic connectivity networks detected in our study were consistent 
with known mouse brain networks—including known functional boundaries with distinct 
network projection such as that observed in the primary and second olfactory bulb networks and 
anterior and posterior cerebellar networks.  Since functional segregations methods do not imply a 
priori knowledge of known anatomical structures but rather performs an unbiased voxelwise 
analysis of the entire brain, the implication of our method to detect 20 known intrinsic 
connectivity networks validates that our acquisition parameters and functional segregation 
methods are robust enough to accurately and consistently detect intrinsic connectivity networks 
in mouse fMRI datasets. Additionally, by designing the pipeline to overlap with the Allen Brain 
Atlas Common Coordinate Framework (v3), these findings illustrate the utility of our pipeline to 
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detect and analyze whole-brain networks in mice in order to advance network neuroscience 
research. 
Although long-circulating iron-oxide nanoparticles exist, the lack of availability of 
comparable commercial contrasts for CBV-weighted fMRI animal research in many countries 
made it essential to introduce a simple method for researchers to produce their own CION 
contrast agents to reliably improve fMRI signal detection for the sake of continuity in global 
neuroscience research.  We validated our CION contrast and showed that it not only maintains 
circulatory steady-state with minimal clearance, but also validated its safety by performing 
toxicity studies to with optimal imaging dosages.  Our findings show that CION can safely and 
successfully be used to measure CBV-weighted fMRI in animals and can detect fMRI signal 
changes associated with sensory stimulation, hypercapnia and optogenetic activation—as well as 
chemogenetic and pharmacological stimulation in Chapter 3.  
Lastly, our finding that LC-NE release can dramatically enhances both brain activity and 
connectivity in the Frontal DMN modules has important implications for understanding how NE 
targets DMN activity changes. Although LC-NE is implicated in modulating behaviors 
associated with the DMN such as day-dreaming and attention reorientation towards salient 
stimulation and medication that enhances NE release has been shown to restore maladaptive 
DMN changes associated with ADHD, the modulatory pathway of LC-NE on DMN has never 
been studied. Our findings suggest that LC-NE release selectively enhances synchronous low 
frequency power, as detected by ReHo and ALFF, within the Frontal module of the DMN, yet 
induced a decreased in both CBV and glucose uptake suggesting that LC-NE can produce a 
mismatch in neurovascular coupling. We confirmed this mismatch was genuinely attributed to 
enhanced changes in brain activity by measuring calcium-weighted neuronal spiking activity in 
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the cingulate cortex following LC-NE release. LC-NE release strengthened the functional 
connectivity among the brain regions that makeup the Frontal module and among the 
interconnected brain regions linking Frontal and Association modules of the DMN.  These 
findings indicate that LC-NE enhances the fidelity of signal transfer among these regions of the 
DMN. Lastly, using a causal model to detect the directionality by which LC-NE modulates these 
DMN changes, we found that LC-NE first causally disrupts the information flow from the 
Retrosplenial-Hippocampal to the Association module resulting in enhanced functional 
connectivity changes observed in the DMN.  For the first time, our findings provide a clear role 
of how LC-NE modulates the DMN that has great implications on how to pharmaceutically 
target disorders with DMN maladaptation. 
 
TECHNICAL CONSIDERATIONS AND LIMITATIONS   
Use of Anesthesia 
All mouse fMRI studies described in this dissertation were acquired under 1% isoflurane 
anesthesia to limit motion and stress-related artifacts during scans.  Although studies have shown 
that a combination of dexmedetomidine and isoflurane produce optimal conditions for the 
detection of intrinsic connectivity networks in mice that closely resemble that acquired from 
awake studies, the very nature of our study investigating the role of LC-NE on DMN did not 
permit us to use dexmedetomidine since it globally suppresses NE release in the brain and under 
awake conditions the LC-NE is known to become activated under conditions of stress such as 
those associated with head fixation.  Though isoflurane has been shown to dose-dependently 
suppress fMRI signals and depress correlated fluctuations within and among intrinsic 
connectivity networks, we used a relatively low levels of anesthesia keeping our mice in a semi-
conscious plane with minimal movement and were capable of extracting reliable and 
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reproducible intrinsic connectivity networks. Nonetheless, since these studies do not fully reflect 
those that would be observed during the awake state, future studies should replicate our findings 
in conscious, head-fixed mice following habituation.  
Though awake fMRI imaging has been carried by several laboratories for over five years, 
it still faces several technical challenges.  Since awake mice must be immobilized within the 
MRI scanner bore that produces loud noised during fMRI acquisitions, fear and stress networks 
are likely activated require habituation to these stressors.  Though most groups perform 
habituation in mock scanner that mimic the head restraint and play a recording of the acquisition 
sounds from the scanner, it has been shown that cortisone levels post-habituation spike when 
habituated rodents are scanned under real MRI conditions.  These results suggest that proper 
acclimation procedures must still be reassessed to reduce stress-related confounds.     
 
Lack of Global Signal and White Matter Regression 
Many mouse fMRI studies regress out the global signal to remove the effects of global 
variations attributed to anesthesia related changes in physiology. Though originally employed to 
produce more focal correlation patterns (85), this practice remains controversial due the potential 
of removing valuable information and introducing anti-correlation artifacts (426).  Likewise, the 
regression of white matter in the brain as a nuisance regressor is also rather controversial (427).  
To avoid potential confounds attributed to this processing, our mouse fMRI pipeline regresses 
changes in physiology by extracting and regressing the CSF signal through ICA denoising.   
 
Use of Clozapine-n-oxide 
Though many studies have shown compelling evidence that CNO does not penetrate the 
blood-brain barrier (380, 428), but rather undergoes reverse metabolism to become clozapine—
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which can both penetrate the blood-brain barrier and bind to DREADD receptors such as the 
hM3Dq receptor utilized in the research conducted in Chapter 4.  Unlike CNO, clozapine is a 
promiscuous ligand capable of binding to many receptors including serotonin, dopamine,	α-
adrenergic, muscarinic and histamine receptors (429)—thus its use as a DREADD ligand seems 
to go against the logic of why DREADD receptors were created. Though more specific 
DREADD ligands are available such as compound 21 (428) and deschloroclozapine (430), which 
show no binding to other GPCRs, we used CNO in our study for the sake of continuity since the 
triple transgenic LC-NE DREADD line was first characterized and shown to alter behavior using 
1 mg/kg of CNO (352, 353).  
 
 
FUTURE DIRECTIONS  
Our findings that NE can alter activity and connectivity in the Frontal module of the DMN 
gives rise to many interesting follow-up studies that may be performed.  The first sensible study 
to perform could be to perform the reverse study, namely inhibiting LC-NE release using 
DREADDs to fully verify the involvement of LC-NE on DMN modulation.  Addition the use of 
awake, habituated triple transgenic LC-NE mice in future studies should also be strongly 
considered.  Awake conditions allow for greater engagement as well as disengagement of the 
salient network that is anti-correlated to the DMN—resulting in more robust fluctuation of intrinsic 
functional network dynamics.  Furthermore, using multispectral fiber photometry, the effects of 
LC-NE on DMN activity on behavior can be assessed using an auditory oddball paradigm (431) 
in the triple transgenic LC-NE mice.  Additionally, detail input output tracing has previously been 
demonstrated on LC-NE neurons using viral vectors that selectively transfect DbhCre mice in a 
retrograde manner to label a selective population of LC-NE neurons that project to a given target 
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site (432).  Using this method, we can label LC-NE projections within the Frontal and Association 
modules of the DMN to detect the primary modulatory input sites. 
Additional studies looking at the role of LC-NE on sensory networks could also be highly 
informative when paired with fMRI.  Though many studies have investigated the role of NE with 
changes in neuronal gain associated with sensory system such as the visual, auditory and 
somatosensory systems, investigating the role of NE on gustatory or olfactory system could prove 
to be a promising target for LC-NE studies since gustatory and olfactory cues are easy to deliver 
within an fMRI study.  As with cautions presented in Chapter 4, it would be imperative that 
multiple modality measurements be made in these systems to confirm network level changes 




APPENDIX 1: SUPPLEMENTAL MATERIALS FOR CHAPTER 3 
 
SUPPLEMENTAL METHODS 
Labeling of CION with a Rhodamine B Fluorophore 
To label CION with Rhodamine B, 200 mg (0.418 mmol) of Rhodamine B was dissolved 
in minimum volume of acetonitrile in a 50 ml beaker and activated with 1-ethyl-3-(3-
(dimethylamino) propyl) carbodiimidehydrochloride (EDC· HCl, 104 mg, 0.543 mmol) in the  
presence of bicarbonate coupling buffer (0.5 ml). After stirring the reaction mixture for 15 h in 
darkness, 0.3 ml 2,2′-(ethylenedioxy)-bis-(ethylamine) (EDEA) was added to the reaction 
mixture and left to stirring at 25°C for another 24 h in darkness. In a separate beaker, a colloidal 
suspension of CION17143 in PBS (4 ml, 17 mg Fe/ml) was activated with 25 mg of EDC in 
presence of bicarbonate coupling buffer. After 24 h of continuous stirring, EDC activated 
CION17143 was added to the contents of the first beaker and stirred for another 24h. Thereafter, 
the reaction mixture was poured to a 30 ml Slide-A-Lyzer dialysis cassette and dialyzed against 
PBS for 4h to remove the unreacted dye and other reagents as well biproducts from the 
nanoparticles. The purified, fluorescent-tagged CION17143 was freeze-dried and stored at 4°C for 







Table S3.1. List of Equipment, Laboratory Supplies and Reagents required for CION synthesis. 
The information provided herein is just to provide a guideline to new users, who intend to set up 
their own contrast agent laboratory and replicate CION synthesis within their own lab setting.  
*Source of equipment and labware are suggestive only. This information is just to provide a 
guideline to new users to recreate the exact conditions utilized in this study.  
** Prices vary on geographical location, vendors and specification of instrument procured. 
  
S/No Equipment Source * Price  Number  Cost  
1. Fisher Scientific™ Isotemp™ Stirring Hotplates FischerSci 539 1 $539 
Accessories 
a. Transparent Shield FischerSci 23.35 2 $46.7 
b. 12mm dia Support Rod FischerSci 39.90 2 $79.8 
c. C-5, Clamp Holder, 12 mm dia. FischerSci 8.86 2 $17.72 
d. 3 60 mm Prong Clamp FischerSci 15.51 2 $31.02 
e. Octagon Magnetic Stirring Bars FischerSci 8.81 2 $17.62 
f. Magnetic Stir Bar FischerSci 36.40 / 6 1 $36.40 
3. Caframo	BDC250	Overhead	Stirrers	 ThomasSci 392.34 1 $392.34 
4. 1.9 L Branson CPX ultrasonic bath  Millipore  556.20 1 $556.20 
5. UNICO Powerspin LX Centrifuge Amazon 492.66 1 $492.66 
6. Vortex Mixer FischerSci 252.88 1 $252.88 
7. Digital	Analytical	Balance	 Amazon 430 1 $430 
Labware (One-Time Purchase) 
1.  Borosilicate Glass Beaker Set (25/50/100/250/500/1000 ml) Amazon 19.95 2 $39.9 
2.  SUPERLELE Glass Beaker Set (500/1000/2000ml) Amazon 22.99 1 $22.99 
3.  Immersion Thermometers FischerSci 12.25 2 $24.5 
4.  Stainless Steel Lab Spatulas Amazon 11.99 1 $11.99 








       




















































































Figure S3.4. Pharmacokinetic profile of CION. (A) Comparison of ΔR2*max of various CION 
formulations. (B-E) Exponential curve fitting of hippocampal ΔR2* signal changes as function of 
time in rats treated with CION 60000, CION 12000, CION 17143 and Feraheme respectively. (F) 
Linear fit of hippocampal ΔR2* signal changes as function of time in rats treated with CION 17143 











































































CNO was obtained from the NIMH Chemical Synthesis and Drug Supply Program 
(Bethesda, MD) and prepared fresh before every study.  CNO was prepared by suspending in a 
minimal volume of DMSO (Sigma-Aldrich, St. Louis, MO) at a concentration of 100 mg/ml. 
CNO and DMSO solution was diluted in saline at a 10% solution (v/v) and sterilized using a 20 
µm filter (Millipore, Burlington, MA). Mice were dosed at 1 mg/kg.  
 
fMRI Pre-processing 
Slice-Time Correction: Slice-time correction interpolating the temporal offsets during 
interleaved acquisitions of slices to eliminate radio frequency pulse excitation leakage artifacts. 
Correction was done by adjusting slice timing to a reference time point using 3dTshift in AFNI. 
 
Motion Correction: Motion correction applies rigid-body transformation to align all 
temporal volumes to a reference volume to correct for head motion during fMRI acquisitions that 
may produce spurious correlations if uncorrected. Our pipeline utilizes 3dvolreg in AFNI.  
 
Brain Segmentation: Brain segmentation, also known as skull-stripping, was performed 
using established U-Net deep-learning skull stripping tool [57].  CBV-fMRI time series were 
averaged to single volume and corrected for image intensity non-uniformities using 
N4BiasFieldCorrection in ANTs. 
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Spatial Normalization: We first generated an averaged interim CBV-fMRI mouse atlas 
which was co-registered and placed through linear and non-linear warping using 
antsRegistrationSyN.sh in ANTs into the template space of the Allen Mouse Brain Atlas (v3).  
The Allen Mouse Brain Atlas utilizes the Mouse Common Coordinate Framework allowing 
researchers to overlap their data into the standardize template space. We then spatially 
normalized all individual subject (n=29 to our interim CBV-fMRI mouse atlas on ANTs.  Linear 
affine transformation matrices and warp field maps were applied across the entire CBV-fMRI 
time series using WarpTimeSeriesImageMultiTransform in ANTs. A final CBV-fMRI mouse 
atlas was generated for future studies using all spatially normalized subjects into the Allen 
Mouse Brain Atlas template space using the deformation template generator 
antsMultivariateTemplateConstruction2.sh in ANTs to form averaged atlases. 
 
Cleaning and De-noising fMRI data: Spatially normalized fMRI datasets were first de-
spiked using 3dDespike in AFNI to eliminate large signal intensity spikes that surpassed ±2.5 
standard deviations above the local median absolute deviation calculated at every time frame 
against ±4 adjacent time frames. Next, the data underwent nuisance variable regression based on 
General Linear Model (GLM) using 3dDeconvolve in AFNI to eliminate the contribution of 
measurable noise from non-meaningful sources such as head motion and periodic physiological 
pulsations that include cardiac, respiratory, vascular and CSF oscillations. The GLM included six 
motion regressors (accounting for motion correction in the X, Y and Z translation directions and 
pitch, yaw, and roll in rotation directions) and CSF oscillations extracted from a mask layer of 
the ventricles of the mouse brain to routinely account for cardiac pulsation noise.  We did not 
regress the global signal since it has been demonstrated to introduce spurious, anti-correlations 
throughout the brain in some cases. The data then underwent spatial smoothing using 0.6 mm 
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full width at half maximum (FWHM) Gaussian kernel to improve signal to noise ratio (SNR). 
The data was then de-trended to remove drifting likely associated with MRI gradient heating 
during acquisitions. Lastly, the data underwent temporal filtering using a bandpass filter for 
frequencies between 0.01-0.01 Hz to extract meaningful low-frequency oscillations while 
eliminating high frequency noises/artifacts.  
 
fMRI Analysis 






















where S0 represents MR signal intensity before iron oxide administration, SpreCNO represents MR 
signal intensity after iron oxide administration but before CNO administration, and SCNO 
represents MR signal intensities after CNO administration. 
 
Modularity Analysis:  Modules refer to groups of nodes that are highly connected with 
each other but less connected with other nodes in a network. The modularity 𝑄 quantities the 
efficacy of partitioning a network into modules by evaluating the difference between the actual 
number of intramodule connections and the expected number for the same modules in a 
132 
randomized network. The objective of a module detection procedure is to find a specific partition 
that maximizes the modularity 𝑄. Newman’s spectral algorithm was used for modular detection.  
To examine whether a network has significantly higher modularity than the random graphs, we 
randomized the original network with preserved strength distribution 1,000 times and calculated 
the mean (𝜇) and standard deviation (𝜎) of those modularity values. We compared the 






which measures how many standard deviations the real modularity is above the mean for 
the random graph. 
 
Sobel Test Calculations:  The mediation effect of each significant path was evaluated using 
the Sobel test whereby the z-value was estimated using the following equation: 
 




where 𝑎 is the mean regression coefficient for the association between independent variable and 
mediator, 𝑏 is the mean regression coefficient for the association between mediator and 
dependent variable, 𝑆bis standard error of 𝑎, and 𝑆d is standard error of 𝑏. 
 
Fiber Photometry 
The fiber photometry setup for this study required triple-excitation continuous wave 
lasers at 488 nm (OBIS Galaxy 488nm LX 100mW, 1236444, Coherent Inc., Santa Clara, CA, 
USA), 561 nm (OBIS Galaxy 488nm LS 80mW, 1275608, Coherent Inc., Santa Clara, CA, 
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USA) and a 644 nm (OBIS Galaxy 640nm LX 75mW, 1236445, Coherent Inc., Santa Clara, CA, 
USA) housed in an OBIS LX/LS Laser Box (1228877, Coherent, Inc.).  The lasers were aligned 
and combined using OBIS Galaxy Laser Beam Combiner (1253556, Coherent Inc., Santa Clara, 
CA, USA) and the beam was sent through a neutral density filters (NEK01, Thorlabs, Newton, 
NJ) and a dichroic mirror (ZT405/488/561/640rpcv2, Chroma Technology Corp., Bellow Falls, 
VA, USA) within a fluorescence cube (DFM1, Thorlabs, Newton, NJ, USA). The combined 
laser beam was cast through an achromatic fiber port (PAFA-X-4-A, Thorlabs, Newton, NJ, 
USA) into a multimode optical fiber patch cable with a 105 µm core (M61L01, Thorlabs, 
Newton, NJ, USA) terminating into a 1.25 mm OD ceramic ferrule connected to the surgically 
implanted optical fiber cannula via a ceramic spilt sleeve (SM-CS125S, Precision Fiber Products 
Inc., San Diego, CA, USA). Emitted fluorescent signals travels back along the patch cable, 
through the emission filters of the dichroic mirror and emission filter (ZET405/488/561/640mv2, 
Chroma Technology Corp., Bellow Falls, VA, USA), then was launched through an aspheric 
fiber port (PAF-SMA-11-A, Thorlabs, Newton, NJ, USA) into the core of an AR-coated 200/230 
mm core/cladding multi-mode patch cable (M200L02S-A, Thorlabs, Newton, NJ, USA). The 
AR-coated multi-mode patch cable was connected to a spectrometer (QE Pro-FL, Ocean Optics, 
Largo, FL, USA) for spectral data acquisition, which was operated by a UI software OceanView 
(Ocean Optics, Largo, FL, USA).  
In order to perform spectral linear unmixing of the spectroscopy data, we used the 
following linear regression algorithm:  
 
𝑌(𝑡) = 𝐴 + 𝐶𝑜l8;.6 ∗ 𝑆l8;.6 + 𝐶𝑜nop8qr6b ∗ 𝑆nop8qr6b + 𝐶𝑜qst=uvw&xby ∗ 𝑆qst=uvw&xby + 𝜀(𝑡) 
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whereby 𝑌 𝑡  is the observed mixed spectrum at any given time and 𝑆l8;.6, 𝑆nop8qr6b and 
𝑆qst=uvw&xby are the normalized reference emission spectra for NE2.1, jRGECO1a and CY5-
conjugated Dextran fluorescent dye, respectively. A is an unknown constant while 𝐶𝑜l8;.6, 
𝐶𝑜nop8qr6b, and 𝐶𝑜qst=uvw&xby	are unknown regression coefficients that correspond to the green, 
red and far-red channels, respectively. Lastly, 𝜀(𝑡) denotes the random error associated with the 
model. The model allow us to estimate A, 𝐶𝑜l8;.6, 𝐶𝑜nop8qr6b, and 𝐶𝑜qst=uvw&xby	at each time 
point. The 𝐶𝑜l8;.6, 𝐶𝑜nop8qr6b, and 𝐶𝑜qst=uvw&xby were further detrended according to their 
baseline period using a homemade Matlab script. The spike SNR during the first 10 min baseline 
and the last 10 min post-CNO recording were calculated following high-pass filtering (cut at 0.1 




Mouse brains perfused in 4% PFA in PBS were post-fixed overnight at 4°C and 
subsequently equilibrated in 30% sucrose in PBS for 48 h at 4°C. Brains were embedded in 
Tissue Freezing Medium (General Data Company, Cincinnati, OH, USA) and cut into 40 µm 
thick section on a cryostat and stored free-floating in 30% sucrose/30% ethylene glycol in PBS at 
−80°C. Free-floating sections were washed in 0.1% Triton X100 in PBS (PBST) and 
subsequently incubated in 0.1M glycine in PBST (30 min, room temperature) and 5% normal 
goat serum in PBST (1 h, room temperature). Cell bodies of Td-Tomato-expressing neurons 
were labeled using rabbit anti-dsRed (1:1,000; 632496, Clontech Laboratories, Mountain View, 
CA, USA) followed by goat anti-chicken Alexa Fluor 488 (1:1,000; A11039, Thermo Fisher 
Scientific, Waltham, MA, USA). EGF-expressing projections were labeled with chicken anti-
GFP (1:10,000; ab13970, Abcam, Cambridge, MA, USA) and mouse anti-NE transporter (NET; 
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1:1,000; 1447-NET, Phosphosolutions, Aurora, CO, USA) primary antibodies, followed by goat 
anti-rabbit Alexa Fluor 568 (1:1,000; A11036, Thermo Fisher Scientific, Waltham, MA, USA), 
and goat anti-mouse Alexa Fluor 633 (1:1,000; A21052, Thermo Fisher, Scientific, Waltham, 
MA, USA) secondary antibodies. After washing, the sections were stained with Neurotrace 
435/455 blue fluorescent Nissl stain (1:50, N21479, Thermo Fisher) and mounted using Prolong 
Diamond anti-fade mountant (Thermo Fisher, Scientific, Waltham, MA, USA). Fluorescent 
images were generated on a Zeiss LSM 880 inverted confocal microscope (Carl Zeiss 
Microscopy, Thornwood, NY, USA) with Plan-Apochromat 10x/0.8 M27 objective using 
maximum intensity projection of Z-stack images through the full thickness of each section.  







Figure S4.1 Validation that heterozygous and homozygous recessive littermate mice do not 
express DREADD-hM3Dq receptors and can serve as hM3Dq-null controls. (A) Littermate control 
mice do not express mCherry-hM3Dq on any LC, A1/C1, A2/C2 or A4 NE neurons nor (B) send 





Figure S4.2 Representative fMRI images. Representative T2*-weighted, single-shot gradient echo 
planar image (EPI) functional scan from a single subject in (A) BOLD-weighted contrast and (B) 
CBV-weighted contrast. (C) Single subject EPI scans (n=29) were spatially warped to the Allen 
Mouse Common Coordinate Framework and Reference Atlas (v3) using Advanced Normalization 
Tools (ANTS) to generate symmetric diffeomorphic EPI atlases for BOLD, CBV and Regional 




Figure S4.3 Detailed ICA maps from baseline fMRI scans.  (A) Group ICA map of 100 ICs 
derived from baseline fMRI of all subjects (n=29) prior to CNO administration. (B) To assure the 
reproducibility of components from ICA analysis, ICA analysis was conducted again using 
randomly order components. The highly similar components could be found in the randomized 





Figure S4.4 Detailed evaluation of ICs associated with DMN.  (A) Selected DMN ICs and their 
corresponding DMN brain regions. (B) Dual regression results of the 17 DMN ICs and RSC seed-
based connectivity map (p<0.001). (C) Spatial similarity between the RSC seed-based 
connectivity map and the dual regression results of all 17 DMN ICs (One-sample t-test, p<0.01). 
(D) To access the quality of the fMRI data, ANOVA analysis was performed among the baseline 
scans of LC-NE, Hoxb1-NE and control groups. No significant FC change was identified in the 




Figure S4.5 Detailed changes in CBV, ReHo and ALFF.  (A) Detailed T-maps of CBV differences 
throughout the entire brain. (B) Detailed T-maps of ReHo difference throughout the entire brain. 
(C) Detailed T-maps of ALFF difference throughout the entire brain.  (D) Detailed spectral domain 
of ALFF—representing the sum of spontaneous low frequency activations within 0.01-0.2 Hz—
was extracted using Welch’s power spectral density (PSD) to generate periodograms and PSD 
maps. ALFF changes in the frontal module in the LC-NE group following CNO administration 
were restricted to lowest frequencies bands and the comparison of area-under-curve (AUC) of 
frequency bands binned into low frequency (LF: 0.01-0.05 Hz), medium frequency 1 (MF1: 0.05-
0.1 Hz), medium frequency 2 (MF2: 0.1-0.15 Hz) and high frequency (MF1: 0.15-0.2 Hz) ranges 
showed only LF bands in the Frontal module of the LC-NE group were statistically enhanced 









Figure S4.7 Detailed PET imaging data.  (A) Detailed T-maps of PET changes at LF bands 
between groups show the most significant changes in the LC-NE group were in brain regions of 
the frontal module of the DMN (p<0.05, FDR-corrected). (B) X and Y plot comparing CBV and 
FDG change show that En1 has significantly larger reduction in glucose metabolism and CBV 
change. Color bar represents the t statistical value. 
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Figure S4.8 Detail graph properties of the mouse DMN and anti-correlation between DMN and 
Insula.  (A) Connector vs Hub Score matrix.  (B) Three-dimensional plot of hubs with their 
respective functional connections. (C) Post-hoc analysis of FC changes within frontal module 
nodes compared to their FC changes with respect to insular nodes in LC-NE mice. (D) Post-hoc 
analysis of FC changes within frontal module nodes compared to their FC changes with respect to 




Figure S4.9 Dynamic causal modeling (DCM) analysis among DMN modules of the control 





Figure S4.10 Modulation analysis among DMN modules of the control group. No modulation was 
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